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Abstract 
Background 
Pain is the ubiquitous human experience, yet displays considerable inter- and intra-
individual variability in health and disease. Many factors have been proposed to 
account for these differences. Pain activates a complex stress response, multiply 
determined through genetic, psychological, physiological and neuroanatomical 
factors. Chronic pain is a central defining characteristic of functional gastrointestinal 
disorders. They represent a major challenge for modern healthcare. An integrated 
understanding of the pathophysiology of these disorders remains to be elucidated. 
 
Aims 
To investigate human psychophysiological responses to visceral and somatic pain in 
health and disease, in order to develop multidimensional and reproducible pain 
phenotypes.  
 
Methods 
Study 1, in healthy volunteers, investigated personality traits, hypothalamic pituitary 
adrenal axes and selective novel non-invasive measures of autonomic tone in 
response to visceral and somatic pain. Study 2 examined the salience of genetic 
polymorphisms of the serotonin transporter. Study 3 evaluated the reproducibility 
of these responses after a period of one year. Study 4 utilised the methods of 
studies 1 and 2 in a case control study of patients with functional chest pain. 
 
Key Results 
Studies 1, 2 and 3 – Two pain phenotypes, or clusters, were found – cluster 1 (39%) 
had higher neuroticism scores, with higher sympathetic and hypothalamic pituitary 
adrenal axis tone at rest, and a predominant parasympathetic response to pain in 
the presence of the short allele of the serotonin transporter. Cluster 2 (61%) 
displayed the converse profile in the absence of the short allele. These responses 
were stable at an interval of one year. Study 4 – similar phenotypes were observed 
in patients with functional chest pain, although the Cluster 1 phenotype was over-
represented in patients in comparison to the controls (71% vs. 29%). 
 
Conclusions and Inferences 
This series of studies provides evidence for the existence of two reproducible 
human pain phenotypes in health, which have clinical salience in patients with 
functional chest pain. By phenotyping pain responses, subject homogeneity in future 
studies may be improved. Furthermore, such phenotyping techniques may open 
new therapeutic avenues by facilitating the selective targeting of nociceptive 
aberrancies, particularly in functional gastrointestinal disorders. 
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Chapter 1 – Introduction 
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1.1 Opening Remarks 
Symptoms are at the very heart of the practice of clinical medicine. A physician 
typically initiates a consultation with the question, “What is your complaint?” 
Physicians structure their differential diagnosis using careful questioning and clinical 
examination by trying to establish patterns in the constellation of symptoms with 
which the patient presents. A symptom is defined as an “...aversively perceived 
internal state” [1]. Normal physiological fluctuations and pathophysiological 
processes may activate interoceptors that generate information regarding the state 
and function of the internal milieu. Whilst the majority of this ascending information 
remains unconscious, when it does enter the consciousness it may be perceived as 
a symptom. Experience of symptoms in the general population is a common 
phenomenon, with 96% reporting that they have experienced at least one symptom 
in any given preceding month [2]. However, symptoms may or may not be 
accompanied by objective signs of underlying disease such as those derived from 
clinical examination, haematological or biochemical parameters or through 
diagnostic imaging. When an individual experiences symptoms for which no organic 
pathology can be identified, these are often referred to as “functional”. In the 
United Kingdom, functional symptoms are estimated to account for up to 20% of 
general practitioners’ visits, thereby representing a large proportion of a physician’s 
workload [3]. However, physicians often find it difficult to explain the nature of 
such functional symptoms satisfactorily to their patients, sadly often referring to 
them as “hypochondriacs” “heartsink” or as “malingerers” [4]. This lack of 
acquisition, on the part of the physician, that a patient’s symptoms are legitimate, 
leads inevitably to increased anxiety and poor satisfaction and compliance with the 
physician and the prescribed treatment (if any). In association, patients experiencing 
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functional symptoms tend to equate the explanation that no organic pathology has 
been found with their symptoms being “imagined”. This lack of legitimisation often 
means that patients resist clarification from the physician and re-present to other 
physicians with similar symptoms, leading to a disproportionate use of healthcare 
resources. Whilst functional symptoms may manifest in a myriad of ways, the 
patient’s most prevalent and disabling complaint is often chronic, unexplained pain. 
Currently, there is no uniform investigational or treatment protocol for patients 
with functional symptoms, yet such symptoms may carry significant morbidity for 
the patient through a reduction in their quality of life, absenteeism and 
presenteeism [5, 6]. 
 
1.2 Aims and Chapter Structure 
This introductory chapter is divided into three separate, yet complementary, parts. 
The first part aims to set the scene for the series of studies that are presented in 
this thesis, in the context of what is already known about functional syndromes, 
where the knowledge gaps lie and how these may be addressed in future. As the 
central defining feature of a heterogeneous group of syndromes known as the 
functional gastrointestinal disorders (FGID) is chronic, unexplained (visceral) pain, 
the second part of the chapter is devoted to the neural mechanisms of visceral 
nociceptive physiology and their modulatory influences. Finally, I shall review the 
peripheral and central mechanisms that have been proposed in explaining the 
concept of visceral hypersensitivity (VH), which is considered by many to be the 
germane hypothesis in the explanation of FGID. 
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1.3 Functional Gastrointestinal Disorders & Functional Somatic 
Disorders 
FGID and functional somatic disorders (FSD) form a highly prevalent, clinically 
important and costly group of syndromes, which frustrate physicians and dissatisfies 
patients. Multiple functional somatic symptoms tend to concomitantly occur in a 
single patient, and may result in FSD or FGID. In the absence of a logical taxonomy, 
based on a mechanistic understanding of the underlying pathophysiology, FSD and 
FGID are often described by their primary symptom or by their implied end organ 
abnormality. Among the most prevalent FSD are chronic fatigue syndrome (CFS), 
fibromyalgia (FM) and FGID such as irritable bowel syndrome (IBS), functional 
dyspepsia (FD) and functional chest pain (FCP)/non-chest pain (NCCP). These 
divisions have facilitated the “ownership” of particular symptom clusters 
(syndromes) by medical sub-specialties. These arbitrary divisions, whilst facilitating 
appropriate referral pathways from primary to secondary/tertiary care, potentially 
mask the considerable overlap between syndromes, thus inhibiting the exploration 
of pathophysiological mechanisms that may be common within these diagnostic 
groupings. It is a matter of great debate whether many of these functional disorders 
are in fact heterogeneous manifestations of the same clinical entity. 
  
1.4 One or Many – To Lump or Split? 
The considerable overlap in the definition and comorbidities between FSD and 
FGID led to the proposal of the hypothesis that all functional syndromes are in fact 
a single disorder [3]. Proponents of this viewpoint are often collectively referred to 
in the literature as the “lumpers”. However, despite the popularity of this 
hypothesis amongst researchers in the field, itself being proposed over 10 years ago 
now, there remains a lack of prospective objective evidence in its confirmation. 
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Those that refute the hypothesis, collectively known as the “splitters”, highlight 
that, despite the many features that are shared, the differences between FSD and 
FGID cannot be ignored. For instance, Moss-Morris et al. recently examined 
differences in the aetiology, or precipitating factors, between CFS and IBS [7]. They 
concluded that anxiety and depression were the predictors for CFS, whereas 
preceding enteric infection predicts IBS. However, it must be noted that these 
“predictors” are not exclusive factors in the aetiology of these disorders. This 
evidence therefore suggests the presence of major aetiological differences between 
the two disorders. Another point of view is that the “lumping” and “splitting” 
viewpoints are not mutually exclusive and that shared vulnerability factors may 
underlie the development of all functional disorders, although specific factors may 
shape their final clinical manifestation or phenotype. The pathophysiology of 
functional disorders is therefore likely to be multi-factorial, yet it remains 
incompletely understood. However, an increasingly important, emerging body of 
evidence has identified the key role of psychophysiological processes. In the 
subsequent sections I shall examine evidence of these key psychophysiological 
processes, particularly with respect to FGID. 
 
1.5 Emerging Perspectives on the Role of Psychophysiological 
Processes in the Pathophysiology of Functional 
Gastrointestinal Disorders 
Epidemiological studies have indicated that co-morbidity with psychiatric disorders 
(mostly mood and anxiety disorders), as well as the prevalence of severe 
psychosocial stressors (including a history of (childhood) sexual or physical abuse), 
is high in FGID [8, 9, 10, 11]. Recent evidence has shown that this is not only true 
in tertiary care, but also in primary care [12] and in non-help-seeking community-
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based populations [9]. A study by Walker et al. evaluated compared 71 patients 
with IBS and 40 patients with inflammatory bowel disease (IBD) using structured 
interviews for psychiatric, gastrointestinal and sexual/physical victimization histories, 
as well as self-reported measures of personality, functional disability and 
dissociation [13]. Despite the absence of demonstrable organic pathology, those 
with IBS had significantly higher rates of depression, panic disorder, and childhood 
sexual abuse. It is also interesting to note that the IBS group also disability ratings 
equal to, or greater than, those of patients with IBD. However, IBS-like symptoms 
are common in patients with IBD and it has been shown that increased disease 
activity in IBD is associated with an increase in anxiety and depression scores [14]. 
It remains controversial whether the patho-aetiology of IBS-like symptoms in IBD 
are a real association or reflect occult inflammation [15].   
 
Behavioural research has also shown that the hypersensitivity to rectal distension 
found in IBS patients is often attributable to hypervigilance for visceral stimuli and a 
greater tendency to label visceral sensation as negative/painful rather than as a 
normal interoceptive sensation [16]. An interesting paper by Naliboff et al. 
examined the longitudinal change in perceptual and brain activation in response to 
repeated visceral stimuli in irritable bowel syndrome patients in comparison to 
health controls [17]. They found that in IBS patients, repeated exposure resulted in 
the habituation, possibly due to down-regulation of affective aspects of nociceptive 
processing. Somatisation and, to a lesser extent, depression are considered to be 
important determinants of symptoms than visceral sensitivity per se in FD, although 
how these relate to an individual’s symptoms remains uncertain [18]. Additionally, 
gastrointestinal (GI), symptom-specific anxiety has been shown to be an important 
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mediator of the relationship between general anxiety and the IBS diagnostic status 
or symptom severity of IBS [19].  
 
1.6 The Biopsychosocial Concept of Functional Disease 
Such epidemiological and psychometric/behavioural evidence has led to a 
biopsychosocial conceptualisation of FGID, for example as formulated by Drossman 
in the “Rome” international consensus reports on FGID [20]. The biopsychosocial 
concept of illness, first explicitly formulated by the late George Engel in 1977, 
postulates that all illnesses, but especially FGID, result from complex reciprocal 
interactions between biological, psychological and social factors [21]. Although this 
model fails to conceptualise the exact nature of these interactions, it remains an 
important psychophysiological framework for explaining the pathophysiology of 
FGID, both in a clinical and a research context. This conceptualisation of illness, 
which interestingly had been applied in yesteryear to peptic ulcer disease prior to 
the discoveries of Warren and Marshall, does “cover all the bases,” which has 
facilitated a considerable proliferation in the proposal of patho-aetiological factors 
underlying FGID. However, this proliferation has been at the expense of developing 
a unified and integrated appreciation of the common underlying mechanisms. This 
marked proliferation in patho-aetiological possibilities is amplified when further 
anatomical subdivisions of functional syndromes by organ, e.g. oesophagus – FCP; 
stomach – FD; colon – IBS (see Figure 1), are taken into account. 
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Figure 1 - The biopsychosocial concept of disease, as related to pain in FGID. This concept 
facilitates the hypothesis generation/testing of a wide range of variables, which inevitably results in 
a lack of integration in the proposed pathophysiological factors. 
 
Given that chronic, unexplained pain is central to the definition of FGID, it is not 
surprising that much of this focus has centred on the investigation and 
characterisation of nociceptive physiology in health and disease.  
 
1.7 Visceral Pain Research  
Research into chronic visceral pain has ‘lagged’ behind its somatic counterpart [22]. 
In addressing this imbalance, the latter part of the 20th century was greeted with 
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great excitement because technological advances in functional neuro-imaging 
techniques would finally herald a new dawn in our understanding of the ‘visceral 
pain neuromatrix’, in health and in particular functional disease (see Hobson et al., 
[23]). However, despite considerable academic and financial investment in 
functional neuro-imaging, its initial promise has not (yet) yielded consistent results 
that are readily applicable to patient groups [24]. It is my opinion, and that of others 
[25], that this may be due to the fact that both the methodology and results from 
these imaging studies have been sufficiently integrated with neither the 
epidemiological and behavioural evidence on the role of psychophysiological 
processes outlined above nor with other branches of neuroscience, especially 
affective, cognitive and autonomic neuroscience. 
 
1.8 The Case for an Integrated Approach 
Therefore, to move the field forward, the development of an integrated 
multidisciplinary research strategy directed towards the identification and 
interaction of vulnerability factors, whether they be genotypic, psychological or 
physiological, is warranted to explain disease genesis, and may ultimately result in 
disease prevention. Given the high comorbidity in all FSD and FGID, as well as 
growing evidence for at least a degree of overlap in their aetio-pathogenesis, it can 
be argued that this integrative approach should be extended beyond the borders of 
the FGID field to include other FSD such as FM and CFS.  
 
1.9 Lessons from Somatic Pain Research 
The somatic pain research community has developed such an integrated strategy, 
and as a result has made considerable progress into unravelling the complex 
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psychophysiological mechanisms by which emotion (e.g. anxiety) and cognition (e.g. 
attention) influence the processing and perception of bodily signals, by amplifying 
them at higher levels and/or interfering with descending pain modulation. This 
knowledge has been borne out of the fruitful integration between different scientific 
disciplines within the somatic pain field over the past decades including, among 
others, psychology, psychiatry, anaesthesia and various branches of neuroscience. 
Such a degree of integration has not yet been achieved within the field of ‘visceral 
sensory neuroscience’/’neurogastroenterology’; however, this may prove to be the 
pivotal step in advancing our understanding of the pathophysiology of FSD and 
FGID. In striving to achieve this goal, newer techniques such as functional neuro-
imaging and genotyping should be utilised, but not at the expense of ‘old friends’ 
such as psychometrics, behavioural research, neurophysiology and autonomic 
neuroscience. Such a strategy may lead to the discovery of integrative, 
multidimensional (visceral) pain “phenotypes”, which may be a first critical step 
towards a pathophysiological, rather than a symptom-based classification, of these 
complex disorders that may be more suitable for future genetic association studies. 
  
1.10  Phenotyping  
“(Endo)phenotypes” can be defined as “measurable components unseen by the unaided 
eye along the pathway between disease and distant genotype” and may be, among 
others, cognitive or neuro/psychophysiological in nature [26]. Phenotyping maybe 
of particular use in aiding the classification and diagnosis of what are almost 
certainly multifactorial and polygenic diseases. In this respect, they have been 
increasingly used in the study of psychiatric disorders, not only in the context of 
genetic studies, but also with the purpose of improving classification and diagnosis 
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[26]. Given the fact that FSD and FGID, like psychiatric disorders, are complex 
multifactorial disorders descriptively defined and based on symptoms, a 
phenotypical approach to these functional disorders is warranted. Moreover, it is 
my opinion that integrative research strategies should be used in the search for 
phenotypes in FGID, rather than focusing on one ‘uni-dimensional’ candidate 
phenotype such as certain personality traits. It should be noted that the high 
overlap with both other FSD as well as mood and anxiety disorders may complicate 
this effort to a great extent, but on the other hand, if an integrative strategy helps 
us to look beyond the symptom and speciality-based boundaries between current 
diagnostic categories, the identification of one or more phenotypes within these 
largely overlapping groups may lead us closer to a pathophysiology-based 
classification of functional somatic and psychiatric disorders alike. Whether 
phenotyping will lead to improvements in treatment, by predicting responders vs. 
non-responders, remains uncertain. To illustrate the case of further integration – 
and the way ahead for this field as I see it – I shall discuss some recent examples of 
integrative autonomic and neuro-imaging studies, and highlight how such an 
integrative strategy may help the burgeoning field of (visceral) pain genetics. 
  
1.11 Integration with Autonomic Neuroscience 
Psychosocial stress is considered to be an important mechanism in the 
development and maintenance of chronic visceral pain [27, 28]. It is therefore 
intuitive to examine the physiological effector mechanisms by which psychosocial 
stress and its neural correlates may influence visceral function. In this respect the 
autonomic nervous system (ANS) is an attractive proposition itself inasmuch that it 
can be influenced by acute, repetitive and chronic psychosocial stressors, the latter 
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having been shown to have the potential to induce a maladaptive response [29]. 
The ANS is responsible for rapid stress responses, since it reacts within seconds of 
stimulation. 
 
1.11.1 The Autonomic Nervous System in Functional Gastrointestinal Disorders 
Research 
Bockus first suggested that an “IBS” type syndrome may be a consequence of an 
imbalance in the ANS in 1928. Landmark observational studies relating to the GI 
motility sequelae of surgical interruption of the ANS date back to the 1950s [30, 
31]. These observations and concepts were not further explored until the late 
1970s and early 1980s in line with the prevailing hypothesis that ANS hyper-
reactivity could explain a significant proportion of alterations in bowel habits in IBS. 
However, the exact role of the ANS in explaining the pathophysiology of FGID has 
been disappointingly inconsistent (see Table 1).  A widely utilised proxy for 
measuring ANS function has been heart rate variability (HRV), which reflects inter-
beat interval fluctuations in heart rate (HR). Power spectral analysis is a method of 
analysing HRV, in which it is postulated that there are a number of rhythms within 
the HRV itself, which are thought to relate to the relative influences of sympathetic 
nervous system (SNS) and the parasympathetic nervous system (PNS) on overall 
autonomic tone. Whilst spectral analysis of HRV is statistically robust, it assumes 
(incorrectly) that respiratory rate is a semi-stationary variable, i.e. the subject is 
breathing at a constant rate of between 10-14 breaths per minute, and that 
sympathetic and parasympathetic tone are reciprocal variables [32, 33]. Perhaps the 
greatest methodological flaw in the spectral analysis of HRV is that it is generally 
analysed offline (i.e. not in ‘real time’), thereby leaving the potential for subjectivity 
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in its interpretation as there are no universally accepted guidelines to its analysis 
[33]. 
 
Author Year Subjects 
Autonomic 
Measures 
Employed 
Stimulus Outcome 
Pellissier et al. 
[34] 
2010 
27 IBS patients (Rome II) 
26 Crohn’s disease, 22 
Ulcerative colitis, 27 
healthy controls 
HRV At rest 
IBS patients had 
higher sympathetic 
tone 
Wan H et al. 
[35] 
2010 
30 female IBS patients 
(Rome II defined) 
20 female healthy controls 
HRV Mental stress 
IBS patients had 
increased 
sympathovagal 
balance 
Manabe et al. 
[36] 
2009 
118 IBS patients (definition 
unclear) 
59 healthy controls 
Continuous wave 
Doppler sonography 
At rest, 
Electrical 
cutaneous 
stimulation, 
Cold pressor, 
Mental stress 
Increased 
sympathetic activity 
in IBS patients 
Camilleri et al. 
[37] 
2008 122 IBS patients (Rome II) HRV At rest 
Increased 
sympathetic activity 
in IBS patients 
Walter et al. 
[38] 
2008 
27 non-characterised IBS 
patients (Rome II) 
13 constipated patients 
18 healthy controls 
Sudomotor skin 
responses 
(sympathetic 
measurement) 
2 sets of isobaric 
rectal distensions 
IBS patients had a 
higher sympathetic 
reactivity 
Tanaka et al. 
[39] 
2008 
59 non-characterised IBS 
patients (Rome II) 
118 healthy controls 
Finger tip blood flow 
(sympathetic 
measurement) 
Cold pressor test 
– ice bag placed 
on left forearm 
for 1 min 
IBS patients had 
higher sympathetic 
reactivity 
Spaziani et al. 
[40] 
2008 
39 non-characterised IBS 
patient (Rome II) 
98 healthy controls 
Baroreceptor 
sensitivity (relative 
measure of 
parasympathetic and 
sympathetic tone) 
1 set of isobaric 
rectal distension 
IBS patients had 
higher sympathetic 
tone +/- 
compromised vagal 
activity 
Jarrett et al. 
[41] 
2008 
35 characterised female 
IBS patients (Rome II) 
38 healthy female controls 
HRV 
None, changes 
noted in rapid eye 
movement (REM) 
vs. non-rapid eye 
movement 
(NREM) sleep 
No difference in 
HRV between IBS 
group and healthy 
volunteers. 
Diarrhoea IBS 
predominant had 
higher vagal tone in 
comparison to 
other subtypes 
Spetalan et al. 
[42] 
2007 
33 characterised (either 
diarrhoea predominant or 
mixed) female IBS (Rome 
I) 
21 healthy female controls 
Respiratory sinus 
arrhythmia (cardiac 
vagal activity) 
Sudomotor skin 
responses 
(sympathetic 
measurement) 
 
Emotional stress 
(emotional 
meaning words) 
Rectal barostat 
distension 
Decreased vagal 
tone at rest in IBS 
group 
Increased 
sympathetic 
reactivity to rectal 
distension in IBS 
group 
Ng et al. [43] 2007 
8 non-characterised 8 IBS 
patients (Rome II) 
8 healthy control 
LF:HF balance of 
HRV (a measure of 
sympathovagal 
balance) 
Colonic 
distension before 
and after 
1000kcal liquid 
meal 
Vagal withdrawal in 
response to feeding 
in IBS group vs. 
control 
Sympathetic 
response post-
prandially in IBS 
group vs. control 
Increase in vagal 
tone in fed state in 
IBS group vs. 
control 
Mazur et al. 
[44] 
2007 
23 IBS patients (Manning 
criteria) 
HRV 
At rest and 
following feeding 
IBS patients had 
increased 
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30 healthy controls (300Kcal meal) sympathetic activity 
at rest 
Van Orshoven 
et al. [45] 
2006 
18 characterised IBS 
patients (Rome II) 
19 healthy controls 
HR 
HRV 
Muscle sympathetic 
nerve activity 
  
Tousignant-
Laflamme et 
al. [46] 
2006 
13 non-characterised 
female IBS patients (Rome 
II) 
13 healthy female controls 
HR 
Sudomotor skin 
response 
Cold pressor test 
to fore foot 
IBS group had 
elevated 
parasympathetic 
tone to pain 
Robert et al. 
[47] 
2006 
75 characterised female 
IBS patients (Rome II) 
HRV 
None, changes 
noted in rapid eye 
movement (REM) 
vs. non-rapid eye 
movement 
(NREM) sleep 
Diarrhoea 
predominant IBS 
group had significant 
vagal withdrawal 
during REM and 
NREM sleep 
Van der Veek 
et al. [48] 
2005 
87 non-characterised IBS 
patients (Rome I) 
36 healthy controls 
SBP 
Baroreceptor 
sensitivity (relative 
measure of 
parasympathetic and 
sympathetic tone) 
Rectal distension 
IBS patients had 
higher sympathetic 
tone at baseline but 
not during rectal 
distension 
Tillisch et al. 
[49] 
2005 
130 non-characterised IBS 
patients (Rome I) 
55 healthy controls 
Sudomotor skin 
responses 
HRV 
Rectal distensions 
Male IBS patients 
showed an 
increased 
sympathetic tone 
and decreased 
parasympathetic 
tone to rectal 
distension 
Waring et al. 
[50] 
2004 
39 non-characterised IBS 
patients (Rome I) 
30 healthy controls 
LF:HF balance of 
HRV (a measure of 
sympathovagal 
balance) 
Orthostatic 
manoeuvres and 
sustained 
handgrip 
exercises 
IBS group had 
reduced vagal tone 
and relative 
sympathetic excess 
Murray et al. 
[51] 
2004 
24 constipation 
predominant IBS patients 
(Rome I) 
12 healthy controls 
Rectal mucosal 
blood flow by laser 
Doppler flowmetry 
(a measure of 
autonomic efferent 
activity) 
Cold pressor test 
and dichotomous 
listening 
IBS group and 
similar efferent 
autonomic activity 
to healthy controls 
during stress but 
took longer to 
return to baseline 
Thompson et 
al. [52] 
2002 
33 female IBS patients 
(stratified into IBS and IBS 
with dyspeptic symptoms) 
(Rome I) 
21 healthy female controls 
 
LF:HF balance of 
HRV (a measure of 
sympathovagal 
balance) 
None, changes 
noted in rapid eye 
movement (REM) 
vs. non-rapid eye 
movement 
(NREM) sleep 
IBS only subgroup 
had increased 
sympathetic tone 
during REM sleep 
compared with IBS 
+ dyspeptic 
symptoms 
Gupta et al. 
[53] 
2002 
20 non-characterised IBS 
patients 
23 healthy controls 
HR and BP 
Rectal distension 
Cutaneous stimuli 
– hot water 
IBS groups had 
higher sympathetic 
tone at rest and 
increased 
parasympathetic 
tone to visceral but 
not cutaneous 
stimuli 
Heitkemper et 
al. [54] 
2001 
103 characterised IBS 
patients 
49 healthy controls 
HRV 
None, 24 hr 
Holter monitor 
recordings 
Increased 
parasympathetic 
tone in constipation 
predominant IBS vs. 
diarrhoea 
predominant IBS 
Elsenbruch et 
al. [55] 
2001 
24 characterised IBS 
patients 
20 healthy controls 
HRV Standard meal 
Diarrhoea 
predominant IBS 
had great increase 
in sympathetic tone 
after meal 
compared to 
constipation 
predominant IBS & 
controls 
Punyabati et 
al. [56] 
2000 
35 non-characterised IBS 
30 healthy controls 
HR responses to 
deep and slow 
breathing (a 
None, but 
subjects tested 
twice at least one 
IBS group had 
increased PNS 
activity which was 
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measure of 
parasympathetic 
tone) 
DBP response to 
sustained handgrip 
(a measure of 
parasympathetic 
tone) 
week apart stable over time 
Orr et al. [56] 2000 
15 non-characterised IBS 
patients 
15 healthy controls 
HRV Sleep vs. waking 
IBS patients have 
higher sympathetic 
tone whilst wake 
and during REM 
sleep compared 
with controls 
Burr et al. 
[57] 
2000 
106 non-characterised IBS 
patients 
41 healthy controls 
HRV 
None, 24Hr 
Holter monitor 
recordings with 
self reported 
episodes of 
abdominal pain 
Reduced vagal tone 
in IBS patients with 
pain 
Adeyemi et al. 
[58] 
1999 
35 non-characterised IBS 
patients 
18 healthy controls 
HRV 
Orthostatic stress 
and deep 
breathing 
IBS group had 
reduced 
sympathetic tone in 
response to 
orthostatic stress 
and reduced 
parasympathetic 
modulation during 
deep breathing 
exercises 
Lee et al. [59] 1998 
40 characterised IBS 
patients 
20 healthy controls 
Sudomotor skin 
responses 
(sympathetic 
measurement) 
HRV 
None, but 
measures 
performed at rest 
and during deep 
breathing 
Decreased vagal 
tone in constipation 
predominant IBS 
during deep 
breathing compared 
to diarrhoea 
predominant IBS 
and controls 
Karling et al. 
[60] 
1998 
18 non-characterised IBS 
patients 
36 healthy controls 
HRV 
None, only 
baseline measures 
taken 
Increased 
sympathetic tone in 
IBS patients at rest 
Fukudo et al. 
[61] 
1987 
20 non-characterised IBS 
patients 
12 healthy controls 
RR variability (a 
simple of measure of 
sympathetic-
parasympathetic 
balance) 
Psychological 
stress (mirror 
drawing) 
IBS patients with 
enhanced motility 
had higher 
sympathetic tone 
Table 1 - A summary of recent studies evaluating autonomic dysfunction in IBS. Characterisation 
refers to whether the authors have classified the predominant bowel habit among their subjects 
with IBS. 
 
In order to address these methodological concerns, a relatively novel measure of 
parasympathetic tone has been developed, known as cardiac vagal tone (CVT) [62]. 
It relies on the principle that the baroreceptor-driven modulation of efferent 
parasympathetic tone from the brainstem can be deduced by knowledge of phase 
shifts in RR interval on the electrocardiogram (ECG), rather than frequency shifts 
[62]. CVT has been well validated in humans in health and disease although, as yet, 
it is not a widely utilised measure in the literature [62].The measurement of CVT 
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using this principle has been incorporated in to a commercially available instrument 
known as the Neuroscope™, which analyses RR intervals to produce a non-
invasive, real time, online, beat-to-beat index of CVT [63]. As demonstrated by Tak 
et al. [64], the central dysautonomic feature in FGID may lie within the PNS; 
therefore, the development of an objective non-invasive efferent parasympathetic 
measure, such as CVT, may prove to be the prerequisite step in examining subtle 
PNS dysautonomia within FGID. A preliminary report, using CVT, has shown that 
62% of patients with FGID have demonstrable PNS dysfunction [65]. These early 
findings, whilst promising, need to be reproduced in a larger group of patients with 
FGID. 
 
1.12 Recent Attempts towards Integration in Visceral Pain 
Autonomic Neuroscience Studies 
Recently, the above described measurements of ANS function have been used to 
compare hitherto poorly characterised relations between brainstem autonomic 
control and personality in response to visceral and somatic pain [66]. Healthy 
subjects, whose psychological profiles were measured using validated 
questionnaires, had ANS recordings, including CVT, taken at rest and in response 
to somatic and visceral pain. Pain at all sites evoked parasympathetic/sympathetic 
co-activation with an elevation in HR, as well as vasodepression. The personality 
trait of neuroticism correlated with a degree of visceral pain-related CVT changes, 
wherein more neurotic subjects tended to increase their CVT in response to pain. 
This study provides evidence that ANS responses to pain are nuanced by 
personality type. Furthermore, the PNS has been proposed as an anti-nociceptive 
pathway [67]. In a human model of central sensitisation (CS), wherein distal 
oesophageal acidification induces variable hyperalgesia in the non-acid exposed 
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proximal oesophagus (secondary hyperalgesia), those who withdrew their PNS tone 
displayed a greater degree of sensitisation, suggesting that these subjects may have 
greater vulnerability to develop symptoms following injury [68]. A further study 
demonstrated that, in response to visceral pain, two distinct psychophysiological 
responses were observable, each with differential pain sensitivity and intimately 
influenced by personality [32]. These reports provide fascinating insights into the 
psychophysiological basis of pain responses, and may provide preliminary evidence 
that multidimensional pain phenotypes may exist in humans. The factors that 
encompass these phenotypes may reflect different vulnerability factors for the 
development of chronic pain syndromes. To further understand these factors, a 
larger study of healthy subjects, across a number of human cultures and 
populations, examining these psychophysiological factors, and other facets of the 
stress axes including the hypothalamic-pituitary-adrenal (HPA) axis and the immune 
system, is urgently needed. Further work is also needed to confirm whether these 
proposed phenotypes meet important criteria such as temporal stability, heritability 
and over-representation in patients with FSD and FGID, in comparison to the 
general population [26]. The natural culmination of this approach would be the 
modification of these vulnerability factors not only in patients to treat the disease, 
but also in a healthy population to facilitate disease prevention. 
  
1.13 Recent Attempts towards Integration in Visceral Pain 
Functional Neuro-imaging Studies  
Functional neuro-imaging studies have identified many of the central neuro-
anatomical circuitry involved in (visceral) nociception. A criticism that can be 
levelled at this body of work rests on the intrinsic nature of FGID as syndromes 
rather than specific disease entities, as well as on inter-individual variations in 
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disease mechanisms, which are generally not accounted, or controlled, for. In 
addition, functional neuro-imaging studies have focused on relatively small groups of 
subjects and not been controlled for the psychological factors that have been 
shown to be crucial in effecting physiological responses to somatic and visceral pain. 
Taking these factors together, it therefore comes as no surprise that these types of 
studies often report conflicting results. Despite these limitations, neuro-imaging 
studies, particularly in healthy subjects, have provided important insights into 
networks associated with the modulation of ascending pain signals by affective and 
cognitive factors. For example, the emotional modulation of visceral sensation and 
pain is associated with higher behavioural responses paralleled by higher activity in a 
brain network consisting of the anterior cingulate cortex (ACC), sub-regions of the 
prefrontal cortex (PfC) and the insula [69, 70]. Interestingly, the involvement of 
similar central networks has been demonstrated in the cognitive modulation of 
visceral sensation [71, 72].  
 
Functional neuro-imaging in patients with FGID has begun to examine the 
relationship between psychosocial factors and brain responses. For instance, 
recently a number of distinct brain networks have been identified in patients with 
IBS; these are postulated to be concerned with different aspects of processing of, 
and responding to, afferent visceral signals. Subsequent observations show that sex 
differences in the cortico-limbic circuitry involved in emotional-arousal, pain 
facilitation and autonomic responses may underlie the observed over-presentation 
of females in FGID populations [73].  
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In IBS, anxiety and depression scores correlate with subjective pain ratings during 
rectal distension. Specific differences in response to pain induction may be observed 
in brain areas depending on anxiety score (in the anterior and medial cingulate 
cortices) and depression scores (in the PfC and cerebellum). Crucially, however, 
differences in brain activity with healthy controls disappear when anxiety and 
depression are controlled for [74]. Even more recently, studies in FD have shown 
that psychological variables (particularly anxiety and abuse history) are associated 
with abnormal brain activity in regions involved in cognitive/affective aspects of pain, 
during both baseline and pain induction. Taken together, these findings may point to 
deficient endogenous pain modulatory responses in FD patients, which may be 
influenced by psychosocial factors [75, 76]. These results are extremely promising 
and highlight the importance of psychological factors in the brain processing of pain. 
However, the exact relationship between these factors, and their role in symptom 
generation, remain to be determined. 
 
1.14 Recent Advances in Genetic Studies in Functional 
Gastrointestinal Disorders 
Considerable recent interest has focused on the role of genetics, generally using a 
candidate gene approach, as vulnerability and susceptibility factors for the 
development of FGID. There is mounting evidence from family and twin studies to 
suggest that the pain experienced in FSD and FGID displays a degree of heritability. 
However, published genetic association studies of chronic pain syndromes and pain 
sensitivity have considerable methodological shortcomings, primarily as a 
consequence of lack of sufficient sample size to detect the likely modest effects. 
Therefore, the pressing need for well powered and appropriately designed genetic 
studies to enable the identification of the genetic factors contributing to the 
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aetiology of FSD and FGID is urgently needed. However, current, purely symptom-
based phenotypes may be far too heterogeneous and too “distant” from their 
genotypical basis. Thus “deconstruction” of these syndromes into multidimensional 
clinical phenotypes, which are more closely linked to genetic mechanisms, may 
increase the chances of success of future studies of reproducibly by identifying 
genetic factors that may be involved in the genesis of FSD and FGID.  
 
1.14.1 Twin- and Familial-Based Aggregation Studies  
Evidence from twin studies and familial aggregation studies has suggested that a 
number of FGID, in particular IBS, display a degree of heritability on the one hand, 
yet are influenced substantially by environmental factors on the other [77, 78, 79]. 
 
1.14.2 The Candidate Gene Approach 
Many studies have identified numerous putative associations between a wide variety 
of genes including catechol-o-methyl-transferse, interleukin-10, serotonin 
transporter (SERT), #-2 adrenergic system and g-protein. However, all too often 
there has been a failure to reproduce these initial findings [80]. A more novel 
approach has been to study the genetic associations between candidate genes and 
physiological phenotypes rather than symptom criteria, its purpose being to identify 
genetic polymorphisms that may culminate in alterations of normal colonic 
physiology (e.g. changes in GI motility, sensory thresholds and compliance, etc.), as 
has been postulated to be the case in the various sub-types of IBS. Of note is that 
spontaneous variations within cannabinoid metabolism, SERT and neuropeptide S 
receptor 1 have been associated with rapid colonic transit, greater cerebral blood 
flow in the emotional motor system of the brain and changes in GI mucosal barrier 
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function, respectively [81, 82, 83]. Even more promising are recent studies 
evaluating the pharmacogenetics of novel treatments for IBS, in particular those 
directed at normalising colonic motility. The overall efficacy, in addition to safety 
concerns, of novel therapies such as alosetron (a 5-HT3 antagonist) and tegaserod 
(a 5-HT4 agonist) has come under intense scrutiny from the regulatory agencies and 
the wider gastroenterological community alike. Studies have shown that genetic 
polymorphisms in the SERT may predict a clinical response to these agents and 
provide a potential method by which treatment may be individually tailored [84, 
85].  
1.14.3 Genome-Wide Association Studies 
As in other common diseases such as coeliac disease, genome-wide association 
studies (GWAS) may prove to be a pivotal method by which the polygenetic 
mechanism that results in FGID may be defined [86]. However, before embarking 
on a multi-centre, and almost certainly a multi-national, GWAS project in FGID, 
which would require considerable investment in terms of time and funding, the 
essential phenotypic components of these disorders need to be further delineated. 
If this prerequisite step is not undertaken, outcomes will be inconsistent and 
potentially even contradictory. 
 
1.15  Perspective – Future Gazing  
Reflecting on the past can only aid in one’s focus in the future. In the past, many 
scientific disciplines have made major contributions to advancing our understanding 
of visceral nociception in health and disease, but often these advances have been 
made in isolation. Future focus therefore must be towards the development of an 
integrative and interfacing research strategy encompassing these seemingly 
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divergent, yet complementary, disciplines. The development of such a research 
strategy will serve to provide further insights into the mechanisms that underpin 
(visceral) nociception in health. However, the key step in this framework is the 
identification of individual vulnerability and susceptibility factors that may underpin 
disease “phenotypes” that lead to chronic pain in FGID, in conjunction with 
initiating factors (such as infection, acute or chronic psychosocial stress). 
Modification and manipulation of these factors – pharmacologically or otherwise – 
may lead ultimately to disease prevention in groups that have been identified as 
being at risk. Furthermore, for those patients in whom FGID have already 
developed, the identification of phenotypes and their link with the genotype may 
lead to individually tailored treatments based not on anecdotal evidence but on 
definitive mechanistic pathophysiology. The sequelae of such an approach may 
culminate in improved outcomes not only for the patient, in terms of their 
symptoms and health-related quality of life, but also the researcher, in terms of 
greater efficiency in the utilisation of limited research resources. Perhaps this 
approach may turn out to be the Rosetta Stone that patients and researchers have 
long needed in FSD and FGID. 
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Figure 2 - A proposed framework for the development of research and treatment in FGID using 
multidisciplinary and dimensional techniques. Adapted from Farmer, Aziz, Tak & Van Oudenhove, 
Journal of Psychosomatic Medicine 2010 [87]. 
 
1.16  Searching for the Rosetta Stone – The Time is Ripe 
The focus of the work presented in this thesis is devoted to the integrated 
examination of human psychophysiological responses to pain, examining specifically 
the stress responsive system of the ANS and HPA axis in the context of personality 
and genetic polymorphisms of the SERT. Many studies have variably implicated 
these factors in the pathogenesis and patho-aetiology of FSD and FGID. To date, 
there is a paucity of evidence linking these factors in an integrated fashion in 
response to experimental noxious visceral and somatic stimuli. However, a paucity 
of evidence does not mean an absence of evidence, and therefore I have chosen to 
examine these factors in this body of work, initially in health and more latterly in 
 59 
patients with FCP. In the following sections, I shall review the neurobiology of 
visceral pain, with particular focus on the mechanisms concerned with the 
modulation of nociceptive physiology that are of particular pertinence to FCP.  
 
1.17  Definitions and Dimensions of Pain 
International Association for the Study of Pain (IASP) defines pain as “...an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage.” [88] Pain is a multidimensional 
experience consisting of sensory-discriminative, affective-motivational and cognitive 
evaluative processes. The sensory-discriminative component of the pain experience 
relates to the localisation and intensity rating, whereas the affective-motivational 
aspects relating to its unpleasantness give rise to emotional aspects such as fear. 
Cognitive evaluative aspects facilitate the interpretation and contextualisation of 
pain and are thus involved in attention, anticipation and the formation of memories 
of the experience [89]. Within clinical practice, pain is one of the most common 
presenting complaints, irrespective or not as to whether it turns out to be 
explained or unexplained [90]. Pain may emanate from a variety of sources, 
including the abdominal viscera, potentially a manifestation of myriad underlying 
pathologies. As with somatic pain, visceral pain varies in intensity from mild 
discomfort to severe pain, and in contrast to somatic pain it can be referred to 
other distant structures such as the right shoulder tip, arm or chest.  
 
1.18  Historical Aspects of Visceral Pain 
Clinicians have appreciated the difference between visceral pain and other types of 
pain for many centuries. However, this is an opportune moment to reflect that it is 
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only just over a century since Lennander* [91] suggested that not all viscera were 
capable of producing pain. Whilst not contentious now, as it is well established that 
pain does not arise from all viscera, in 1901 this was a major step forward. Firstly, 
what Lennander had not appreciated in the early 20th century was that visceral pain 
can arise from the mechanical distension of the capsule of a hollow organ, such as 
the liver, as the organ contained within distends or becomes inflamed. Secondly, 
tissue injury per se may not be required for production of visceral pain, unlike its 
somatic counterpart. Finally, the nociceptive threshold for visceral pain may change 
in response to previous stimuli or injury. On this latter point, Gebhart comments 
that “...in contrast to somatic pain the adequate stimuli for production of visceral 
sensation, including pain, are not yet fully appreciated” [92]. It was not until HG Wolff’s 
seminal papers in the Journal of Clinical Investigation, entitled “Aspects of Pain”, in 
the 1930s and 1940s that a true understanding of the application of adequate painful 
stimuli to produce visceral pain began to develop. Wolff’s “volunteer” was known 
as “Tom”, who was otherwise healthy, apart from having a gastrostomy. Wolff 
found that touching or heating the gastric mucosa failed to produce any nociceptive 
sensation. However, when the mucosa was treated with mustard powder, causing 
vasodilation, or when Tom was anxious, the mucosa would become intensely 
sensitive to such stimuli. Wolff’s experiments [93] are generally regarded as the 
basis for the terms “allodynia”, where a previously innocuous stimulus is regarded 
as painful, and “hyperalgesia”, where a painful stimulus is perceived as more painful 
than previously. In understanding the complex mechanisms that lead to the 
                                            
* Professor KB Lennander was a Professor of Surgery at the University of Upsala in Sweden at the 
turn of the 20th century. Interestingly, he bequeathed all of his estate to research and medical 
student bursaries. 
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development, maintenance and modulation of visceral pain, it is important to detail 
the functional neuroanatomy and physiological processes involved. 
 
1.19  Sensory Innervation of the Gastrointestinal Tract 
The sensory innervation of the GI tract is complex, receiving a dual sensory supply 
from the central nervous system (CNS), referred to as extrinsic afferents, in 
addition to its own integrated network arising from the enteric nervous system 
(ENS), known as intrinsic afferents. These complementary systems closely regulate 
the secretomotor function of the GI tract. The sensory neurones involved in pain 
detection and transmission are known as nociceptors. 
 
1.19.1 Nociceptors 
A nociceptor may be defined as “...a primary sensory neurone that is activated in 
response to a (noxious) stimuli that is capable of causing damage...”[94]. In order to 
achieve this function, a nociceptor requires a receptor, which is located at its 
peripheral terminus. When activated, the receptor triggers neuronal depolarisation, 
ultimately culminating in the conscious awareness of pain. Nociceptors may be 
classified based on their physical characteristics, such as size, myelination and their 
responsiveness to specific stimuli such as acid, heat or mechanical deformation. 
Some nociceptors may respond to more than one form of stimuli and are thus 
known as polymodal, whereas others may normally be silent but recruited in 
response to prolonged inflammation. Nociceptors have one of two types of axons, 
the first of which are known as A$-nociceptors, containing myelinated fibres, which 
allow rapid conduction, and the second C-nociceptors, which are unmyelinated 
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with slower conduction velocities. The differences between nociceptors are 
summarised in Table 2. 
Fibre Type 
Fibre 
Diameter 
Conduction 
Velocity 
Myelination Distribution 
Type of 
pain 
experienced 
A$ 2-5µM 5-15 m/s ++ 
Skin surface, 
muscles, 
joints 
Rapid, 
severe, 
localised 
A/#% 5-20µM 70-120 m/s +++ Spinal cord 
Cutaneous 
touch and 
pressure 
C <2µM 0.5-2 m/s - All tissues 
Slow, diffuse, 
dull, aching 
Table 2 - A comparison of the different types of nociceptors. 
 
As a consequence of these differences, pain is often felt in two distinct phases. The 
first pain is mediated by A$ fibres, is of rapid onset, well localised and sharp in 
nature. Subsequently, this first pain gives way to a second pain, which is diffuse in 
nature and characterised by a dull sensation. The critical difference between 
cutaneous (somatic) and visceral nociceptors is the stimulus that induces their 
activation. For instance, cutting or burning may activate cutaneous nociceptors, yet 
visceral nociceptors are not activated by these stimuli. Conversely, visceral 
nociceptors are activated by distension, ischaemia or mesenteric traction. High 
threshold nociceptors respond to mechanical stimuli in the noxious range, whereas 
low threshold receptors encode stimulus intensity in the magnitude of their 
discharge from the innocuous (physiological) to the noxious range. High threshold 
receptors exclusively innervate organs from which pain is the only conscious 
sensation, such as the heart and kidneys. 
 
1.19.2 Intrinsic Sensory Innervation – the Enteric Nervous System 
The ENS is situated within the wall of the GI tract. It comprises two neural plexi 
that extend throughout its length. The myenteric (Auerbach's) plexus lies between 
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the longitudinal and smooth muscle layers. The submucosal (Meissner's) plexus is 
found between the circular smooth muscle layer and the mucosa. These plexi have 
an intricate system of inter-neurons and interconnecting neurones that connect 
ganglia with each other and with the other plexi. These networks have functional 
heterogeneity and structural complexity akin to that observed in the CNS. Their 
main functions are in the local regulation of motility, mucosal transport, blood flow 
and luminal secretion. Motor neurones located within the ganglia of the ENS 
coordinate and regulate these functions from inputs supplied by local sensory 
neurones, although they also receive inputs from the CNS via the ANS. 
 
 
 
Figure 3 - The association of the myenteric (Auerbach’s) and submucosal (Meissner’s) plexi within 
the GI tract, adapted from Barrett, GI Physiology, 2006 [95]. 
  
1.19.3 Extrinsic Sensory Innervation 
The GI tract has a dual sensory innervation from the CNS. Visceral afferents 
project to the CNS via the vagus nerve to the brainstem (vagal afferents) or 
through splanchnic nerves to the spinal cord (spinal afferents).  
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1.19.3.1 Vagal Afferent Neurones 
The vagus nerve innervates a large portion of the viscera, hence the origins of its 
name meaning, “wandering.” The vagus nerve innervates the whole of the GI tract 
apart from the distal third of the colon [96]. Between 70-90% of these afferents are 
unmyelinated C-fibres, with their cell bodies located in the nodose ganglia, which lie 
in close proximity to the jugular foramen, with the notable exception of afferents 
arising from the oesophagus, which lie more proximally in the jugular ganglia. 
Around 85% of the fibres that comprise the vagus nerve are afferent and project 
viscerotopically to the nucleus of the solitary tract (see Table 3). 
 
Rostrocaudal viscerotopic 
organisation of the Nucleus of the 
Solitary Tract 
Afferents 
Rostral third Oral and pharyngeal visceral afferents 
Middle third Oesophageal, gastric and intestinal 
afferents 
Caudal third Baroreceptors, cardiac and respiratory 
afferents 
Table 3 - Rostrocaudal organisation of the afferent input to the nucleus of the solitary tract. 
 
Second-order neurones project from the nucleus of the solitary tract to sites in the 
brainstem, hypothalamus and amygdala. Cortical projections from the brainstem 
include the orbitofrontal, anterior cingulate and insula cortex and on to the 
secondary somatosensory cortices. Vagal afferents are believed to mediate non-
noxious physiological sensations such as satiety due to their low response 
thresholds [96]. However, recent data has suggested a more complex role for vagal 
afferents in the mediation of nociception. 
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1.19.3.2 Vagal Anti-nociception 
Recent work by Chen et al. has provided evidence that sub-diaphragmatic vagal 
afferents may modulate visceral pain through central inhibition [97]. In this study, 
visceromotor responses from the anterior abdominal wall were measured in 
response to graded colorectal distension in rats, following bilateral 
subdiaphragmatic vagotomy. It was demonstrated that, following vagotomy, 
visceromotor responses were enhanced to all grades of colorectal distension. 
Evidence for the role of vagal afferents in (anti) nociception emanates from 
observations that the stimulation of cervical vagal afferents inhibits the 
responsiveness of spinothalamic neurones to noxious stimuli, possibly through 
engagement and recruitment of the opioidergic system [98, 99]. These observations 
may have particular salience to the data that will be presented in Chapters 3 and 6, 
also see section 2.8. 
 
1.19.3.3 Vagal Afferent Receptor Types 
Vagal afferents contain three types of receptors, namely mucosal, tension and 
polymodal. Mucosal receptors are silent but are activated by chemokines and 
inflammatory mediators in response to inflammation, and display a degree of 
mechanosensitivity [100]. Tension receptors are mechanosensitive, exhibiting a 
linear response to wall tension in the physiological range [101]. They convey 
important physiological information regarding motility to the CNS. Finally, 
polymodal receptors have features in common with mucosal and tension receptors. 
Their role is thought to be involved in the detection of rapid movement of boluses 
in the oesophagus [102]. 
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1.19.4 Spinal Afferent Neurones 
Spinal afferents project from the visceral organs, via their cell bodies in the DRG, to 
the splanchnic nerves and onwards to the sacral, lumbar and thoracic spinal cord. 
They constitute 5-10% of all afferents input into the thoracic and lumber roots of 
the spinal cord, with the majority of these traversing the pre- and paravertebral 
ganglia en route [100]. Spinal afferents are contained in the cardiac and splanchnic 
nerves and pass through the white rami to join with the spinal nerves before 
entering the DRG. The oesophagus is innervated craniocaudally by afferents from 
the DRG, located from the first cervical to the third lumbar level. In similarity to 
vagal afferents, the various types of spinal afferents are located in different layers of 
the wall of the GI tract. Tonic mechanoreceptors have tonic basal activity and 
respond linearly to wall tension, thus suggesting that their function may concern 
satiety signalling in organs such as the stomach and colon [103]. In addition, they 
are also believed to signal noxious distension stimuli, and due to these broad 
response characteristics are often known as wide dynamic range 
mechanoreceptors. High threshold mechanoreceptors have low basal activity, only 
respond to the distension stimuli of noxious intensity and are chemosensitive [96]. 
Silent nociceptors are inactive at rest, but respond to chemical and mechanical 
stimuli in the presence of inflammation. Finally, mucosal receptors have 
characteristics similar to those previously described for vagal mucosal afferents, and 
respond to chemical stimuli within the GI tract [95]. Figure 4 shows a schematic 
representation of the different types of afferent neurones that innervate the GI 
tract. 
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Figure 4 - The different types of sensory neurons innervating the GI tract by intrinsic and extrinsic 
afferents. These include two populations of intrinsic sensory neurones that originate in the 
submucosal plexus (SMP) and myenteric plexus (MP) of the ENS, namely vagal afferents from the 
nodose ganglion and spinal afferents from the DRG. CM = circular muscle, LM = longitudinal 
muscle, NG = nodose ganglion. From Holzer, GI afferents as targets for novel drugs for the 
treatment of functional bowel disorders, European Journal of Pharmacology 2001 [104]. 
 
 
1.19.5 Spinal Pain Processing  
From the cell bodies in the DRG, spinal visceral afferents enter the spinal cord and 
ascend, or descend, one or two spinal levels in the dorsolateral fasciculus† before 
terminating in the grey matter. Second-order neurones have their cell bodies in the 
                                            
† The dorsolateral fasiciculus is also known as Lissauer’s tract, named after the German neurologist 
Heinrich Lissauer (1861 - 1891), who was the student of Carl Wernicke. 
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dorsal horn and relay information to the brain through a number of ascending 
pathways. 
 
1.19.6 The Dorsal Horn of the Spinal Cord 
Central pathways for nociceptive processing commence at the level of the dorsal 
horn of the spinal cord. Projections from the spinal afferents terminate mainly in 
laminae I and V, where they are organised in a segmental manner over several 
spinal segments‡, possibly accounting for the poor localisation of visceral pain 
observed in clinical practice (see Figure 5). For instance, oesophageal sensation is 
represented in the cervical, thoracic and lumbar regions, and is of particular 
relevance to the studies contained herein. Visceral and spinal (somatosensory) 
afferents enter the spinal cord in close proximity, possibly explaining the 
phenomenon of viscerosomatic convergence, whereby visceral pain is often 
referred to nearby somatic structures, e.g. right shoulder tip pain as a consequence 
of cholecystitis.  
                                            
‡ Rexed divided the spinal grey matter into a series of 10 laminae in four regions – the dorsal horn 
(L1-V1), the intermediate zone (LVII), the ventral horn (LVII & IX) and the central canal (LX). 
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Figure 5 - Schematic representation of the viscerotopic distribution of spinal afferent fibre 
innervation of the GI tract. The bars represent peak distributions (dark shade) and ranges (white) 
shown for each visceral organ. E = oesophagus. From Bertould et al, Neuroanatomy of extrinsic 
afferents supplying the GI tract [100]. 
 
Complex inter-neuronal networks in the dorsal horn not only transmit nociceptive 
information to the brain, but also play a central role in the modulation of 
descending control from higher centres, through the modulation of synaptic 
function. 
 
1.19.7 Ascending Spinal Pathways 
The anterior lateral and posterior tract convey sensory information to the 
supraspinal structures. These are summarised in Figure 6.  
 
1.19.7.1 The Anterior Lateral System 
The anterior lateral system comprises the spinothalamic, spinorecticular, 
spinomesencepahlic and spinolimbic tracts. The spinothalamic tract projects to the 
thalamus, and third-order thalamocortical fibres subsequently project to the 
somatosensory, insula and medial prefrontal cortices. They mediate sensations such 
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as pain, cold, warmth and touch and are of particular importance in sensory 
discrimination and the localisation of visceral and somatic stimuli. The 
spinorecticular tract transmits sensory information, particularly reflexive and 
affective-motivational components, to the reticular formation in the brainstem and 
onwards to the thalamus, PfC and ACC. The spinomescencephalic tract projects to 
various regions of the brain including the PAG, locus coeruleus and the medulla. 
Finally, the spinolimbic tract projects to areas such as the amygdala, thalamus, 
hypothalamus and other limbic structures, and is thought to be important in 
mediating the motivational dimension of the pain experience [105]. 
 
1.19.7.2 The Posterior System 
The posterior system consists of three synapsing tracts – first-order dorsal column 
neurones, the post-synaptic dorsal column pathway via the fasciculus gracilis to the 
nucleus gracilis and the spinocervical tract to the thalamus. Although not thought to 
convey nociceptive information, animal models in which lesions are placed in the 
posterior system have been shown to attenuate responsiveness to colorectal 
distension [106]. 
 71 
 
Figure 6 – The main central pathways conveying visceral sensation, consisting of the anterior (black 
line) and posterior (red line) systems, to supraspinal structures. Adapted from Knowles and Aziz, 
Basic and Clinical Aspects of Gastrointestinal Pain, Pain 2009 [96]. 
 
1.19.8 Visceral Pain Processing within the Brain 
Recent advances in functional neuro-imaging such as fMRI, MEG and positron 
emission tomography have facilitated great advances in the understanding of the 
complex subcortical and cortical interactions that comprise the “visceral pain 
neuromatrix.”  
 
1.19.8.1 The Thalamus 
The thalamus is located in the dorsal portion of the brainstem and comprises 50-60 
nuclei arranged in six groups in each hemisphere. The thalamus receives ascending 
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nociceptive information from both the anterior lateral system and the posterior 
system, and can be regarded as a relay centre supporting a number of diverse 
functions including sensation and motor function and other cognitive processes 
such as language [107]. In particular, projections from the lateral thalamic nuclei are 
believed to mediate the sensory discriminatory aspects of pain perception, in 
contrast to those from the medial thalamic nuclei, which mediate affective and 
motivational aspects [106]. 
 
1.19.8.2 The Cerebral Cortex 
1.19.8.2.1 The Primary and Secondary Somatosensory Cortices 
The primary (SI) and secondary (SII) somatosensory cortices process non-noxious 
somatosensory information, such as pressure and warmth, in addition to noxious 
stimuli, receiving input from the ventro-posterior lateral nuclei of the thalamus. SI 
and SII facilitate the modulation of motor activity in response to these stimuli. 
Neurones from both areas are thought to encode the sensory discriminative aspect 
of nociceptive processing, with SII involved in the recognition and cognitive-
evaluative aspects of the pain experience [108].  
 
1.19.8.2.2 The Insula 
The insula (or insular cortex) has a number of roles including interoceptive 
awareness and emotion. It receives projections from SII and the ventro-posterior 
medial nucleus of the thalamus, and has been shown to be activated by visceral 
stimuli [109]. Of particular note are not only thalamic interactions with the ANS in 
mediating homeostatic processes, but also its ability to generate an afferent 
response through its sympathetic and parasympathetic branches.  
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1.19.8.2.3 The Cingulate Cortex 
The cingulate cortex, consisting of the anterior, medial and posterior divisions, is an 
extensive area of the limbic system [110]. There is growing evidence surrounding 
the role of the ACC in the processing of visceral and somatic sensation [111]. The 
perigenual ACC has functional connections with the brainstem autonomic nuclei, 
and is involved in visceromotor control and the modulation of autonomic and 
emotional responses to aversive stimuli [112]. For instance, in patients who have 
had therapeutic bilateral cingulotomy, there is a reduction in the affective and 
intensity ratings of noxious heat and cold stimuli, thus providing experimental 
support for the role of the cingulate cortex in the perception of innocuous and 
noxious thermal stimuli [113].  
 
1.19.8.2.4 The Amygdala 
The amygdala also forms part of the limbic system and plays a central role in 
emotion and emotional reactivity [114]. Experimental evidence, recently reviewed 
by Benarroch, suggests that the amygdala modulates nociception by providing the 
link between pain and emotion [115]. Sensory information is conveyed from the 
amygdala to the lateral and basolateral nuclei from the thalamus, ACC and the 
insula. The central nucleus of the amygdala, also known as the nociceptive amygdala, 
has widespread connections with forebrain areas, the thalamus, hypothalamus and 
brainstem. Thus, output from the amygdala may mediate a range of nociceptive 
modulating responses given its diverse connections with brain areas involved in 
attention, cognition, fear and stress responsiveness.  
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1.19.8.2.5 The Prefrontal Cortex 
Activation of the PfC is commonly observed in imaging studies in response to 
visceral and somatic stimulation, but its exact role remains uncertain [116]. Studies 
have demonstrated that activation of the PfC is not linearly associated with the 
magnitude of a noxious stimulus, suggesting its role is concerned with general 
stimulus detection [117]. As Derbyshire comments, in his excellent review paper 
concerning the imaging of visceral pain, “...the PfC is involved in the regulation and 
organization of behaviour and cognition....”; it is therefore likely that the PfC has a role 
in stimulus detection and modification of behaviour in response to visceral pain 
[116].  
 
1.19.8.3 Overall Remarks Concerning Central Visceral Pain Processing 
Functional imaging studies using visceral and somatic stimuli have demonstrated that 
a large number of distinct brain regions are involved in the processing of visceral 
and somatic sensation. Presumably, the different regions capture different 
dimensions of visceral and somatic sensory experience. The greater involvement of 
the cingulate cortex during visceral stimulation, relative to somatic stimulation, 
could explain the greater affective responses that are observed to experimental 
visceral stimuli. 
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Figure 7 - Schematic of the ascending pathways, subcortical structures, and cerebral cortical 
structures involved in processing pain. PAG, periaqueductal gray; PB, parabrachial nucleus of the 
dorsolateral pons; VMpo, ventromedial part of the posterior nuclear complex; MDvc, ventrocaudal 
part of the medial dorsal nucleus; VPL, ventroposterior lateral nucleus; ACC, ACC; PCC, posterior 
cingulate cortex; HT, hypothalamus; S-1 and S-2, first and second somatosensory cortical areas; 
PPC, posterior parietal complex; SMA, supplementary motor area; AMYG, amygdala; PF, pre-frontal 
cortex. Adapted from: Price, Psychological and neural mechanisms of the affective dimension of 
pain, Science, 2000 [118]. 
 
1.20  Modulatory Influences on Visceral Pain 
A large body of evidence posits that visceral pain can be modulated by extra-
nociceptive neuronal and non-neuronal factors. In the following sections I will 
introduce the modulatory influences on visceral pain that are of particular salience 
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to this thesis, namely stress and personality, descending spinal pathways, the ANS, 
the hypothalamic-pituitary adrenal axis and genetic factors.  
 
1.20.1 Stress and Personality (Psychological) Influences 
In many ways, the idea that personality may modulate pain is not in the least 
surprising. There is an abundance of evidence in the literature that both acute 
stress and psychological traits influence visceral and somatic pain. It has been well 
characterised in many disorders of chronic pain, including FGID, that affective 
disorders are over-represented in patient populations [119, 120]. The link between 
negative emotion and visceral sensation has been well demonstrated in humans. For 
example, when anxiety is induced by mental stress, there is an increase in the 
subjective pain and unpleasantness reported to colorectal balloon distension [121]. 
A recent study has provided evidence that the altered central processing of visceral 
pain in IBS may be, in part, mediated by excess anxiety and depression observed in 
such patients through differences in the affective motivational aspects of central 
nociceptive processing [74]. Potentially, these differences may be mediated through 
differential activation of the insula and ACC [69]. Evidence from a number of 
functional neuroimaging studies has suggested that differences in the affective-
motivational components between visceral and somatic pain may be accounted for 
by preferential activation of the insula and ACC. However, more recently, Dunkley 
et al. demonstrated that when unpleasantness of the experimental noxious stimuli is 
controlled for, these differences are less evident [122].  
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1.20.2 Descending Spinal Pathways & Diffuse Noxious Inhibitory Control 
Descending pathways from supraspinal centres can modulate the pain experience, 
through either facilitation or inhibition. At the cortical level, the ACC is an 
important source of descending modulation through its projections to the amygdala 
and PAG matter. A distinct pain modulating system involves a spino-bulbar spinal 
pathway where activity of wide dynamic range nociceptive spinal neurones is 
inhibited by a second, anatomically distinct, stimulus. This system is termed diffuse 
noxious inhibitory control (DNIC). This system is considered to be the biological 
basis of counter-irritation induced analgesia. DNIC can be assessed experimentally, 
using heterotopic stimulation, for instance using rectal distension and the cold 
pressor test [123]. DNIC has been shown to be abnormal in patients with FM and 
IBS [124, 125].  
 
1.20.3 The Autonomic Nervous System 
The ANS is a hierarchically controlled, bi-directional brain-body interface that 
integrates afferent inputs and central motor output for homeostatic processes. The 
ENS is considered by many authorities to be a further extension of the effector 
pathways of the ANS [100]. Sympathetically mediated mechanisms have been 
implicated in the pathophysiology, and nomenclature, of several chronic pain 
syndromes [126]. Furthermore, there is accumulating evidence of the role of vagally 
mediated inhibition of visceral nociception [127]. Iovino et al. evaluated the ability 
of the ANS to modulate visceral sensation by inducing sympathetic tone, using 
negative pressure to induce venous pooling, in response to visceral distension 
[128]. It was found that increasing sympathetic tone heightened the perception of 
visceral, but not somatic, stimuli. The mechanisms by which the ANS may modulate 
pain are incompletely understood. The pro-nociceptive actions of the SNS may 
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relate to the release of catecholamines and prostaglandins, which in turn may 
activate afferent fibres [129]. The mechanism of action of vagally mediated analgesia 
remains uncertain, with many hypotheses being proposed – the most reproduced of 
which concerns interactions with the cannabinoid system at the level of the 
brainstem, which may have important therapeutic implications for the future [130, 
131].  
 
1.20.4 Vagal Tone and the Polyvagal Theory 
The vagus nerve has two distinct brainstem nuclei, which are thought to have 
complementary but distinct regulatory actions. As mentioned in section 1.19.3.1 
(see page 64), the vagus nerve is primarily a sensory nerve, innervating a 
considerable proportion of the viscera, with the ultimate destination of the afferent 
vagus being the nucleus of the solitary tract. The efferent vagus has two motor 
nuclei; the NA and the DMNx. The NA gives rise to myelinated fast-effector 
neurones that innervate the heart, larynx and upper gut, and modulates vagal tone. 
In contrast, the DMNx of the vagus gives rise to unmyelinated slow effector 
neurones that innervate the heart and lower gut.  
 
Output from the NA allows subtle alterations in vagal tone which may be involved 
in behavioural inhibition and bonding. The withdrawal of vagal tone reduces the 
external constraint on intrinsic sino-atrial node automaticity, which allows the HR 
to increase rapidly and facilitate behavioural activation. Conversely, output from the 
DMNx results in a profound bradycardia, akin to an “emergency stop” in driving, 
which occurs in immobilisation behaviours such as death feigning and passive 
avoidance and is considered a primitive defence response; these differences are 
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summarised in Figure 8. It is these differing outputs that are the basis of the 
“Polyvagal Theory” proposed by Porges [132]. Polyvagal theory provides evidence for 
the hierarchical and phylogenetic development of the cardiac vagal complex in the 
brainstem, comprising outputs from the NA and DMNx, which facilitate increasingly 
complex behavioural patterns. Porges suggests that the dual vagal efferent output 
from the brainstem may serve a number of phylogenetic purposes:   
& By allowing the organism to engage in social interactions quickly, by 
alterations in behaviour through rapid, yet subtle, activation of the NA.  
& As a profound defence response through activation of the DMNx. 
 
Figure 8 – A summary of the efferent vagal outputs from the brainstem in facilitating behavioural 
processes. CVC is equivalent to CVT. 
 
In humans, it is not possible to non-invasively measure these different components 
of vagal tone, at least not with current technology. However, evidence has 
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demonstrated the importance of vagal tone in facilitating behaviour and self-
regulation. For example, children with higher vagal tone have been shown to have 
greater emotional expression to negative mood induction and lower rates of 
affective disorders in adulthood [133]. In adults, a low baseline vagal tone predicts a 
negative emotional response to mental stress [134]. In clinical populations, vagal 
tone has been shown to modify behaviour, e.g. patients with generalised anxiety 
disorder exhibit lower resting vagal tone and an inability to suppress it in response 
to stress [64, 135]. 
  
1.20.5 Hypothalamic Pituitary Adrenal Axis 
The HPA axis is a major part of the neuroendocrine system and plays a pivotal role 
in facilitating the body’s response to stress. It affects a complex series of direct 
influences and feedback interactions between the hypothalamus, the pituitary and 
the adrenal glands. One of its major functions is the orchestration of the adaptation 
responses to stress, in that it regulates many body processes including digestion, 
the immune system, mood, sexuality and energy storage and expenditure.  
 
Adrenal glucocorticoid secretion is regulated by pituitary secretion of the adreno-
corticotrophic hormone (ACTH), which is in turn under the control of two 
secretagogues, corticotrophin-releasing hormones (CRH) and arginine vasopressin 
(AVP). These are released into the pituitary portal blood from cells in the 
hypothalamic paraventricular nucleus. AVP is a potent synergistic factor with CRH 
in stimulating ACTH secretion, although it has little ACTH secretagogue activity 
per se [136].  
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In a non-stressful situation, HPA axis activity is characterised by diurnal pulsatile 
variations in activity, which peak during the morning [137]. Under these conditions, 
the amplitude of CRH and AVP pulses increases in the early hours of the morning, 
resulting in an increase in ACTH and cortisol secretion into the general circulation. 
During stress, both the synchronisation and amplitude of CRH and AVP increase, 
resulting in increases of ACTH and, subsequently, cortisol. Contingent to the 
magnitude and duration of the stress, other factors such as angiotensin II, cytokines 
and other inflammatory mediators may potentiate this activity [138].  
 
Cortisol is a glucocorticoid that is synthesised in the zona fasciculata of the adrenal 
cortex and exerts its effects through its ubiquitous cytoplasmic receptors. It is 
released in response to ACTH and plays a pivotal role in the regulation of most 
essential physiological processes. For instance, cortisol influences energy 
metabolism, maintenance of electrolyte balance, BP, immune modulation, stress 
responses and cell proliferation. In addition, it regulates memory and cognitive 
functions through its interactions with the limbic dopaminergic system and the 
amygdala, thereby influencing mood, anxiety levels and the formation of memories 
[139]. Therefore, considering the central influences of the HPA axis are very similar 
to those involved in the processing of nociception, it is not surprising that it can 
modulate pain responses. 
 
Dysfunction of the HPA axis has been recognised in a number of chronic pain 
syndromes including FGID [140]. In a study by Dinan et al., the HPA axis was 
examined in a group of 76 IBS patients and 75 healthy controls. It was found that, in 
the IBS group, irrespective of IBS sub-type, there was over-activity on the HPA axis 
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and an excess of the pro-inflammatory cytokines interleukin (IL)-6 and IL-8.84 
Interestingly, the former has been proposed recently as a potential measurable 
index of pain severity [141, 142].  
 
Corticotrophin releasing factor (CRF) is considered central in the coordination of 
the stress response through its influences on autonomic, emotional and 
immunological pathways. Its release is particularly dependent on inputs from the 
limbic system, an area that I have already highlighted as important in nociceptive 
processing. CRF is up-regulated in response to intestinal inflammation, stress and 
psychopathologies such as anxiety and depression, and has recently been shown to 
mediate enhanced visceral nociception in a rat model of VH [143]. In humans, Nozu 
and Kudaira have shown that CRF may induce rectal hypersensitivity in response to 
repeated rectal distension in a cohort of healthy volunteers [144]. Furthermore, 
recent data from Larauche et al. demonstrates that CRF receptor subtype 1 
(CRF(1)) plays an important role in the development and maintenance of 
hypersensitivity to visceral distension [145]. Thus, CRF(1) antagonists represent a 
novel target for drug development as they may prevent, or reduce, the 
development and maintenance of visceral hypersensitivity [146].  
 
1.20.6 Genetic Influences 
The modulation of visceral pain perception appears to be at least partially 
determined by genetic inheritance. In clinical and healthy populations it has long 
been noted that some individuals are more sensitive to pain than others – in a 
similar manner as the response to analgesic medications. Genetic variability 
contributes to the determination of an individual’s biological traits, the phenotype. 
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This genetic influence on the phenotype is variably expressed through variations in 
the pattern and quantity of protein transcription. The environment has a significant 
impact on this protein transcription and therefore, ultimately, cell function. Perhaps 
some of the most exciting insights that genetic science has permitted in the study of 
pain biology have been the identification of rare mutations of the sodium channel 
gene SCN9A that encodes the sodium channel Nav1.7. Gain of function mis-sense 
mutations have been found to cause primary erythermalgia and paroxysmal 
extreme pain disorder, whereas non-sense mutations result in loss of function 
leading to conditions known as channelopathy-associated insensitivity to pain [147]. 
Whilst these observations provide novel insights into nociceptive physiology how 
they may relate to functional pain syndromes is unclear. It is unlikely that a single 
gene mutation will be identified to explain these disorders due to their high 
prevalence across different human populations. 
 
1.20.7 Overall Remarks Concerning the Modulation of Visceral Pain Perception 
The neurobiology of visceral pain is complex, yet there are many interrelated 
biological systems that may influence and modulate the perception of visceral pain. 
Within the FGID literature, aberrancies within these biological systems have been 
implicated in their pathophysiology. Figure 9 shows a schematic representation of a 
selection of these modulatory pathways. 
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Figure 9 - A schematic representation of the modulatory influences on the perception of visceral 
pain. Adapted from Goodhand J & Rampton DS, Psychological Stress and Coping in IBD, Gut 2008 
[148]. 
 
1.21 Visceral Hypersensitivity 
Many hypotheses have been proposed to explain the origin of symptoms in FGID, 
but no single factor has achieved primacy in the literature, largely because of the 
heterogeneity of these disorders. However, a common feature of FGID is that 
patients often display a heightened sensitivity to experimental gut stimulation, which 
is termed VH. This observation has spawned a large research effort from academia 
and the pharmaceutical industry alike in identifying the molecular mechanisms that 
are responsible for this epiphenomenon. Chronic episodic abdominal pain and 
discomfort cause appreciable morbidity in FGID and are integral components of the 
diagnostic criteria of these disorders. It has been 35 years since Ritchie – and 
subsequently others – demonstrated that a proportion of patients with FGID 
display elevated pain sensitivity to experimental gut distension – VH [149, 150, 151, 
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152]. Whether these observed alterations in visceral sensitivity are part of a global 
phenomenon of generalised sensory dysfunction is controversial [153, 154, 155, 
156]. Therefore, the putative pathophysiology of VH may be conceptualised as 
being due to aberrant processes that may arise at any level of the visceral 
nociceptive pathway.  
 
1.21.1 Peripheral Visceral Nociceptive Afferent Pathways  
Noxious stimuli may cause the peripheral release of several inflammatory mediators 
such as K+, H+, adenosine triphosphate, 5-hydroxytryptamine (5-HT), bradykinins 
and prostaglandins [157, 158], which may elicit a number of effects including the 
activation and peripheral sensitisation (PS) of nociceptive afferent nerves by 
reducing their transduction thresholds and by inducing the expression and 
recruitment of previously silent nociceptors. The main consequence of these 
inflammatory mediators is an increase in pain sensitivity at the site of injury, known 
as primary hyperalgesia [159]. A number of ion channels, neurotransmitter 
receptors and trophic factors have been implicated in the development of PS. 
Whilst it is beyond the scope of this thesis chapter to examine all of the possible 
mechanisms previously studied in the literature, I will highlight some of the more 
important advances in our understanding of the molecular mechanisms of PS: the 
transient receptor potential vallinoid receptors (TRPV) 1 & 4, the protease 
activated receptor 2 (PAR(2)), NO (NO) pathways, mast cells, enterochromaffin 
(EC) cells, 5-HT pathways and voltage gated sodium channels (VGSCs).  
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1.21.1.1 Transient Receptor Potential Vallinoid Receptors and Protease 
Activated Receptors  
TRPV1 and 4 are members of a larger family of TRPV channels that serve many 
sensory functions ranging from hearing to mechanosensory transduction [160, 161]. 
The TRPV1 receptor may be activated by heat as well as exogenous ligands such as 
capsaicin and its analogues, and is thought to play an important role in 
mechanotransduction in the GI tract and to the development and maintenance of 
VH[160, 162]. A recent study by Akbar et al. showed that there was a 3.5-fold 
increase in the density of TRPV1 immunoreactive fibres in the colonic biopsies of 
patients with IBS when compared to healthy controls [163]. Furthermore, in rat 
models, TRPV1 receptor antagonists have been found to ameliorate VH [164]. Early 
results from human studies evaluating this novel class of analgesic have yielded 
promising results [165, 166]. TRVP4 is a mechanotransductive osmosensitive 
channel that has been recently associated with VH [167]. Further evidence for 
TRPV4’s role in VH comes from an elegant study recently reported by Cenac et al., 
where a TRPV4 agonist induced VH in response to colorectal distension in mice, 
although this effect was lost in TRPV4-/- knockouts [168]. The TRPV4 receptor 
closely interacts with PAR(2), which is expressed by nociceptive neurons in the gut, 
and agonists of PAR(2) have been found to cause hyperexcitability of intestinal 
sensory neurons [169]. PAR(2) may be preferentially activated during inflammation 
by serine proteases, which have been found in increased quantities in colonic 
mucosal biopsies in patients with IBS [170]. Inhibition of serine proteases in vitro 
reduces sensory afferent nerve discharge, thereby possibly preventing TRPV4 and 
PAR(2) sensitisation [171]. TRPV4 may present a particularly exciting potential 
therapeutic target for the future, owing to its preferential distribution within the 
colon [167].  
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1.21.1.2 The Nitric Oxide Pathway 
Three NO synthase isoforms (inducible, neurogenic and endothelial) catalyse the 
formation of endogenous NO. Inducible (NOS2) and neurogenic NO (NOS1) are 
ubiquitously present within the nervous system and the endothelium, and 
endogenous NO may modulate the efficacy and tolerability of opioid analgesics 
[172]. The NO pathway also aids in the regulation of GI motility and mucosal 
integrity [173]. Lithium, widely used in the treatment of bipolar disorder, mediates 
some of its actions through the NO pathway, and it has been recently shown by 
Shamshiri et al. that chronic lithium administration attenuates sensitivity to colonic 
distension, increasing nociceptive thresholds and decreasing stool frequency in a VH 
rat model [174]. 
 
1.21.1.3 Mast Cells, Enterochromaffin Cells and 5-Hydroxytriptamine 
Up to 20% of patients with IBS report that their symptoms are initiated following an 
episode of acute infection, which may be GI or non-GI; a phenomenon known as 
post-infectious IBS (PI-IBS)[175]. In this group, increased numbers of EC cells, mast 
cells and T-lymphocytes may be observed in the lamina propria of colonic biopsies, 
suggesting the presence of a low-grade inflammatory infiltrate [176]. Piche et al. 
have shown that the degree of mast cell infiltration is positively associated with the 
degree of fatigue and depression in IBS patients [177]. Mast cells, per se, have been 
shown not to modulate visceral nociception, but are nevertheless essential in the 
development of VH; in mast cell deficient rats, the development of VH can be 
ameliorated with mast cell stabilisers in a dose-dependent manner [178, 179]. 
Interestingly, treatment with a mast cell stabiliser, disodium cromoglycate, in 
conjunction with exclusion diets may be of some symptomatic benefit in a small 
percentage of patients with diarrhoea predominant IBS [180]. However, there is 
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little evidence to suggest that anti-inflammatory medications per se are useful in the 
treatment of IBS possible be due to this disorder not being a purely as a sequelae of 
inflammation. EC and mast cells contain 5-HT, one of the major neurotransmitters 
of the ENS, which is involved in signal transduction of visceral stimuli, in addition to 
effecting changes in GI motility [181]. Increases in 5-HT bioavailability, through 
increased availability and reduced uptake, have been observed in models of post-
inflammatory VH and may manifest as changes in gut sensorimotor function. 
Pharmacotherapeutic interventions directed towards the 5-HT pathway, most 
notably 5-HT3 antagonists, 5-HT4 agonists and most recently 5-HT1A antagonists, 
have had, at best, only a modest effect in the modulation of visceral pain, and the 
restoration of abnormal bowel habit to normal is due to mainly a series of adverse 
events and concerns over safety [182, 183, 184].  
 
1.21.1.4 Voltage Gated Sodium Channels 
VGSCs are pivotal in nerve impulse conduction and are targets for clinically 
important analgesics such as lignocaine. Data from the last decade has shown that 
certain VGSC isoforms (Nav1.3-1.9) are predominantly expressed in peripheral 
sensory afferent neurones, and that the expression and functional properties of 
these isoforms can be dynamically regulated in vivo in response to axonal injury or 
inflammation and may play an important role in the generation of PS [185].  
 
1.21.2 Central Sensitisation 
However, sensitisation is not solely confined to the periphery. When a noxious 
stimuli is transmitted from the periphery, it induces a constellation of changes at 
the spinal dorsal horn by the activation of intracellular signalling cascades 
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(comprehensively reviewed by Anand et al. [186]). This may lead to CS (CS) and 
amplification of the nociceptive response to the stimuli (secondary hyperalgesia), 
and previously innocuous stimuli may provoke a nociceptive response (allodynia). 
Whilst these observations have been long recognised in somatic pain, increasingly 
CS is thought to play a central role in the development and maintenance of VH 
[153, 187]. In a landmark paper, Sarkar et al. demonstrated the concept of CS in a 
reproducible oesophageal model in humans, in which hydrochloric acid was infused 
into the healthy distal oesophagus [153]. Pain thresholds were not only reduced in 
the acid-exposed distal region, but also in the adjacent proximal unexposed region. 
This effect of CS was prolonged, lasting up to five hours after 30 minutes of acid 
exposure, suggesting that the duration and magnitude of CS of the non-exposed 
proximal oesophagus was related directly to the intensity of acid exposure in the 
distal oesophagus (see Figure 10).  
 
Figure 10 – The effects of distal oesophageal acidification on proximal oesophageal and chest wall 
pain thresholds to electrical stimulation, from Sarkar et al., Contribution of CS to the development 
of NCCP, Lancet 2000 [153]. 
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Prostaglandin E2 (PGE2) and the n-methyl d-aspartate (NMDA) receptor have been 
elucidated as the most important molecular factors in the development of CS at the 
spinal dorsal horn [188]. Human pharmacological studies have demonstrated that 
antagonism of the PGE2 or the NMDA receptor prevents the development of CS 
within the oesophagus, and antagonism of the NMDA receptor with ketamine may 
even reverse established VH [189, 190]. CS may also occur after a noxious stimulus 
is applied to an anatomically distant site. For instance, oesophageal sensitisation may 
occur after a noxious stimulus is applied to the duodenum and balloon distension in 
the left colon may result in rectal sensitisation [191, 192]. In patients with IBS, 
following repetitive distension of the sigmoid colon, CS may ensue as manifested by 
rectal hyperalgesia and increased viscerosomatic referral to experimental rectal 
distension [193]. 
 
1.21.3 Overall Remarks Concerning Visceral Hypersensitivity 
The clinical observation that patients with FGID may be hypersensitive to 
experimental visceral stimulation has had a considerable influence on the direction 
of research in the field for the last three decades. This research has implicated 
many putative candidates, which Figure 11 aims to summarise. This breadth of 
knowledge has been achieved through convergent and complementary research 
strategies from a number of academic disciplines that include 
neurogastroenterology, molecular pharmacology, neurophysiology and psychology, 
to name but a few. However, if the scientific community is to further unravel the 
mysteries of VH in FGID, we need to adopt a tailored, individualistic approach by 
characterising our patients in terms of their clinical phenotype, genetics and visceral 
nociceptive physiology. It is these assertions in particular that underpin much of the 
work contained herein.  
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Figure 11 - A summary of the factors that have been implicated in the development and 
maintenance of VH. Adapted from Farmer and Aziz, Visceral Pain Hypersensitivity in Functional 
Gastrointestinal Disorders, British Medical Bulletin 2009 [194].  
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Chapter 2 - Methods 
2 General Methods 
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2.1 Chapter Overview 
In aiming to identify and characterise human pain phenotypes, it was necessary to 
utilise a number of seemingly different, yet complementary, neuroscientific 
methods. In this chapter I shall provide a general overview of the methods used in 
this thesis.  
 
I sought to define pain phenotypes based on genotype, personality traits, ANS and 
HPA axis responses to visceral and somatic pain. In assessing personality traits, a 
number of self-reported questionnaires were used, which included the Big-Five 
Inventory (BFI), Eysenck’s Personality Questionnaire (EPQ-R), Spielberger’s State 
and Trait Anxiety Inventory (STAI-S) (STAI-T), the Weinberger Adjustment 
Inventory (WAI) and the Hospital Anxiety Depression Scale (HADS). Somatic and 
visceral pain were induced by nail bed pressure and by mid-oesophageal balloon 
distension respectively. Real time non-invasive brainstem ANS responses to pain 
were measured using the Neuroscope biosignals acquisition system. HPA axis 
responses to pain were measured using standard total serum cortisol assays. 
Genotyping of the 5-HT long polymorphic region (5-HTTLPR) was undertaken 
using sequence-specific polymerase chain reactions (SSP-PCR).  
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2.2 Psychological Trait Measures 
Personality has been conceptualised from a variety of theoretical perspectives and 
at various levels of abstraction. Personality trait theory has been the major 
approach to the study of human personality. Traits can be defined as habitual 
patterns of behaviour, thought or emotion, and are considered to be relatively 
stable over time. Allport pioneered the scientific study of personality using two 
approaches, the first of which he achieved by intensively studying a small number of 
individuals (idiographic), and secondly by examining common responses across a 
large number of individuals (normothetic). Within this framework, Allport classified 
these as central traits, common across cultures and cardinal traits, by which an 
individual can be recognised. Many authorities have advocated integration of the 
idiographic and normothetic approaches, thereby allowing the evaluation of unique 
responses of the individual interpreted in the context of underlying perceptual 
processes across populations [195]. Contemporary personality research has 
focused on the normothetic approach and has been used on an iterative basis 
process, leading to a rapid escalation in the number of personality traits that have 
been proposed, and scales designed to measure them. Most notably, Hans Eysenck, 
working at the Institute of Psychiatry in the 1950s, used factor analysis to 
demonstrate that particular clusters of personality traits correlate together reliably. 
In this series of studies contained herein, I chose to use validated questionnaires to 
measure personality, rather than (semi)-structured interviews such as the Myers-
Briggs personality test, for ease and reproducibility of administration. Of note in 
this respect is a study by McCrae who demonstrated that correlational analyses 
showed that the four indices related to the Myers-Briggs type indictors did measure 
aspects of the major dimensions of normal personality but the five-factor model 
 95 
provided an alternative basis for interpreting of such findings within a broader, 
more commonly shared conceptual framework, as discussed below [196]. 
  
2.2.1 Two Taxonomies 
Central to the goals of scientifically defining personality traits has been the creation 
of taxonomies, through factor analysis, thus facilitating the accumulation and 
communication of empirical findings by using a standard vocabulary, often through 
the use of self-report questionnaires. Two major taxonomies have emerged: 
Eysenck’s three-factor model and McCrae and Costa’s five-factor model. Eysenck 
proposed that personality is based upon three orthogonal factors containing the 
traits of extroversion, neuroticism and psychoticism. These factors are considered 
continuous scales and can be used to describe inter-individual differences in 
personality. In contrast, McCrae and Costa proposed the five factors mode of 
personality containing the traits of neuroticism, openness, conscientiousness, 
extroversion and agreeableness [197]. Whilst both of these taxonomies were 
developed using factor analysis and a lexical approach, they do have important 
differences. Firstly, Eysenck’s three-factor model has been proposed to have a 
biological basis (see section 2.2.2, page 96), although the five-factor model does not 
purport to have any particular theoretical basis. Secondly, many of the facets of the 
five-factor model correlate with one another, in contrast to the orthogonal three-
factor model, and finally the three-factor model contains the trait of psychoticism. 
Common to both models are the personality traits of neuroticism and 
extroversion. Neuroticism can be defined as an enduring tendency to experience 
negative emotional states. Individuals with a higher neuroticism score are more 
likely to respond poorly to environmental stress and interpret ordinary situations 
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as threatening and minor frustrations as being hopelessly difficult. Extroversion may 
be defined as a state of being predominantly concerned with, and obtaining, 
gratification from extraneous sources. Those with high extroversion scores enjoy 
interacting and are enthusiastic, talkative, assertive and gregarious. Using a lexical 
approach to evaluate personality it could be argued that such an approach merely 
maps out the lexicon of personality rather than personality itself. However, if this 
was singly the case one would not necessarily expect this method to be successful 
across cultures and languages. Furthermore, with the exception of neuroticism in 
the five-factor model, many of the factors overlap with one another suggesting that 
the distribution of an individual’s personality is simply isomorphically “mapped” 
onto a singly factor but is continuously distributed across each of them.     
 
2.2.2 Eysenckian Theory & Eysenck’s Personality Questionnaire-Revised 
Eysenck emphasised that personality and temperament have both a genetic and 
biological basis. He described several dimensions of personality, but the most 
enduring are extroversion-introversion and neuroticism-emotional stability. Central 
to the extrovert-introvert dimension is cortical arousal, with “performance level” 
being linked to an optimum level of arousal. For example, extroverts are under-
aroused whilst introverts are chronically over-aroused. Eysenck characterised 
neuroticism by its association with high levels of anxiety and negative effect. He 
proposed the biological basis of this was a reduction in activation thresholds within 
the ANS and limbic system. The EPQ-R measures the three factors of personality 
and can be administered using a 100-item self-reported questionnaire. It has been 
well validated and is widely used in personality research [198]. The main limitations 
of the EPQ-R are that it takes a considerable amount of time for a subject to 
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complete, in addition to the answers to the questions being “yes” or “no” – the 
latter not always fully reflecting an individual’s viewpoint.  
 
2.2.3 Big Five Inventory 
The BFI was developed to facilitate the rapid and flexible assessment of McCrae and 
Costa’s five dimensions of personality, in contrast to more established based 
measures such as the NEO-personality inventory (NEO-PI) [199]. In many ways the 
usefulness of the NEO-PI has been limited due the large number of items that it 
contains (240 items). In contrast, the BFI contains only 44 items, where the 
respondent agrees or disagrees with a series of statements on a five-point Likert 
scale. A recent study has demonstrated that the BFI has substantial reliability and 
validity and has excellent concordance with the NEO-PI [200]. The BFI is widely 
available in the public domain, and a copy of this questionnaire is shown in 
Appendix 1.  
 
2.2.4 Spielberger State and Trait Anxiety Inventory 
The Spielberger state and trait anxiety inventory (STAI) is a widely used instrument, 
measuring transient and enduring levels of anxiety, respectively [201]. Each subscale 
contains 20 items, with each question being scored on a four-point Likert scale. The 
STAI has been validated widely and displays excellent test-retest reliability [202]. 
Trait anxiety is often considered to be a sine qua non facet of neuroticism, with 
many authors using these terms interchangeably [203].  
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2.2.5 Weinberger Adjustment Inventory 
The WAI measures self-restraint and overall adjustment, assessing the subscales of 
distress, anxiety, depression, low self-esteem, low well-being, self-restraint, 
suppression of aggression, impulse control, responsibility and consideration of 
others [204]. Within these scales are measures of self-deception. The concept of 
self-deception is based on the hypothesis that people who deny having negative 
thoughts and feelings are self-deceptive, as most people have these from time to 
time. In essence, this produces a self-deception or “lie” score and is useful in 
ascertaining if individuals are responding to self-report questionnaires in a biased 
manner. In a study by Jamner and Schwartz, self-deception levels, whilst not 
associated with pain sensory thresholds, were associated with significant differences 
in affective ratings of pain [205]. Therefore, in the studies presented in this thesis, 
the WAI was utilised exclusively for the “lie” score, in that it was used as an 
exclusion criterion to improve the reliability of answers given in the self-report 
questionnaires, as well as to improve homogeneity in affective pain ratings among 
participants. 
 
2.2.6 Hospital Anxiety Depression Scale 
The HADS was developed to provide clinicians with a reliable, valid and practical 
tool for anxiety and depression screening [206]. It is extensively used as a research 
and clinical tool and has been subjected to extensive validation [207]. It is 
composed of 14 items, seven of which are relevant to anxiety and seven to 
depression, with each item having four possible responses scored 0, 1, 2 or 3. The 
two subscales of anxiety and depression have been found to be independent 
measures. Scores on each subscale of less than, or equal to 7, are considered 
normal [208]. Recent studies have demonstrated that anxiety and depression, even 
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in occult form, can influence pain perception across a variety of experimental 
paradigms [209, 210]. Additionally, anxiety and depression are considered risk 
factors for the development of a multitude of chronic pain disorders. For these 
reasons, in the healthy volunteer studies contained in this thesis, sub-clinical anxiety 
and depression were screened for by using HADS, and a score of greater than 7 
was used as an exclusion criterion.  
 
2.2.7 Limitations of Self-Report Questionnaires 
Self-report questionnaires are a relatively blunt instrument for measuring 
personality traits, and are open to a number of difficulties including recall bias and 
social desirability. As previously discussed, recall bias may be influenced by self-
deception. Social desirability is the propensity for individuals to report what they 
think the experimenter wants to hear rather than an accurate self-report. The use 
of structured interviews and completion of questionnaires by a third party can 
improve the accuracy of these measures, but it can also increase the logistical 
complexity of a study. 
 
2.3  Pain Induction Methods 
2.3.1 Visceral Pain Induction 
Within the GI tract, experimental visceral pain can be induced electrically, 
chemically, thermally or through mechanical distension. Many studies have used a 
variety of methods to distend the gut mechanically – physiologically, using nutrient 
meals, or mechanically, using balloon or bag distension. Recent work within the 
field has used mechanical distension as the favoured method, as stimulation intensity 
and duration are easier to control. In particular, the barostat method has become 
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very popular, a method based on volume changes in an air-filled balloon at a 
constant pressure [211]. However, major limitations with this technique in early 
studies were that latex-based barostat devices were prone to deformation and data 
was not corrected for air compressibility. Furthermore, a common 
misapprehension lies in the assumption that mechanoreceptors in the GI tract are 
often considered as purely tension, volume or pressure receptors. In fact, 
Gregerson et al. demonstrated that circumferential stress or strain correlate more 
closely with receptor response than stimulus intensity per se [212]. For these 
reasons, simple balloon distension of the oesophagus was used in this study.  
 
2.3.1.1 Oesophageal Distension Catheter Assembly 
During early pilot studies, oesophageal distension balloons were constructed using 
4cm lengths of thin, distensible polyurethane tubing (Medasil, Leeds, UK). These 
were tied and glued 1cm apart and mounted over perforations in the distal 3cm of 
a commercially available nasogastric tube (Pennine Healthcare, Derby, UK). 
However, there were limitations to this technique. Firstly, the balloons often failed 
at unpredictable distension volumes. Secondly, they often leaked air when a volume 
greater than 40mls of air was introduced, and finally the balloons did not distend in 
a mechanically reproducible manner. I therefore commissioned Sandhill Scientific to 
produce a bespoke, single-use oesophageal distension catheter. These were 
constructed with a polyurethane balloon mounted on to a nasogastric tube. The 
Sandhill distension catheter (Sandhill Scientific, Oxford, UK) has centimetre 
markings placed on the tube in addition to two ports, one for balloon inflation and 
one infusion port, although the latter was not used in this series of studies (see 
Figure 12, panel A). Following extensive bench testing, the Sandhill distension 
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catheters did not leak air, and reproducibly failed at a mean distension volume of 
60mls (SD +/- 2.1mls) (see appendix 2). I regarded this as a safety feature, as it 
meant that the distension balloon failed prior to causing any oesophageal damage.  
 
2.3.1.2 Limitations of the Oesophageal Distension Catheter 
It is noteworthy that two limiting factors were observed with both types of 
oesophageal distension catheter. Firstly, the catheters did not have any facility to 
record manometric parameters, thereby allowing accurate identification of the 
lower oesophageal sphincter. Using the centimetre markings on the Sandhill 
catheter, placement within the oesophagus could be measured accurately, based on 
insertion distance from the nose or mouth combined with knowledge of the 
average oesophageal length in adults. Li et al. retrospectively examined 152 
oesophageal manometric studies to determine the length of the oesophagus and its 
relationship to sex, height and weight [213]. Whilst there were no differences in 
oesophageal length in relation to height and weight, males did have longer 
oesophaguses than females, although this difference was small (1cm). As this 
difference is very small, I chose not to vary the insertion depth based on these 
criteria. Catheters were therefore placed at 35cm ab nares and 32cm ab oral, in 
order to stimulate the distal oesophagus and thus visceral mechanoreceptors. In 
order to confirm that the catheter had not looped the balloon was inflated slowly 
to where to the subject’s first sensation and they were then asked to indicate 
where that sensation was felt (usually in the mid/lower chest). If there was any 
doubt as to whether there was looping then the catheter was re-positioned. 
Following deflation of the distension balloon within the oesophagus, secondary and 
tertiary contractions occasionally occurred, which caused traction on the in situ 
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catheter, particularly in the naso-pharynx. A consequence of this was that it 
induced gagging and displacement of the balloon from the intended insertion depth. 
In order to address these concerns, the catheter was taped to the subjects face and 
subjects were asked to hold the catheter between their right thumb and index 
finger to prevent displacement. The position of the catheter was checked at regular 
intervals. 
 
2.3.1.3 Application of Visceral Pain – Oesophageal Distension Catheter Inflation 
During these series of studies, manual inflation of the oesophageal distension 
catheters was used with a 50ml Luer lock syringe (Beckton Dickinson, Oxford, UK) 
at an estimated rate of 5mls per second. It could be argued that automated phasic 
inflation of the balloon, such as that provided by a pump-driven system, might be a 
more desirable method of inflation in that it has greater reproducibility. However, I 
chose to use manual inflation to give flexibility in the volume of distension and on 
the basis that it could be varied to the subject’s pain toleration threshold. Subjects’ 
were warned that the stimulus was about to be applied in order to try and 
standardise any effects of habituation. This method of visceral pain induction 
facilitated the delivery of a simple nociceptive stimulus with a rapid withdrawal. 
However, it is possible that such a rapid distension invoked a withdrawal response 
to pain but my hope was that any potential effect of this would be limited by 
administering multiple stimuli over a period of time. Technically, it is not currently 
possible to increase volumes dynamically using the automated method between 
stimuli –such that may be needed to reach a subject’s pain toleration threshold – 
given that a subject may habituate or sensitise to the stimulus, to a greater or lesser 
degree.
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Figure 12 - Panel A shows the oesophageal distension catheter. Panel B shows a study participant 
with the oesophageal distension catheter in situ. 
 
2.3.1.4 Quantity and Timing of Oesophageal Distensions 
During pilot work, I determined the optimal quantity of oesophageal distensions as 
a series of 7 stimuli, as I found this was the balance between a subject’s habituation 
and sensitisation (see appendix 2). An inter-stimulus interval of two minutes was 
chosen, as this has been demonstrated to be the optimal time window for 
evaluating ANS responses to pain in the context of recovery of these parameters to 
near baseline levels prior to the proceeding stimulus [214, 215]. 
 
2.3.2 Somatic Pain Induction 
Somatic pain can be experimentally induced using thermal, electrical or mechanical 
methods in the presence or absence of sensitising agents. Many studies in the 
somatic pain literature utilise thermal pain, either heat or cold, although the 
psychophysical properties of thermal pain display considerable intra- and inter-
individual variation [216]. For the purpose of comparability with the 
aforementioned visceral pain induction techniques, mechanical nail bed pressure 
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applied to the subject’s left thumbnail was chosen as the somatic pain stimulus in 
this series of studies. 
 
2.3.2.1 Nail bed Pressure Device 
The medical physics department at Hope Hospital, Manchester has developed a 
simple, manually operated, spring-loaded device, to which a strain gauge (Advanced 
Force Strain Gauge, Mecmesin, West Sussex, UK) is attached (see Figure 13). A 
blunt rod was attached to the strain gauge, thus allowing focal pressure to be 
applied to the nail bed. The quantity of the pressure, measured as force in 
Newtons, could be ascertained from the strain gauge.  
 
Figure 13 - The nail bed pressure device used for the administration of somatic pain to subjects’ 
left thumbnail, to a pressure of 78.61N. 
 
2.3.2.2 Limitations of the Nail Bed Pressure Device 
One limitation of this device relates to subjects who have small thumbs, in that the 
spring-loaded device occasionally reached its maximum downward pressure before 
the blunt rod made full contact with the nail bed. In these subjects, the blunt rod 
was changed for a slightly longer version in the same experimental set up. A further 
limitation is that one could regard nail bed pressure as deep somatic stimulation, in 
contrast to superficial somatic stimulation, and hence not dissimilar to visceral pain. 
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However, given recent evidence for the commonalities of all pain modalities, this 
approach is not unreasonable [96]. 
 
2.3.2.3 Application of Somatic Pain – Nail Bed Pressure 
During these studies, nail bed pressure was applied manually to the subject’s left 
thumbnail for similar reasons of flexible delivery of the noxious stimulus, as outlined 
in section 2.3.1.3, page 102. Moreover, the temporal characteristics of this somatic 
stimulus, in terms of its phasic nature, were reasonably similar to those associated 
with visceral pain. 
 
2.3.2.4 Quantity and Timing of Nail bed pressures 
During pilot work, I determined the optimal number of nail bed pressure 
applications to be a series of 7, as I found this was the balance between habituation 
and sensitisation (see appendix 2). An inter-stimulus interval of two minutes was 
chosen for similar reasons to those outlined in section 2.3.1.4, page 103. 
 
2.4 Response Measurement Techniques 
In attempting to measure individual affective ratings of visceral and somatic pain, 
visual analogue scales (VAS) and verbal report scales (VRS) were used in these 
studies. 
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2.4.1.1 Visual Analogue Scales 
A VAS permits subjects to “quantify” various components of an experimental pain 
experience, although they remain a relatively crude measure. This property can be 
improved by adding weighting and individualising the scales [217]. Computerised 
scales, in which the participant uses their left hand to move a mouse, thereby 
moving a cursor to an appropriate point on the scale, were used in the pilot 
studies. However, it was found that when a subject moved their hand, it introduced 
movement artefact into the ECG and skin conductance traces, rendering them 
unsuitable for further analysis.  
 
2.4.1.2 Verbal Report Scales 
In order to minimise movement artefact, subjects were asked to report pain 
intensity and unpleasantness using a VRS. Similar anchor points were used for pain 
intensity (0 - no sensation, 5 – strong but not painful, 10 – worst pain imaginable) 
and pain unpleasantness (0 – not unpleasant, 5 – moderately unpleasant, 10 – worst 
imaginable unpleasantness) (see Figure 14). Many subjects initially found it difficult 
to distinguish between these measures. In order to explain this further, the subjects 
were instructed to imagine listening to their iPod, or similar, in that the “volume of 
the music” represented the pain intensity and the “genre of the music” the pain 
unpleasantness. Subjects were told that they could use whole numbers or fractions 
of whole numbers in their verbal ratings. Subjects were also instructed to rate the 
pain approximately 45 seconds after stimulus, and were prompted by the 
experimenter if they failed to do so.  
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Figure 14 - The verbal report scale for pain intensity and unpleasantness used in this series of 
studies. 
 
2.5 Hypothalamic-Pituitary-Adrenal Axis Responses to Pain 
2.5.1 Serum cortisol  
As discussed in Chapter 1, the HPA axis is central in orchestrating the body’s 
response to stress. The final effector of this axis is the glucocorticoid hormone, 
cortisol. The majority of cortisol circulates whilst bound to the corticosteroid-
binding globulin or albumin, preventing it from penetrating the membrane of the 
target cell. Approximately 3-5% of cortisol is in its bioactive, unbound form, and it 
can be assayed in a number of biological fluids including peripheral blood, saliva and 
urine.  
 
2.5.2 Factors that may Potentially Confound Serum Cortisol Measurements 
The measurement of serum cortisol can be confounded by a number of factors, 
which I have attempted to identify and control for in this series of experiments 
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[218]. I will now review the evidence for each of these factors individually and the 
strategies used in this series of studies for their control. 
 
2.5.2.1 Diurnal Variation of Cortisol 
Cortisol displays a distinct diurnal variation, with the highest concentrations 
observed in the morning soon after awakening and lowest in the evening [219]. 
Therefore, all experiments contained in this thesis were conducted in the 
afternoon, commencing at 1400 hrs, as it is the midpoint between the zenith and 
nadir of cortisol concentrations.  
 
2.5.2.2 Effect of Physical Activity on Cortisol 
Heavy short-term activity may increase cortisol [220]. However, a more recent 
study has suggested that cortisol levels are not raised significantly from basal during 
transportation to and from work [218]. In these respects, the subjects were 
instructed to avoid heavy physical activity for at least two hours before participating 
in the studies, but could use public or private transportation to reach the 
laboratory for the study. 
 
2.5.2.3 Effect of Age, Gender & Menstrual Cycle on Cortisol 
Nicolson et al. investigated basal cortisol levels and their reactivity in response to 
cognitive stress tasks in a group of healthy subjects [221]. This study demonstrated 
that basal levels of cortisol increase in age, although these age differences are not 
apparent until the age of 70. Consequently, I chose the upper age limit of 65 years 
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to limit this variability. Studies report conflicting data on gender differences in basal 
cortisol levels. For example, Seeman et al. found that awakening cortisol levels 
were higher in females, yet Lovallo et al. found no difference [222, 223]. Given 
these data, I did not stratify cortisol responses to pain by sex in this study. A 
criticism that can be levelled at both Seeman and Lovallo’s studies are that they did 
not control for the stage of menstrual cycle in their female populations. Andreano 
et al. found that basal cortisol levels are elevated during the mid-luteal phase of the 
menstrual cycle [224]. Therefore, I studied all the female participants during the 
follicular phase of their menstrual cycle, i.e. from day 1 to day 15. Evidence suggests 
that oral contraceptive pill use does not influence cortisol, and therefore females 
who were taking the oral contraceptive pill (OCP) were not excluded from these 
studies. 
  
2.5.2.4 Effect of Alcohol and Smoking on Cortisol 
Chronic alcohol intake may be associated with an elevation of basal cortisol levels 
and a reduction in HPA axis reactivity to psychological or physiological stress [225, 
226]. Studies by Gianoulakis et al. and Kokavec et al. observed that moderate 
alcohol intake did not alter either basal cortisol levels or reactivity of the HPA axis 
[227, 228]. In light of this evidence I screened participants for alcohol dependency 
using the CAGE questionnaire [229]§ and excluded those who consumed more 
alcohol than is recommended in the Royal College of Physician’s publication – 
“Alcohol – can the NHS afford it?”, i.e. 21 units per week for men and 14 units per 
week for women [230].  
                                            
§ The CAGE questionnaire, the name of which is an acronym of its four questions, is a widely used 
method of screening for alcoholism.  
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There is good evidence from a number of studies that habitual cigarette smoking 
and the acute ingestion of nicotine increases cortisol levels [231, 232]. Therefore, 
current smokers and ex-smokers who were taking nicotine replacement therapy 
were excluded from these studies.  
 
2.5.2.5 Effect of Diet on Cortisol  
Eating provokes a physiological challenge to the HPA axis, exemplified by a recent 
study reporting that cortisol levels remain elevated for up to two hours after a 
meal, regardless of its composition [223]. Thus, subjects were asked to refrain from 
eating or drinking (also see section 2.5.2.6, page 110) for two hours prior to 
participating in the studies. 
 
2.5.2.6 Effect of Drugs and Caffeine on Cortisol 
Several types of medication may alter basal cortisol levels. In particular, those 
subjects who were currently taking steroid-containing medications (e.g. those on 
inhaled corticosteroids for asthma) were excluded from the study. Cortisol 
responses to caffeine are variable depending on the time and quantity ingested, 
generally leading to a decrease in cortisol secretion in caffeine-naïve subjects, 
although these differences are attenuated in those who consume caffeine on a 
regular basis [223]. Therefore, subjects were asked to refrain from consuming 
caffeine for at least two hours prior to the study.  
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2.5.2.7 Time Lag between Stress and Cortisol Secretion 
A recent study by Scholtz et al. examined the time lag of various parameters in the 
HPA axis, including cortisol, in responses to stress [233]. It was found that 
discernable cortisol responses were not maximally evident until 10 minutes after 
the stress. In the series of studies that I performed, peripheral venous blood was 
sampled for cortisol at three time points during the experiments: at the end of the 
baseline period, two minutes following the end of somatic pain stimulation and two 
minutes following the end of visceral stimulation. These time points were chosen to 
account for the time lag in serum cortisol production. 
 
2.5.2.8 Cortisol Sampling and Assay  
Where the measurement of serum cortisol has been used, the results of many 
studies have been contaminated by the (unintentional) stress of venepuncture. This 
has led to the development of elaborate and complex sampling systems [234]. 
However, the use of such complex sampling systems in these series of studies was 
impractical. Therefore, all subjects had an intravenous cannula (18G Venflon, 
Beckton Dickinson, UK) inserted in to the left antecubital fossa, from which 
peripheral venous blood was sampled, so that the subjects only underwent 
venepuncture once, thus aiming to standardise any potential effects of this added 
stress. I found that the patency of the intravenous cannula was maintained without 
the need for an intravenous infusion of 0.9% heparinised saline. This was of 
particular importance, as infusion of 0.9% saline can potentially give rise to a 
reduction in serum cortisol levels through dilutional effects. In order to prevent any 
cross contamination between samples, a three-way extension set (Extension set, 
SmartSite®, Cardinal Health), with clamps on each of the three lines, was attached 
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to the intravenous cannula. Therefore, at each sampling point during the study, 
peripheral venous blood was taken from an unused line. The aim of this approach 
was to limit cross contamination between serial samples (see Figure 15). Peripheral 
venous blood was collecting in silica clot-activating SST™ Vacutainers (Vacutainer, 
Beckton Dickinson, UK) and transferred to the Blood Services Department at the 
Royal London Hospital immediately after the completion of the study. 
 
Figure 15 - Apparatus used for serial sampling of serum cortisol to limit cross contamination and 
the repeated stress of venepuncture between samples. 
 
Serum total cortisol was assayed for this study by the Blood Services Department 
at the Royal London Hospital using a competitive chemiluminescent assay (Chiron 
Diagnostic ACS:180 analyser, Bayer Healthcare, NY, USA). Using this method, 
cortisol in the sample competes with cortisol labelled with an acridinium ester for a 
limited quantity of polyclonal rabbit antibody, which is coupled to paramagnetic 
particles. The cortisol concentration in the sample is then inversely proportional to 
the relative light units detected in the ACS:180 analyser. 
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2.6 Genotyping Methods 
2.6.1 Deoxyribose Nucleic Acid Extraction 
Ten millilitres of peripheral venous blood from participants in these studies was 
collected in anticoagulant Vacutainers containing ethylene-diamine-tetra-acetic acid 
(EDTA)-coated blood tubes (Vacutainer, Beckton Dickinson, UK) and stored at -
80°C until the deoxyribose nucleic acid (DNA) was ready to be extracted. Samples 
were coded with the participants’ unique identifying number and the date and time 
when the blood was sampled. DNA was extracted using a modification of Miller’s 
salting out procedure [235]. After allowing the samples to thaw, blood was 
transferred to a 15ml polypropylene tube (Beckton Dickinson, Oxford, UK), and 
then centrifuged at 2500rpm to separate RBC from WBC. The Buffy coat was 
aspirated from the top of the RBC and placed into a fresh 15ml polypropylene tube. 
Any RBC contaminating the WBC were removed by the addition of 10mls of red 
cell lysis buffer (144mM NH4Cl, 1mM NaHCO3). Tubes were placed in an inverter 
and inverted at a rate of 15 cycles per minute for 30 minutes. The samples were 
then centrifuged at 2500rpm for 25 minutes to pellet the WBC. The supernatant 
was discarded and the white cell pellet washed again with red cell lysis buffer. The 
process of inversion and centrifugation was repeated. The remaining supernatant 
was discarded and the white cell pellet was either stored at -20°C for future DNA 
extraction or extracted immediately.  
 
The WBC pellet was then re-suspended using 3mls of nuclear lysis buffer (10mM 
Tris-HCl pH 8.2, 400mM NaCl, 2mM Na2EDTA pH8.0). The proteins were then 
precipitated by the addition of 1ml of 6M NaCl and separated from the DNA by the 
addition of 2mls of 24:1 chloroform:isoamyl alcohol. Samples were agitated until a 
homogenous, milky solution was formed, and centrifuged at 3000rpm for 30 
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minutes. After centrifugation, three visible layers were in evidence: firstly, a lower 
phase containing chloroform, dissolved lipids and lipoproteins, secondly an interface 
of cell debris and finally an upper phase containing DNA from the lysed WBC. The 
upper phase, approximately 2-3 mls, was removed and transferred in to a new tube 
and 10 mls of 100% ethanol added. The tubes were inverted several times, resulting 
in the precipitation of DNA (see Figure 16), which was then removed using a small 
orange stick, transferred into sterile 1.5 mls eppendorfs and left to air dry in a 
sterile environment for 30 minutes to allow evaporation of excess ethanol. Finally, 
the DNA was re-suspended in an appropriate amount of sterile water (Baxter, UK) 
and stored at -20 °C until required.  
 
 
 
 
 
 
 
 
 
Figure 16 - DNA extraction following precipitation. Adapted from Google Images.  
 
2.6.2 Deoxyribose Nucleic Acid Quantification 
DNA concentration was quantified using a Nanodrop spectrophotometer (Thermo 
Scientific, Delaware, USA). This process is based on the principle that DNA 
optimally absorbs light at a wavelength of 280nM. This absorption can be measured 
and converted into optical density and subsequently into DNA molarity. The arm of 
the Nanodrop was lifted and 1 µL of RNA-ase free water (Qiagen, Sussex, UK) 
placed on the pedestal to initialise the blanking mechanism of the instrument. A 
total of I-2 µL of each sample was placed on to the Nanodrop spectrophotometer 
and the pedestal was replaced. DNA concentrations were recorded electronically. 
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2.7 Sequence-Specific Polymerase Chain Reaction 
2.7.1 General Principles 
SSP-PCR is a simple method of demonstrating the presence of an allelic variant at a 
single gene locus. The process uses short oligonucleotide sequences (primers) that 
are designed to bind uniquely to the section of DNA containing the single 
nucleotide polymorphism (SNP) of interest. Of central importance is the presence 
at the 3’ end of the specific complementary nucleotide to the particular SNP variant 
of interest. Two near-identical primers are therefore designed to characterise the 
SNP, the only principle difference between the two primers being the single 
complementary nucleotides at the 3’ end. 
 
When a patient’s DNA is denatured and the SNP exposed, a mismatch between it 
and the nucleotide at the 3’ end of the primer will lead to a failure to bind, and 
consequently amplification will not occur. Conversely, a perfect match between 
primer and SNP will lead to the binding and initiation of replication and 
amplification by PCR. The presence, or absence, of the specific reaction products 
can then be visualised under UV light using gel electrophoresis. 
 
2.7.2 Specific Principles of a Sequence-Specific Polymerase Chain Reaction for 
Genotyping the Serotonin Transporter Long Promoter Region 
5-HTTLPR is a functional polymorphism of the gene SCL6A4 encoding for the 
serotonin transporter. It is located on chromosome 17q 11.2, and is 37.8Kb in 
length. Insertion/deletion in the 5’-flanking promoter region creates a long (L) and 
short (S) allele. This 5-HTTLPR polymorphism is located in the guanine-cytosine-
rich area comprising a 20-23-bp repeating unit. The S and L alleles have 14 and 16 
repeating elements, respectively. In contrast to standard SSP-PCR, when 
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genotyping, 5-HTTLPR amplification products are measured against a “ladder” of 
known molecular weights, demonstrating the presence of a 484bp product, 
designated the S allele, and 528 bp product, designated L allele, as first suggested by 
Lesch et al. [236]. Genotyping of this insertion/deletion polymorphism of the 5-
HTTLPR was performed in duplicate using previously published primers (see 
section 2.7.3.1, page 116). 
 
2.7.3 Amplification and Reaction Conditions 
As a single reaction was necessary to genotype the 5-HTTLPR, up to 96 samples 
could be assayed at a single time (see Figure 17). In preparation for amplification a 
13µL volume of reactants was added and mixed in each reaction well. This reaction 
volume contained 5µL of primer mix, 8µL of PCR buffer and 80ng of genomic DNA. 
 
2.7.3.1  Primer Mix 
Primers for the 5-HTTLPR, (Sigma Genosys, Poole, UK), manufactured at crude 0.2 
µM scale and lyophilised, were re-suspended in sterile distilled water (Baxter, UK) 
to a concentration of 2 µg/µl. The specific primers used were those reported by 
Camilleri [84] (forward primer 5’-GGCGTTGCCGCTCTGAATGC-3’ and reverse 5’-
GAGGGACTGAGCTGGACAACCAC-3’) and Pata [237] (forward 5’-
GCCGCTCTGAATGCCAGCAC-3’ and reverse 5’-GGAGGAACTGACCCCTGAAACTG-3’). 
Primer mixes were prepared with sterile distilled water (Baxter UK) and 40 µl/mls 
cresol red indicator (Sigma Ltd, Poole, UK), which undergoes a pH-related colour 
change from orange to purple on the addition of genomic DNA. This was useful in 
both excluding the presence of contamination of plates during plate production and 
confirming the effective inclusion of DNA to all wells prior to amplification. 
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2.7.3.2 Polymerase Chain Reaction Buffer 
The PCR buffer (TDMH mix) was made up to 8µL per reaction. For each reaction 
this included (NH4)2SO4, 1.5 - 2.5 mM MgCl2, 200mM of individual nucleotides 
(dNTPs) (Bioline Ltd, London, UK) and 0.32 units of Taq polymerase (Biotaq TM, 
Bioline Ltd, London, UK).  
 
2.7.3.3 Genomic Deoxyribose Nucleic Acid 
A total of 80ng of genomic DNA from each individual was added to each well, 
making a total reaction mix of 13 µL. Multi-channel pipettes with sterile tips were 
used to speed the process of plate preparation. Finally, 10µl of mineral oil was 
added to each well and the plates were then sealed with an adhesive sheet. 
 
2.7.3.4 Amplification Reaction 
The plate was then placed in a PCR machine (MJ Research, Mass, USA) (see Figure 
17), using the following cycling parameters: after denaturing at 96°C for one minute 
the cycling parameters were as follows: five cycles of 96°C for 25 seconds, 70°C 
for 45 seconds and 72°C for 45 seconds; 21 cycles of 96°C for 25 seconds, 65°C 
for 50 seconds and 72°C for 45 seconds; and four cycles of 96°C for 25 seconds, 
55°C for 60 seconds and 72°C for 120 seconds.  
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Figure 17 – PT200 PCR machine and a 96-well reaction plate. 
 
2.7.3.5 Gel Electrophoresis 
Following PCR, amplification products were separated on 2% agarose gels (Bioline, 
UK) with 0.5 X Tris Borate EDTA (TBE) buffer (Sigma, Poole, UK) and were 
stained with 10µL of Sybr Safe (Invitrogen, UK). Ten millilitres of orange G loading 
buffer (150mls glycerol (Sigma, Poole, UK), 350mls 0.5 X TBE, 0.125 g Orange G 
(Sigma, Poole, UK)) was added to each sample before they were all loaded in to the 
wells of the gel. Electrophoresis was carried out at 220 Volts for 30 minutes. Gels 
were transferred on to UV illuminator (DigiGenius, Imgen, VA, USA) and 
photographed using a digital camera (Olympus, Japan). Based the presence of a 
484bp fragment or 528bp fragment, or both, amplification products were 
genotyped as SS, LL or LS respectively (see Figure 18). 
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Figure 18 - A typical 2% agarose gel with 5-HTTLPR amplification products detailing its 
interpretation across 12 individuals. 
 
2.8 The Autonomic Nervous System  
The last three decades have witnessed the recognition of the fundamental role that 
the ANS plays in the pathophysiology of a number of disorders including 
cardiovascular mortality and chronic pain [238]. ANS function can be measured 
directly using a needle recording of the peroneal nerve, and direct stimulation of 
vagal nerves can be facilitated through implantable vagal stimulators. However, 
these methods are invasive and impractical for experimental studies. Therefore, 
indirect measures of ANS function have been developed, the most popular being 
HRV. In this section I shall provide an overall critique of the theory underling HRV 
in addition to the more novel non-invasive, beat-to-beat measures of autonomic 
tone used in this series of studies. 
 
2.8.1 Heart Rate Variability 
The clinical relevance of HRV was first appreciated in 1965 when Hon et al. [239] 
demonstrated that foetal distress was preceded by alterations in the inter-beat 
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intervals between successive R waves in the ECG, before any appreciable changes 
occurred in the HR itself. This epiphenomenon in the oscillations in the interval 
between successive heartbeats is known as “HRV”, which has been used in 
preference to crude HR in the majority of the more recent autonomic research. In 
deriving physiologically salient measures from HRV, two methods have been 
developed – the first is time domain analysis and the second relates to the 
frequency domain using spectral analysis.  
 
2.8.1.1 Time Domain Analysis 
Variations in HR may be examined using time domain analysis. In a continuous ECG 
recording, the interval between consecutive normal QRS complexes on the ECG is 
known as the normal-to-normal (NN) interval. From the NN interval, statistical 
time domain measures can be derived and are divided into two classes, firstly those 
derived from the direct measurement of NN intervals and secondly those derived 
from the difference between NN intervals. The simplest variable is the SDNN 
(standard deviation of normal-to-normal RR intervals), which reflects the cyclic 
components of variability within the recording. Other commonly used measures are 
detailed in Table 4. The major disadvantage of these methods is the limited 
statistical power for the evaluation of short-term recordings of less than five 
minutes.  
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Variable 
(units) 
Description Physiological Relevance 
SDNN  
(ms) 
Standard deviation of the normal RR (NN) 
interval reflecting all of the cyclic 
components responsible for variability in 
the period of recording. 
An overall estimate of HRV, but 
does not indicate the contribution 
of any particular influence. 
SDANN  
(ms) 
Standard deviation of the averages of NN 
intervals calculated over a short period of 
time, usually less than five minutes. 
Reflects the influence of circadian 
rhythms on autonomic function. 
pNN50  
(%) 
The proportion of NN intervals having a 
difference of >50mSec. 
Reflects predominant vagal 
influence on variability. 
Triangular 
Index  
(ms) 
The integration of the density distribution 
of all the NN intervals as a function of the 
maximum density. 
Overall estimate of HRV similar to 
SDNN. 
RMSSD  
(m/s) 
The square root of the means squared 
differences in successive NN intervals. 
Estimate of the short-term 
components of HRV. 
Table 4 – Time domain analysis variables and their physiological relevance. Table adapted from 
www.atcormedical.com.  
 
2.8.2 Spectral Analysis 
The ANS activity that influences HRV is periodic in its nature, with sympathetic and 
parasympathetic components oscillating at different frequencies. The purpose of the 
frequency domain analysis of HRV (spectral analysis) is to dissect HRV into its 
specific frequency components. This analysis defines the variance, often referred to 
as ‘power’, contained in each frequency component and has become the 
predominant model for exploring HRV, and therefore autonomic function, to date. 
When considering short-term recordings obtained in resting conditions, the HRV 
spectrum is characterised by three major components at high (HF), low (LF) and 
very low (VLF) frequency. These rhythms can be divided further and are considered 
to reflect the following:  
 
& Ultra-low frequencies (<0.003 Hz) reflecting circadian rhythms.  
& Very LF (0.003-0.05 Hz) reflecting thermoregulatory cycles. 
& Mid-LF (0.05-0.15 Hz) reflecting mixed sympathetic and parasympathetic 
control, although this is controversial. 
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& HF (0.15-0.4 Hz) reflecting respiratory frequency in the resting healthy adult 
human, which is under parasympathetic influence. 
 
The HF band represents respiratory sinus arrhythmia, as this is generally thought to 
represent vagal output to the heart, and this is termed cardiac vagal control (CVC). 
A caveat to this is that it assumes semi-stationarity of the respiratory rate at 
between 10-12 breaths per minute. Therefore, an experimenter needs a co-
operative subject, willing to control their breathing, or what is termed paced 
breathing, within the HF band. A central methodological criticism of this measure of 
CVC was highlighted by Denver, who commented that, “…techniques such as paced 
breathing artificially elevate the CVC making its measurements unreliable.” [240]  
 
The problems associated with stationarity assumptions are not confined to 
respiratory frequency. In long recordings of HRV, in particular those over 24 hours, 
the physiological mechanisms responsible for the modulation of LF and HF 
components cannot be considered to be stationary. Spectral analyses of recordings 
taken over such periods of time are often reported in the literature in a single time 
block, i.e. the whole 24-hour period, or in shorter segments, often of five minutes, 
with the results averaged over the whole time period. Thus, spectral analyses 
performed in either of these periods provide averages of the modulations 
attributable to the LF and HF components, but such averages obscure detail 
regarding specific autonomic modulation. Furthermore, spectral analysis provides a 
measure of the degree of autonomic modulation of HRV by its different 
components, rather than the level of autonomic tone, and as such represents 
modulatory influences rather than autonomic tone per se (cf. beat-to-beat measure 
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in section 2.9, page 124).  
 
2.8.3 Sympathovagal Balance 
Further to the spectral analysis of the HRV and its component frequencies, many 
studies in the literature examine the ratio between LF and HF, giving a measure of 
sympathovagal balance. This method assumes two factors: direct reciprocity 
between LF and HF and that LF and HF purely represent the sympathetic and 
parasympathetic modulation of HRV. These assumptions are not scientifically sound 
for a number of reasons. Eckberg and colleagues demonstrated that there is a 
greater parasympathetic influence in the LF in comparison to the SNS – blocking 
the vagal component of the LF with atropine had little change on LF, whereas the 
converse was evident with sympathetic blockade [241]. Porges suggested that HF 
may reflect CVC from the NA, whereas the LF may reflect CVC from the DMNx 
[242]. In attempting to redress these methodological issues, Porges designed a 
moving polynomial filter [243], a complex statistical method that utilises a time 
domain approach (moving averages) and smoothing filters to evaluate dynamically 
the rhythmic oscillations of the varying RR frequencies. Porges’ technique has the 
added value of having pre-existing sex and age normal values for humans. However, 
Porges’ filter is not the end of the story, as this technique’s temporal resolution is 
poor beyond one minute for LF and two minutes for HF. Indeed, it has been 
recommended that this method of analysis is not used for more than two minutes’ 
worth of data. Nevertheless, despite these drawbacks, the LF:HF ratio of the 
sympathovagal balance remains a commonly utilised method of measurement in 
autonomic neuroscience research.  
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2.9  Beat-to-Beat Measures 
Beat-to-beat measures overcome these difficulties, as they represent direct 
measures of autonomic tone, irrespective of time frame or assumptions of 
respiratory stationarity. Examples of beat-to-beat measures are CVT and cardiac 
sensitivity to the baroreflex (CSB).  
 
2.9.1 Cardiac Vagal Tone 
CVT is a measure of parasympathetic stimulation to the heart via the vagus nerve. 
In ventricular systole, BP increases momentarily causing baroreceptor activation in 
the carotid sinus and pulmonary circulation, which increases their rate of discharge 
[244]. This initiates a vago-vagal reflex, via medullary neurones in the nucleus of the 
solitary tract, by stimulating preganglionic neurones of the vagal nerve to increase 
firing. This increase in cardiac vagal activity causes a reduction in the rate of 
spontaneous depolarisation of the sino-atrial node, thus widening the RR interval 
and decreasing HR. The vagal response to baroreceptor stimulation takes around 
240ms in humans, which is fast enough to delay the subsequent systole [245]**. 
Notwithstanding the SNS influence on HR, mainly through changes in peripheral 
vascular resistance which takes place more slowly, it should be possible to deduce 
vagal tone in a non-invasive manner by measuring beat-to-beat changes in RR 
intervals.  
 
Based on these principles, the Neuroscope™ (MediFit Instruments, Essex, UK) is a 
novel piece of technology that analyses the RR interval to produce a real time index 
of parasympathetic activity known as CVT. A standard 3 lead ECG is recorded. The 
                                            
** This physiology underpins the clinically used measure of carotid sinus massage as a “vagal 
manoeuvre” in the treatment of supra-ventricular tachycardias. 
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Neuroscope’s input is the ECG waveform, which it samples at 5kHz. The acquired 
QRS complexes are then compared to a QRS template generated from the initial 
stages of the recording. If there is sufficient similarity between the recorded 
complex and template, a 1mV pulse is generated by voltage oscillators. Thus, the 
time between 1mV pulses is equivalent to the RR interval on the ECG. The 
Neuroscope circuit sends this pattern of 1mV pulses in to two circuit limbs known 
as the high pass limb and the low pass limb. The high pass limb tracks the incoming 
signal without transforming it, whereas the low pass limb produces a damped 
version of the signal. The lower the rate of HRV, the slower the rate of change of 
the incoming signal, whilst the closer the output match between the high and low 
pass limbs, the lower the CVT. Conversely, the higher the HRV, i.e. the faster the 
rate of change of the incoming signal, the more damped the low pass circuit output 
is in comparison to the high pass limb, resulting in a higher CVT reading (see Figure 
19).  
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Figure 19 - The beat-to-beat measure of cardiac vagal tone as measured by the Neuroscope, using 
voltage oscillators with high (non-damped) and low (damped) circuit limbs. 
 
This methodology of measuring CVT has been validated in humans and animals 
[246]. CVT is measured on an experimentally derived linear vagal scale (LVS). Zero 
on the LVS was derived from six fully atropinised healthy volunteers, and 10 units 
on the LVS established in the same volunteers in the supine position in the fasting 
state (i.e. maximal vagal activity). [62] Thus, CVT can be considered a validated 
marker of efferent parasympathetic tone from the brainstem on the heart.  
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2.9.2 Cardiac Sensitivity to the Baroreflex 
In addition to the derivation of CVT, the Neuroscope also measures CSB, a 
validated, non-invasive beat-to-beat measure of parasympathetic afferent activity. 
Incorporated in the Neuroscope system is a non-invasive continuous BP 
measurement using the Portapress system (Finapress, Amsterdam, Netherlands). 
From this, the Neuroscope uses the raw Nexfin waveform to calculate the 
arithmetic mean of the BP (BP), as opposed to the mean arterial blood pressure 
(MAP) that is commonly used in the clinical setting (MAP = DBP + 1/3(SBP – DBP). 
The MBP that is calculated by the Neuroscope is the true arithmetic mean of the 
BP, i.e. DBP, dicrotic notch and the SBP. By integrating the RR interval data with 
the BP data, the change in pulse interval per unit change in SBP over a 10-second 
period can be calculated; this is termed CSB, which is expressed as a ratio of 
'mmHg/'RR interval (see Figure 20). 
 
 
 
 
 
 
 
 
 
Figure 20 - CSB is a beat-to-beat measure of parasympathetic afferent tone derived from changes 
in BP and expressed as a function of change in RR interval. 
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Therefore, the Neuroscope allows the beat-to-beat measures of the efferent and 
afferent limb of the effects of parasympathetic tone on the heart, without the 
methodological difficulties that are associated with spectral analysis of HRV.  
 
2.9.3 Selective Sympathetic Measures 
2.9.3.1 Vasomotor 
Mean arterial pressure has been shown to correlate with invasively recorded 
sympathetic activity, as assessed by photo-plesythymography [247]. Photo-
plesythymography records MAP on a beat-to-beat basis and has been validated 
against invasive arterial pressure measurements in humans [248]. However, it must 
be noted that if the cuff is applied to a subject’s finger for a considerable period of 
time, a degree of vasoconstriction can ensue. Selecting the correct size cuff is of 
utmost importance, as selecting the wrong size can result in large fluctuations in BP 
readings. The BP cuff was placed on the subjects’ right middle finger in this series of 
experiments. The analogue readings from the Nexfin were transmitted to the 
Neuroscope, where they were digitised and integrated into the beat-to-beat data, 
as discussed. 
 
2.9.3.2 Sudomotor  
The sudomotor, or skin conductance response (SCR), measurement has been used 
for more than 100 years, and is a measure of selective central sympathetic control 
over sweat gland activity. It can be defined as the “…momentary change of the 
electrical potential of the skin, (it) may be spontaneous or reflexively evoked by a variety 
of internal or by externally applied arousal stimuli.”[249] This simple electro-
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physiological measure assesses sympathetic cholinergic sudomotor function, and 
represents a transient change in the electrical resistance of the skin that is 
associated with sweat gland activity elicited by a stimulus that evokes an arousal or 
orienting response. Although human neuroanatomical efferent sweat pathways have 
not been fully determined yet, animal studies have shown that efferent sweat fibres 
originate in the hypothalamic preoptic sweat centre and descend through the 
ipsilateral brainstem and medulla to synapse with the intermediolateral cell column 
neurons. Unmyelinated postganglionic sympathetic class C fibres arise from the 
sympathetic ganglia to join the major peripheral nerves and reach the sweat glands 
[249]. There are two interacting types of sweat response, namely thermal and 
emotional. Emotional (mental) sweating control has multiple interactions, with 
emotional, cognitive and neuroendocrine functions, and is controlled at multiple 
levels within the CNS, mainly at the ACC.  
 
There are two main methods of SCR acquisition, firstly to measure spontaneous 
impedance changes across digits (often referred to as galvanic skin responses or 
“GSR”), or secondly to pass a small, constant current across the digit and record 
impedance changes as it crosses the digit (usually called the SCR) – with the latter 
felt to be more reliable. The Powerlab (AdInstruments, UK) biosignals acquisition 
system can digitally record SCR, which were recorded at baseline and in response 
to pain. The SCR electrodes were placed on the subjects’ right index and ring finger 
in this series of experiments. Figure 21 details a typical SCR tracing. 
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Figure 21 - A typical SCR tracing. The black vertically dashed lines represent the application of a 
noxious stimulus, and the red line represents the SCR trace. 
 
2.10 Summary of Autonomic Measures 
The battery of autonomic measures used in this series of studies covers mixed 
measures (HR), parasympathetic efferent tone from the brainstem (CVT), 
parasympathetic afferent tone (CSB), sympathetic vasomotor (MBP) and 
sympathetic sudomotor (SCR). These are summarised in Figure 22. 
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Figure 22 - A summary of the autonomic measures used in this study. The blue outline indicates 
those measures acquired by the Neuroscope (HR, MBP, CVT, CSB) and the yellow outline those 
acquired by the Powerlab (SCR). 
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Chapter 3 – Human Psychophysiological Responses 
to Visceral and Somatic Pain 
 
3 Human Psychophysiological Responses to Visceral & Somatic  
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3.1 Chapter Overview 
Pain is a variable and individual experience activating a complex stress response. 
Whilst acute pain may confer a survival advantage, chronic pain is common and 
maybe associated with considerable morbidity. The pathophysiological mechanisms 
that give rise to chronic pain syndromes are incompletely understood. Susceptibility 
factors that have been proposed for the development of chronic pain syndromes 
include the personality trait of neuroticism and abnormalities in the PNS and HPA 
axis. In this chapter, for the first time, I shall explore the relationship between 
personality traits and ANS and HPA axis responses to visceral and somatic pain in 
health. In all, 120 healthy volunteers had personality traits assessed using validated 
questionnaires, and had validated ANS parameters measured at baseline and 
continuously thereafter. Seven painful visceral stimuli (mid-oesophageal balloon 
distension) followed by seven painful somatic stimuli (nail bed pressure) were 
administered to the subjects’ pain tolerance, with an inter-stimulus interval of two 
minutes. Serum cortisol was measured at baseline and following visceral and 
somatic stimulation. Cluster analysis identified two psychophysiological groups: 
cluster 1 (n=47, 39.1%) had higher neuroticism, while anxiety scores, with lower 
extroversion scores, had higher basal sympathetic tone (higher baseline HR & lower 
CVT), higher baseline cortisol but a PNS predominant response to visceral and 
somatic pain. Cluster 2 (n=73, 60.9%) had the opposite profile. In health, two 
distinct psychophysiological profiles exist in response to visceral and somatic pain, 
which may represent distinct phenotypes in response to pain. The clinical relevance 
and temporal stability of these phenotypes warrants further investigation. 
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3.2 Introduction 
Pain is the ubiquitous human experience, yet displays considerable inter- and intra-
individual variability in health and disease. Pain activates a complex stress response, 
multiplied and determined through genetic, psychological, physiological and 
neuroanatomical factors, which maybe in turn responsible for these inter and intra-
individual differences. Whilst acute pain is a protective mechanism, potentially 
conferring a survival advantage, chronic pain such as that seen in FM or IBS has far-
reaching implications and exerts a significant burden on society not only in terms of 
economic cost through increased healthcare utilisation, but also human cost 
through failure to fulfil potential [250, 251]. Interaction between the biological 
processes that represent susceptibility factors for the development of chronic pain 
is incompletely understood [252]. The biological substrates for the susceptibility 
factors for chronic pain have been proposed by many authorities to be the stress 
responsive systems, namely the ANS and HPA axis, which can be considered to 
represent the biological interface between the external environment and internal 
milieu, capable of integrating afferent nociceptive inputs with central connections 
and culminating in efferent motor outputs. Characteristics of these stress 
responsive systems have been shown to influence pain sensitivity [253]. 
 
In the wider clinical context, the personality traits of neuroticism, the ANS and 
HPA axis, have been investigated extensively as potential aetio-pathophysiological 
factors in chronic pain and affective disorders [64, 254, 255]. Recent meta-analyses 
have implicated subtle PNS dysfunction and higher baseline HPA axis tone in 
chronic somatic and affective disorders, respectively [64, 255, 256]. However, the 
manner in which these factors interact with each other to lead to the development 
of the clinical phenotype has not been determined. Therefore, it is not surprising 
 135 
that many studies have singly, and variably, implicated these factors in clinical 
populations in which chronic, unexplained pain is a defining feature. Inevitably, this 
has led to considerable heterogeneity in the reported effect sizes that these factors 
have in the pathogenesis of disorders of chronic pain. Thus, there is an urgent need 
to further delineate the complex relationship between personality, ANS and HPA 
axis responses to pain, and to integrate these factors in to the development of 
human pain phenotypes. The development of such phenotypes may reduce the 
heterogeneity of study populations in the future, potentially improving our 
understanding of the complex interrelated mechanisms of pain in health and disease. 
The latter is the prerequisite step in improving treatments and clinical outcomes.  
 
3.3 Hypothesis 
Therefore, my hypothesis was that, in health, distinct pain phenotypes exist based 
on personality traits, HPA axis and patterned ANS responses to visceral and 
somatic pain.  
 
3.4 Methods 
3.4.1 Subjects 
A cohort of 135 healthy volunteers, aged 18-60 years, was recruited for the study. 
Ethical approval for the study was granted by the East London and the City Ethics 
Committee 2 (ref 08/H0703/47). The study was performed in accordance with the 
Declaration of Helsinki. Subjects with a history of current or chronic pain, GI, 
neurological, cardiovascular or psychiatric problems were excluded. Current 
smokers, those currently taking any medications and those with subclinical anxiety 
or depression were also excluded, as assessed by the HADS [208, 257]. All female 
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participants were studied during the follicular phase of their menstrual cycle. Those 
subjects who exceeded the self-deception score, as assessed by the WAI, were 
excluded from the analysis [258].  
 
3.4.2 Pain Induction Techniques 
3.4.2.1 Visceral Pain Induction – Oesophageal Balloon Distension 
Commercially available oesophageal distension catheters, with an inflatable balloon 
mounted at the distal end (Sandhill, UK), were used during the study. Subjects were 
intubated with the oesophageal catheter, with the aid of a water-based lubricating 
jelly (KY Jelly, Johnson & Johnson), either trans-nasally or per-orally according to 
preference. The balloon was positioned in the mid/distal oesophagus at 32cm ab 
oral or 34cm ab nares. Local anaesthetic spray was not used during intubation. 
Subjects were allowed to rest for 10 minutes following intubation, prior to the 
application of visceral pain, to allow a period of “orientation” to the presence of the 
catheter. Painful stimulation was achieved by inflating the balloon at a rate of 
5ml/second to the subject’s pain tolerance threshold (PTT). The PTT was defined 
as the point at which the subject could not tolerate further stimulation. Subjects 
were then asked to rate the pain on a VRS measuring intensity (10, worst 
imaginable pain, to 0, no sensation) and unpleasantness (10, worst imaginable 
unpleasantness, to 0, neutral).  
 
3.4.2.2 Somatic Pain Induction – Nail Bed Pressure 
A strain gauge (Mecmesin, UK) was mounted on to a specially designed spring-
loaded device such that the extension probe incorporated a thin, blunt rod applied 
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to the subjects’ right thumb, 5mm from the cuticle, producing a stimulus of nail bed 
pressure ranging from touch to painful. Each painful somatic stimulus was achieved 
by applying nail bed pressure manually to the subject’s PTT. Pain intensity and 
unpleasantness were rated on the VRS scale, as per visceral pain.  
 
3.4.3 Personality, Psychological State and Trait Measures 
Self-report validated questionnaires were administered to evaluate state and trait 
measures of personality. The BFI and EPQ-R were used to measure the personality 
traits of neuroticism and extroversion [259, 260]. State and trait anxiety were 
assessed using the STAI-S and STAI-T [261]. 
 
3.4.4 Autonomic Measures 
Digital arterial BP was measured using a photoplethysmographic technique whereby 
a cuff was attached to the inter-phalangeal portion of the right middle finger, from 
which SBP, DBP and MBP are derived (Portapress, Finapress, Amsterdam, 
Netherlands). ECG electrodes (Ambu Blue Sensor P, Denmark) were placed in the 
right and left subclavicular areas and cardiac apex, following skin preparation 
(Nuprep, Weaver & Co, USA) to reduce impedance and improve signal. The ECG 
was acquired at a rate of 5 kHz using a commercially available biosignals acquisitions 
system, which allows validated ANS parameters to be measured in real time 
(Neuroscope(, Medifit Instruments, UK). The Neuroscope measures the ANS 
variables of HR, CVT and CSB. SCR are a measure of sympathetic sudomotor 
response to stimuli, through changes in electrical impedance [262]. Skin on the right 
index and ring fingers was wiped with water and allowed to dry. Skin conductance 
electrodes were then attached to the subject, and the skin impedance for that 
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subject was zeroed using a commercially available bioamp (Powerlab, 
AdInstruments, UK). Skin impedance was then recorded and subsequently analysed 
off line. 
 
3.4.5 Cortisol Measurement 
Serum total cortisol was assayed by the Blood Services Department at the Royal 
London Hospital using a chemiluminescence immunoassay (Nichols Advantage, 
Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). 
 
3.5 Protocol 
Subjects attended for one visit lasting three hours. Upon arrival they completed a 
consent form and then their height and weight were measured. Subjects were 
studied in the afternoon (from 1400-1600hrs) in a temperature-controlled (21-22° 
C), quiet laboratory. Subjects subsequently completed the personality and 
psychological state and trait questionnaires. Subjects were reclined at 45 degrees 
on a bed or reclining chair. The ANS recording equipment was then attached and 
five minutes of baseline data (resting/no stimulation) acquired. Autonomic 
parameters were recorded in accordance with the recommendations of the Task 
Force of the European Society of Cardiology [238]. All subjects had an 18G 
intravenous cannula (Venflon, Beckton Dickinson, UK) placed in the left antecubital 
fossa. Blood was taken at baseline for serum cortisol and a further sample stored in 
an EDTA tube at -80°C (Vacutainer, Beckton Dickinson, UK) for subsequent 
genetic analysis. A three-way, needle-free valve port was attached to the intra-
venous cannula in order to limit cross contamination between successive cortisol 
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samples (SmartSite Extension Set, Cardinal Health, Rolle, Switzerland). The study 
protocol is summarised in Figure 23. 
 
Figure 23 - A summary of the experimental protocol. 
 
Subjects received seven somatic stimuli to PTT, with an inter-stimulus interval of 
two minutes and a 10-minute rest period after the stimuli were completed. Subjects 
were then intubated with the oesophageal distension catheter and allowed to rest 
for 10 minutes. Subjects then received seven visceral stimuli to PTT, with an inter-
stimulus interval of two minutes. The subjects received a verbal cue five seconds 
prior to each painful stimulus delivery in an attempt to standardise any effects of 
anticipation. If the stimulus contained any artefact (such as coughing, sneezing, 
movement or swallowing) it was rejected and subsequently not analysed. Venous 
blood for cortisol (Vacutainer, Beckton Dickinson, UK) was sampled at baseline, 
two minutes after the final visceral stimulation, and then again two minutes after the 
final somatic stimulation.  
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3.6 Statistical Analysis 
Categorical variables are expressed as percentages. The Chi-squared test or 
Fisher’s exact test were used to compare groups. Continuous variables are 
expressed as mean " SEM. The ANS and HPA axis data was normally distributed, 
and group comparisons were undertaken using a two-tailed Student’s t-test, and for 
the multi-group comparison a one-way ANOVA with Bonferroni correction. Mann-
Whitney U Tests were used to compare personality state and trait scores. 
Correlational analysis was performed using Pearson or Spearman’s correlation, as 
appropriate. Two-step cluster analysis was performed, with input factors defined a 
priori based on a previous preliminary report [215]. Input parameters were 
neuroticism, extroversion, baseline CVT and 'change in CVT to visceral and 
somatic pain. Commercially available statistics packages (SPSS, Chicago, IL, USA and 
GraphPad, San Diego, CA, USA) were used for the analysis. P<0.05 was considered 
to be of statistical significance.  
 
3.7 Results 
3.7.1 Subject Characteristics 
In all, 120 healthy subjects completed the study (68 male) with a mean age of 28.9 
years (range 19-58 years) and a mean body mass index (BMI) of 25.68 kg/m2 "0.38 
kg/m2. Of the 120 subjects, 89 were Caucasian (74.16%), 29 were Asian (24.2%) and 
two Afro-Caribbean (1.6%). Fifteen subjects did not complete the study; four were 
excluded as they exceeded the self-deception score, three had subclinical anxiety or 
depression and eight did not tolerate oesophageal intubation. 
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3.7.2 Psychological Characteristics 
The mean scores across the self-report questionnaires are shown in Table 5. 
Correlations between state and trait measures are shown in Table 6. There were 
good correlations between neuroticism and extroversion, as measured by the BFI 
and EPQ-R (see yellow boxes in Table 6); therefore, data presented hereafter will 
only refer to those personality traits measured by the BFI. 
 
Questionnaire Mean SEM 
Big Five Inventory 
Extroversion 3.57 0.07 
Neuroticism 2.70 0.08 
Openness 3.70 0.04 
Conscientiousness 3.71 0.06 
Agreeableness 3.82 0.05 
Eysenck Personality Questionnaire Revised 
Extroversion 16.55 0.41 
Neuroticism 9.40 0.54 
Psychoticism 5.14 0.30 
Spielberger State and Trait Anxiety Inventory 
State Anxiety 32.10 0.79 
Trait Anxiety 35.22 0.84 
Hospital Anxiety & Depression Scale 
Anxiety 3.3 0.18 
Depression 1.63 0.13 
Table 5 - The mean personality state and trait scores. The scores contained herein are consistent 
with healthy populations. 
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BFI EPQ-R 
Spielberger Anxiety 
Inventory 
 
Extroversion Neuroticism Openness Agreeableness Conscientiousness Extroversion Neuroticism Psychoticism 
State 
Anxiety 
Trait 
Anxiety 
Extroversion  -0.53*** 0.16 0.19* 0.08 0.68*** -0.38*** -0.13 0.01 -0.11 
Neuroticism -0.55***  -0.40*** -0.40*** -0.2* -0.56*** 0.71*** 0.12 0.19* 0.36*** 
Openness 0.15 -0.39***  0.17 0.2* 0.05 -0.22* -0.03 -0.09 -0.27** 
Agreeableness 0.18** -0.4*** 0.17  0.44*** 0.1 -0.25** -0.37*** -0.12 -0.26** 
B
FI 
Conscientiousness 0.08 -0.2** 0.21** 0.43***  0.009 -0.12 -0.3*** -0.15 -0.22** 
Extroversion 0.51*** -0.34*** 0.05 0.1 0.009  -0.36*** -0.04 -0.28** 0.56*** 
Neuroticism -0.31*** 0.53*** -0.22* -0.25** -0.12 -0.36***  0.01 0.41*** 0.56*** 
E
P
Q
-R
 
Psychoticism -0.13 0.11 -0.03 -0.37*** -0.30*** -0.04 0.01  -0.04 0.01 
State Anxiety 0.01 0.49*** -0.09 -0.12 -0.15 -0.28** 0.41*** -0.04  0.79*** 
Sp
ielb
erger 
A
n
x
iety 
In
ven
to
ry 
 
Trait Anxiety -0.16 0.56*** -0.28** -0.26** -0.26* -0.22* 0.56*** 0.01 0.8***  
Table 6 - Two-tailed Pearson correlation coefficients between each personality traits as given by the BFI, EPQ-R and the STAI-S/T. The yellow boxes highlight the 
correlation coefficients between extroversion and neuroticism between the BFI and EPQ-R demonstrating good correlation.  *p<0.05, **p<0.01, ***p<0.001. 
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3.7.3 Stimulus Toleration  
The amount of stimulus tolerated from the first to seventh stimuli increased for 
both visceral (30.3mls ± 0.63 vs. 44.08mls ± 0.84, two-tailed paired t-test p<0.0001) 
and somatic pain (62.17N ±1.83 vs. 76.84N ±2.1, two-tailed paired t-test p<0.0001). 
The mean tolerated somatic stimulus positively correlated with the mean visceral 
stimulus (r=0.39, two-tailed p<0.0001) (see Figure 24).  
 
3.7.4 Affective Ratings of Visceral and Somatic Pain 
Visceral pain was rated as more unpleasant, but not more intense than somatic pain 
(7.67 ± 0.11 vs. 6.26 ± 0.14, two-tailed unpaired t-test p<0.0001) (see Figure 25).  
 
 
Figure 24 - The mean quantity of somatic stimulus tolerated across the seven stimuli vs. the mean 
quantity of visceral stimulus tolerated across the seven stimuli. These were positively correlated, 
two-tailed Pearson r=0.39 p<0.0001. 
 
 
 144 
 
Figure 25 - Panel A shows the median affective ratings for somatic and visceral pain intensity. Panel 
B shows the affective ratings for somatic and visceral pain unpleasantness. Visceral pain was rated 
as the more unpleasant, unpaired t-test, p<0.0001. 
 
3.7.5 Hypothalamic Pituitary Adrenal Axis Responses to Pain 
Sequential serum cortisol results were available in 84 subjects (55 male, mean age 
27.6 years, range 19-56). Mean baseline serum cortisol, mean post-somatic pain 
serum cortisol and mean post-visceral pain cortisol were 262.9 nMol/L ± 11.26, 
338.9 nMol/L ± 12.29 and 371.7 nMol/L ± 16.33, respectively (see Figure 26).  
 
 
Figure 26 – Mean serum cortisol at baseline, post-somatic pain and post-visceral pain. One-way 
ANOVA with Bonferroni correction, F(2,84)=16.98, p=0.0015, !=0.12.  
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3.7.6 Autonomic Nervous System Responses to Pain 
In comparison to baseline, changes were evident in all ANS parameters following 
somatic and visceral stimulation, except for CVT (see Table 7). In summary, pain 
caused cardiomotor, sudomotor and vasopressor increases with the concomitant 
withdraw of CSB. However, it is interesting to note that CVT, in comparison to 
baseline, withdrew to somatic pain yet increased to visceral pain. 
 
Variable Baseline 
Mean (±SEM) 
Somatic 
Pain 
Mean (±SEM) 
Visceral 
Pain 
Mean (±SEM) 
Baseline vs. 
Somatic Pain 
Baseline vs. 
Visceral Pain 
HR (bpm) 
68.77 
±1.03 
73.28 
±1.11 
76.48 
±1 
P<0.0001 P<0.0001 
SBP (mmHg) 
126.6 
±1.66 
141.2 
±2.09 
145.2 
±2.01 
P<0.0001 P<0.0001 
DBP (mmHg) 
61.73 
±1.34 
71.09 
±1.4 
74.04 
±1.25 
P<0.0001 P<0.0001 
MBP (mmHg) 
83.13 
±1.13 
94.43 
±1.5 
97.67 
±1.4 
P<0.0001 P<0.0001 
CVT (LVS) 
9.66 
±0.43 
8.88 
±0.41 
10.72 
±0.63 
P=0.02 P=0.08 
CSB 
(!RR/!mmHg) 
7.53 
±0.36 
6.21 
±0.27 
6.18 
±0.24 
P<0.0001 P<0.0001 
SCR (µS) 
2.98 
±0.34 
16.47 
±0.92 
14.75 
±0.81 
P<0.0001 P<0.0001 
Table 7 - Mean baseline, somatic pain and visceral pain autonomic variables, and statistical 
comparison between them (two-tailed paired t-test). 
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3.7.7 Relationships between Personality Traits, Affective Pain Ratings and 
Physiological Measures of Responses to Pain 
3.7.7.1 Personality, Stimulus Toleration and Affective Pain Ratings 
Neuroticism negatively correlated with the median quantity of somatic and visceral 
stimulation that was tolerated (Pearson r-0.3, two-tailed p=0.002 and Pearson r=-
0.28, two-tailed p=0.002 respectively). Affective ratings of pain were not correlated 
with the personality measures of neuroticism, extroversion or state and trait 
anxiety. 
 
3.7.7.2 Personality, Baseline Autonomic Variables and Dynamic Autonomic 
Responses to Pain 
Baseline CVT was correlated negatively with neuroticism (Pearson r=-0.52, two-
tailed p<0.0001). Conversely, baseline HR was correlated positively with 
neuroticism (Pearson r=0.38, two-tailed p=0.002). The relationship between the 
dynamic peri-stimulus pain-related CVT change was examined by calculating 
!change in CVT in the 30 seconds pre- vs. the 30 seconds post-stimulus – time 
points considered to demonstrate the maximal change in this parameter [215]. A 
preliminary study has suggested that the pain related change in CVT maybe of 
importance in defining the autonomic response to pain [214]. The degree and 
direction of CVT change were correlated for somatic and visceral pain (Pearson 
r=0.43, two-tailed p<0.0001). Neuroticism was correlated positively with a change 
in CVT to somatic and visceral pain (Pearson r=0.4, two-tailed p<0.0001, Pearson 
r=0.49, two-tailed p<0.0001). In summary, subjects either increased or decreased 
their CVT to pain and there was a trend for them to do so in the same direction 
for both somatic and visceral pain, i.e. to increase or decrease their CVT to pain. 
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Higher neuroticism scores were associated with a higher baseline HR, lower 
baseline CVT and an increase in CVT to visceral and somatic pain (see Figure 27). 
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Figure 27 - Panel A demonstrates the correlation between the direction and magnitude of dynamic 
CVT responses to visceral and somatic pain with the majority of subjects either increasing or 
decreasing their CVT to visceral and somatic pain (Pearson r=0.43, two-tailed p<0.0001). Panel B 
& C demonstrates the correlation between neuroticism and dynamic CVT change to somatic 
(Pearson r=0.4, two-tailed p<0.0001) and visceral pain (Pearson r=0.49, two-tailed p<0.0001).  
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Figure 28 - Panel A, B and C illustrate the correlations between neuroticism and baseline, post-somatic pain and post-visceral pain cortisol levels (Pearson r=0.6, two-
tailed p<0.0001, Pearson r=0.6, two-tailed p<0.0001 & Pearson r=0.67, two-tailed p<0.0001 respectively). 
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3.7.7.3 Personality and Hypothalamic Axis Responses to Pain 
Neuroticism was correlated positively with baseline, post-somatic pain and post-
visceral pain cortisol (Pearson r=0.6, two-tailed p<0.0001, Pearson r=0.6, two-
tailed p<0.0001 & Pearson r=0.67, two-tailed p<0.0001, respectively). STAI-S was 
correlated positively with baseline, post-somatic pain and post-visceral pain cortisol 
(Pearson r=0.27, two-tailed p=0.01, Pearson r=0.26, two-tailed p=0.01 & Pearson 
r=0.48, two-tailed p=0.0002, respectively).  
 
3.7.8 Cluster Analysis 
A two-step cluster analysis was performed, as this was a large data set with 
normally and non-normally distributed data. Input parameters were neuroticism, 
extroversion, baseline CVT and !change in CVT to visceral and somatic pain. These 
input parameters were defined a priori based a previous preliminary study [214]. 
The optimum solution was two clusters, with cluster 1 containing 47 subjects 
(39.1%) and cluster 2 containing 73 subjects (60.9%). The cluster silhouette 
coefficient was 0.7. The 2-step clustering method was utilised as it makes no 
assumptions as to the distribution of the data and the number of clusters. Other 
methods of cluster analysis, such as k-wise or hierarchical, were not used as there 
are a number of assumptions that are not met with this data set. Further 
comparison of means and categorical variables between the two groups is shown in 
Table 8. In summary, cluster 1 had higher neuroticism scores, lower extroversion 
scores and higher trait anxiety scores. At baseline, cluster 1 had a higher resting 
HR, SCR and cortisol with lower CVT and CSB. In response to somatic pain, 
cluster 1 tolerated less stimulus, habituated less, had higher cortisol and increased 
CVT and CSB, albeit with an attenuated HR response. In response to visceral pain, 
 151 
similar patterned responses were observed. Cluster 2 displayed the converse 
profile with higher basal PNS tone with PNS withdrawal and SNS activation to pain. 
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Variable Cluster 1 (n=47) Cluster 2 (n=73) P Value 
Demographics 
Male: Female 27 : 20 41 : 32 1 
 Mean Age 29.36 ± 1.3 28.52 ± 0.94 0.6 
Caucasian : Non-Caucasian 31 : 16 58 : 15 0.13 
Personality Traits Mean (±SEM) Mean (±SEM)  
BFI Neuroticism 3.75 ± 0.1 2.0 ± 0.07 <0.0001 
BFI Extroversion 2.94 ± 0.09 3.99 ± 0.07 <0.0001 
STAI-T 38.13 ± 1.33 33.34 ± 1.05 0.005 
STAI-S 33.5 ± 1.3 31.23 ± 0.98 0.06 
HPA Axis Mean (±SEM) Mean (±SEM)  
Baseline Cortisol  
(nMol/L) 
298.6 ± 16.76 225.1 ± 12.66 0.0008 
Post-somatic Pain Cortisol 
(nMol/L) 
406.7 ± 19.47 296.3 ± 12.77 <0.0001 
Post-visceral Pain Cortisol 
(nMol/L) 
476.1 ± 24.7 303.2 ± 15.54 <0.0001 
Baseline Autonomics Mean (±SEM) Mean (±SEM)  
HR (bpm) 72 ±1.87 66.7 ± 1.12 0.01 
MBP (mmHg) 84.8 ± 2.2 82.08 ± 1.72 0.34 
CVT (lvs) 7.13 ± 0.46 10.89 ± 0.57 0.0001 
CSB (!RR/!mmHg) 5.99 ± 0.49 8.51 ± 0.49 0.0009 
SCR (µS) 3.57 ± 0.69 2.18 ± 0.23 0.02 
Somatic Pain Mean (±SEM) Mean (±SEM)  
Mean stimulus (N) 62.77 ± 0.27 73.81 ± 2.1 0.001 
Habituation 
(!% 1st vs. final stimulus) 23.47 ± 4.36 34.66 ± 2.9 0.03 
!HR (%) 2.12 ± 1.09 6.45 ± 1.08 0.007 
!MBP (%) -0.05 ± 0.96 -0.51 ± 0.48 0.48 
!CVT (%) 28.81 ± 6.6 -10.3 ± 2.2 <0.0001 
!CSB (%) 27.2 ± 10 4.8 ± 4.1 0.02 
!GSR (%) -0.32 ± 0.3 2.8 ± 0.3 0.01 
Visceral Pain Mean (±SEM) Mean (±SEM)  
Mean stimulus (ml) 35.9 ± 0.97 39.46 ± 0.87 0.009 
Habituation 
(!% 1st vs. final stimulus) 42.94 ± 4.8 54.2 ± 4.06 0.04 
!HR (%) -0.3 ± 0.7 4.05 ± 1.0 0.0025 
!MBP (%) -3.35 ± 1.3 -1.67 ± 0.39 0.15 
!CVT (%) 50.09 ± 9.3 -0.92 ± 3.3 0.03 
!CSB (%) 44.2 ± 12.09 15.88 ± 7.0 <0.0001 
!GSR (%) -0.44 ± 0.22 2.6 ± 0.1 0.01 
Table 8 – Phenotypic differences between clusters. Demographic, personality traits, baseline 
autonomic, visceral and somatic pain differences between cluster 1 and cluster 2 are shown. For 
categorical variables, p value is derived from Fisher's exact test and all other continuous variables 
were compared using unpaired t-tests or Mann-Whitney U test depending on the normality of the 
data. 
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3.8 Discussion 
3.8.1 Pain Phenotypes 
I have demonstrated the existence of two phenotypic profiles based on personality, 
autonomic and HPA axis responses to visceral and somatic pain in a relatively large 
group of healthy volunteers. The first profile, comprising approximately one-third 
of the individuals in this study, had higher neuroticism and trait anxiety scores and 
was characterised by higher resting HR and cortisol but with lower CVT, although 
during pain tolerated less quantity of stimulus, habituated less but increased CVT 
and CSB. In other words, neurotic-anxious individuals were characterised by a 
sympathetic predominant resting state with a paucity of parasympathetic tone at 
rest but a predominant parasympathetic response to pain. 
 
Conversely, the second profile, accounting for approximately two-thirds of the 
study population, had higher extroversion scores and less trait anxiety and was 
characterised by a lower resting HR and cortisol but a higher CVT, with a 
withdrawal of CVT and CSB to pain with a concomitant increase in HR. This group 
tolerated a greater quantity of stimulus and habituated more. This profile can be 
characterised as having a predominant parasympathetic resting state with a 
sympathetic patterned defence response to pain. Figure 29 summarises these 
differences. It must be acknowledged that subjects’ with absent/incomplete data, 
such as those who did not have sequential cortisol results available, could have 
altered the clusters. However, the a priori defined input variables did not include 
any of these measures so cluster membership per se would not be altered. 
However, bias may have occurred the apparent differences in phenotypic, particular 
with respect to HPA axis data. It must also be noted that in Paine et al. the measure 
used to assess vagal tone was not CVT, but cardiac vagal control from the NA 
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(CVC NA), which is determined by the application of a polynomial filter application 
to the ECG inter-beat interval series. There is no data that examines the 
correlation or level of agreement between CVT and CVC NA but given that both 
parameters purport to measure efferent PNS tone, this did not seem to be an 
unrealistic comparison. As discussed in chapter 1, the personality traits of 
neuroticism and extroversion are often considered to be inversely correlated with 
one another. It could be argued that using BFI-N and BFI-E are not discriminatory 
as input factors in the cluster analysis. However, as part of the aim of this study was 
to further investigate the preliminary findings of Paine et al. this was the reason for 
using both BFI-N and BFI-E as input factors in the cluster analysis [214]. 
Furthermore, in the correlational analysis performed comparing BFI-N vs. BFI-E, the 
correlation was not perfect with an r=-0.53 thus suggesting only limited strength of 
inverse correlation between the two variables.  
 155 
 
Figure 29 - A summary of the two phenotypes identified in response to visceral and somatic pain in 
a cohort of healthy volunteers. 
 
3.8.2 Patterned Defence Responses in Animals 
Similar patterned defence responses have been reported in differentially anxious 
animals [263, 264]. These studies have characterised dichotomous autonomic 
responses to a noxious stimuli as being parasympathetic predominant, termed 
passive coping or tonic immobilisation, or sympathetic dominant, termed fight or 
flight. For example, Valance et al. demonstrated that birds with high emotional 
reactivity, akin to higher neuroticism and anxiety scores in humans, have higher 
motor inhibition in response to acoustic stimulus than birds with low emotional 
reactivity [265]. In mammals, stimulation of specific areas within the PAG has been 
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shown to produce dichotomous patterned autonomic defence responses. In 
particular, simulation of the ventrolateral PAG, which receives inputs from the 
nucleus of the solitary tract and from the spinal dorsal horn, produces responses 
similar to those seen in cluster 1, i.e. a reduced sympathetic and increase 
parasympathetic response with a relative bradycardia. Lesions in this area abolish 
this freeze/tonic immobility response [266]. Conversely, lesions in the dorsolateral 
PAG block a fight/flight response, whereas stimulation enhances it, i.e. a similar 
pattern to cluster 2 [267]. Based on this evidence in animals, it is interesting to 
speculate that cluster 1 may preferentially activate the ventrolateral PAG in 
response to pain, whilst cluster 2 may preferentially activate the dorsolateral PAG. 
 
3.8.3 The Role of the Parasympathetic Nervous System in Analgesia 
There is mounting evidence on the role of the PNS in anti-nociception and 
inflammation [268] (also see section 1.20.4, page 78). A recent meta-analysis of 
functional somatic syndromes, which are characterised by chronic, unexplained pain 
and an excess of neuroticism, concluded that patients have lower parasympathetic 
activity at rest [64]. A similar relative paucity of basal parasympathetic activity was 
observed in cluster 1. It has been well characterised that neuroticism confers 
increased pain sensitivity and that electrical stimulation of the vagus nerve, used in 
the treatment of refractory epilepsy, reduces pain sensitivity [269]. An intriguing 
possibility therefore is that, in health, whilst neuroticism predisposes to increased 
pain sensitivity, increasing parasympathetic tone to pain acts as an analgesic 
mechanism to offset this sensitivity (see Figure 30). The central connections for 
such a mechanism are likely to be complex but may involve preferential activation 
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of the limbic system, an area where higher activity has been shown to be associated 
with neuroticism [270].  
 
Figure 30 – A highly schematic representation of the potential effects of vagal mediated analgesia. 
Neuroticism and genetic factors have been proposed to confer heightened sensitivity to somatic 
and visceral pain. In healthy subjects who are more neurotic, an increase in (cardiac) vagal tone 
was observed in this study, which may mediate a behavioural response (freeze/tonic immobility) 
and increase analgesia to “offset” this sensitivity. 
 
3.8.4 Challenging the Dogma of “Fight or Flight” 
Cannon formulated the term “fight or flight” over 80 years ago, capturing the 
essence of the ANS-mediated motor phenomenon that occurs in response to a 
threat [271]. This phrase has led to certain assumptions and expectations of the 
“normal” physiological response to a threat or to stress. Moreover, it is a 
testament to Cannon’s phraseology that it remains in common parlance, yet the 
term ignores recent major advances in stress research. In many ways, "fight or 
flight" responses misrepresent the ordered sequence of responses that mammals 
exhibit in response to an acute stressor. Gray proposed four distinct responses 
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that proceed sequentially in response to an increasing threat [272]. The sequence 
begins with "the freeze response" corresponding to what clinicians typically refer to 
as “hypervigilance”. This initial freeze response is the "stop, look and listen" 
response associated with fear. Specifically, ethological research has demonstrated 
that prey that remain "frozen" during a threat are more likely to avoid detection 
because the visual cortex and retina of mammalian carnivores primarily detect 
moving objects [273]. After this initial freeze response, the next response in the 
sequence is an attempt to flee, and once this has been exhausted there is an 
attempt to fight. Thus, "freeze, flight then fight" is the proper order of responses 
rather than "fight or flight." Freeze responses have been well characterised in 
humans when faced with life threatening situations. For instance, a behavioural 
freeze response may be seen in some victims of violence who exhibit extreme 
passivity during the assault. In light of Cannon, and subsequently Gray’s, 
formulations, it is worth considering the possible relation to the two phenotypes 
that have been identified in this study. Cluster 1 mounts a predominant 
parasympathetic response to pain, thus displaying a greater freeze response than 
cluster 2. Cluster 1 represents a significant proportion of the study population, 
approximately one-third of the individuals studied, suggesting that this response to 
a threat is evolutionarily conserved and may permit a survival advantage. However, 
it is important to acknowledge the importance of the often conflicting demands of 
biological and social imperatives. For instance, in a military situation, when a soldier 
encounters a sign of threat, the socially appropriate response, i.e. the response 
demanded by his military training and reinforced by other members of his unit, is 
usually the "stop, watch and listen" heightened alertness response. This behaviour is 
consistent with the biological predisposition toward the first part of the sequence – 
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the freeze response. However, as the reality of contact with the enemy grows, the 
biological and situational demands are no longer in concert. The evolved response 
to flee is in now in direct conflict with military training, further increasing the 
intensity of this already stressful experience, something that many authorities have 
implicated in the aetiology of post-traumatic stress disorder [274]. Military training 
and experience may influence the nature of this initial response, thus suggesting that 
social factors and learning may overcome these conflicts. Although there is no 
evidence for an over-representation of extroversion in the military, training and 
experience have been shown to modulate autonomic responses to stress [275]. 
Whether the sequence of response is different untrained individuals’ has not been 
fully studied. It is interesting to hypothesise that there might be some distinct 
switching point/mechanism that engages the flight or flight mechanism following a 
freeze response. Another interesting point is whether this “trait”, if genetic, can be 
altered or influenced to change the response. 
  
3.8.5 Distinct Clusters or a Spectrum of Responses? 
An important question relates to whether the clusters that are proposed in this 
study represent a distinct phenotype or a spectrum of responses. Similar 
controversy exists within personality research as to whether differences in traits 
are most informatively expressed in a dichotomous manner (such as extroversion 
or neuroticism) or thorough more continuous measures (such as neurotic-introvert 
or extrovert-emotionally stable). The results contained herein provide evidence for 
both approaches through correlational analysis for the former and cluster analysis 
for the latter. However, it is interesting to note that the two clusters are defined 
multi-dimensionally across a number of interrelated but distinct biological systems, 
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and not solely defined with respect to personality. In addition, the cluster silhouette 
coefficient was 0.7, indicating a good degree of separation between the two groups. 
These arguments taken together lend more weight to a dichotomous proposal, but 
further work is warranted to further validate these phenotypes in a larger cohort of 
subjects. Furthermore, there are several barriers in attempting to relate personality 
traits with physiological processes. Firstly, the cardinal personality traits of 
neuroticism have been called “surface trait measures” and may be somewhat 
removed from the physiological effector mechanisms themselves [276]. Secondly, it 
may be naïve to think that personality traits have an isomorphic distribution across 
the central connections that drive these physiological effectors. Future studies may 
benefit by exploring these findings using narrower trait measures of personality 
such as sensation seeking, sensory sensitivity and interoceptive sensitivity.  
 
3.8.6 Relevance to Clinical Populations 
The relevance of these pain phenotypes to clinical populations is uncertain, but it is 
fascinating that many of the factors associated with cluster 1 have been implicated 
as associated clinical features in many chronic, unexplained pain syndromes. For 
instance, evidence from many studies of IBS has implicated personality traits, 
dysautonomia and the HPA axis in their pathophysiology [54, 277, 278]. However, 
these factors have generally been reported in isolation and have not always been 
reproducible. This lack of (reproducible) progress may arise from a number of 
fundamental difficulties in the approaches that have been employed in studying 
these, almost certainly, poly-pathophysiological and polygenic disorders. By using 
methods similar to those employed in this study, and in attempting to define 
phenotypic differences using a multidimensional approach, understanding of these 
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disorders might be improved in future studies through the improvement of 
subjects’ homogeneity. These methods may allow the scientific community to “go 
back to the drawing board” in improving its definition of disease phenotypes, which 
ultimately may allow for more directed, targeted and potentially more efficacious 
therapies. 
 
3.9 Conclusions 
In summary, I have provided novel evidence of the existence of two 
multidimensional pain phenotypes based on personality traits and autonomic and 
HPA axis responses to visceral and somatic pain. Further work is now needed to 
ascertain whether there is a genetic component to these phenotypes and whether 
they are temporally stable. In the following chapter, I shall explore the genetic basis 
of these phenotypes. 
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Chapter 4 - Genotyping Pain Phenotypes by the 
Serotonin Transporter Long Polymorphic Region 
4 Genotyping Pain Phenotypes by the SERT Long Polymorphic  
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4.1 Chapter Overview 
Many studies have implicated genetics differences in the explanation of the variation 
in human pain sensitivity. Evidence suggests that FGID display a degree of 
heritability. The serotoninergic system plays an important role in 
neurotransmission, and polymorphisms of the 5-HTTLPR have been shown to alter 
SERT transcription and function. The 5-HTTLPR is composed of two alleles, the 
dominant short (S) allele and the long (L) allele. The primary aim of this study was 
to evaluate the hypothesis that there is a genetic component to the pain 
phenotypes identified in Chapter 3, by examining 5-HTTLPR polymorphisms. The 
secondary aims were to explore putative associations between 5-HTTLPR 
genotype, pain sensitivity, personality and anxiety traits in association with dynamic 
HPA axis and ANS responses to pain. In all, 107 subjects were genotyped using SSP-
PCR (63 male, median age 27.5 years, range 19-53 years). Of the 107 subjects, 77 
were Caucasian (73.9%), 16 Asian (14.9%), 9 Japanese (8.4%) and 3 Afro-Caribbean 
(2.8%). The distributions of genotypes were in Hardy-Weinberg equilibrium. The 
presence of the S allele was associated with the following: higher neuroticism 
scores, higher state and trait anxiety scores, higher baseline cortisol, increased 
reactivity of the HPA axis to visceral pain and an increase in CVT to visceral and 
somatic pain. Furthermore, those individuals with an absent S allele were over-
represented in the cluster 2. These results provide evidence that polymorphisms in 
the 5-HTTLPR may form part of a genetic component to pain phenotypes, and the 
functional sequelae of these polymorphisms interact at multiple levels in the pain 
neuromatrix. 
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4.2 Introduction 
Exploring the genetic basis of variation in human pain sensitivity is central to 
advancing our understanding of the biology of pain. Through the identification of 
putative genetic candidates, important insights into the molecular physiology of pain 
sensitivity may be characterised. In addition, this process of identification may 
facilitate a more complete appreciation of inter- and intra-individual variability in 
clinical responsiveness to pharmacotherapeutics, which may potentially lead to the 
individualisation of treatment. Whilst recent evidence has provided important 
insights in to the genetic basis of the variation in pain sensitivity and therapeutic 
response, considerable controversy remains. In many ways this is not surprising 
given the size of the human genome, the complexity of the biology of pain, the 
variability of study design, alternative statistical approaches and, to date, relatively 
small sample sizes.  
 
Familial aggregation and twin studies in clinical populations of FGID have provided 
evidence that there is a substantial component of heritability in disorders, the most 
studied being IBS [78] [77]. Whilst this genetic component has been well 
established, the contribution of the shared environment to this syndrome has not 
been completely resolved.  
 
IBS is a prevalent example of an FGID, which is characterised by chronic abdominal 
pain in association with a disturbance in stool form or frequency. The 
pathophysiology of this disorder is incompletely understood, but is thought to be 
multifactorial, involving peripheral and central mechanisms which induce 
aberrancies of GI tract motility and nociceptive processing [279]. Within this 
 166 
disorder it is interesting to note that there is an excess of psychiatric co-morbidity, 
including anxiety and depression, for which the personality trait of neuroticism is a 
risk factor [280]. Anxiety-related traits such as neuroticism are central, fundamental 
and continuously distributed dimensions of the normal human personality [281]. In 
a similar fashion to that alluded to in IBS, twin studies have indicated that between 
40-60% of the variation in these traits is heritable [282]. Variance in personality, and 
to a lesser extent IBS subtype, is considered to be the result of a complex 
interaction between the environment and an individual’s genetic profile (see Figure 
31).  
 
Figure 31 - A schematic representation of the relative influences of genetic and environmental 
factors on IBS. 
 
In attempting to study the genetic basis of disease, the most frequently utilised 
methodology has been the candidate gene approach, where genes, whose putative 
function is hypothesised, play a role in the pathophysiology of the disorder under 
consideration. In these respects the serotoninergic system represents an attractive 
candidate for study in FGID and pain, in that it plays a pivotal role in 
neurotransmission that contributes not only to a wide range of physiological 
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processes (such as motor activity, food intake and sleep) but also in cognitive 
processes and emotional states such as mood and anxiety. Moreover, the 
serotoninergic system is the target for many clinically efficacious drugs that are used 
in the treatment of FSD, FGID and affective disorders. The single, most studied 
genetic association is the serotonin transporter long polymorphic region (5-
HTTLPR). In humans the transcriptional activity of the serotonin transporter 
(SERT) gene, SLC64A, is modulated by the 5-HTTLPR, which is located upstream of 
the transcription start site. SERT regulates the magnitude and duration of 
serotoninergic neurotransmission both centrally and peripherally.  
 
4.3 Structure and Function of the Serotonin Transporter 
SERT is a member of the large solute carrier transporter family, and its gene is 
designated SCL6A4. In humans, SERT is a monomeric protein encompassing 630 
amino acids consisting of 12 transmembrane domains (TMD) (see Figure 32). SERT 
expression has been demonstrated in a number of human tissues including the 
stomach, small bowel and the CNS [283, 284]. A large extracellular loop between 
TMD 3 and 4 offers potential sites for glycosylation and phosphylation [285]. Amino 
acids in the TMD 1 and 3 are major determinants of 5-HT binding, with the 
phosphorylation and dephosphorylation of these areas regulating the potential 
density of SERT on the cell membrane. 
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Figure 32 - The serotonin transporter with its 12 transmembrane domains, extracellular loops and 
intracellular amino- and carboxy-terminal tails. Adapted from Murphy DL, Lesch K-P, Nature 
Reviews Neuroscience, 2007 [286].  
 
SERT facilitates the reuptake of 5-HT through a number of steps via the co-
transport of Na+ and Cl- and counter-transport of K+ [287]. Firstly, 5-HT, Na+ and 
Cl- bind to a single site that is accessible from the extracellular space, inducing a 
conformational change in the SERT and thereby providing access to the cytoplasm. 
In this conformation, 5-HT, Na+ and Cl- disassociate from the SERT, entering the 
cell and allowing K+ to bind to the same site, which allows access from the 
extracellular space and in so doing allowing the process to reoccur. Within the GI 
tract, 5-HT is stored in EC cells, which release the 5-HT in response to mechanical 
and chemical stimuli prompting peristalsis, secretion and vasodilation. In addition, 5-
HT release also affects a complex array of sensory signalling through various sub-
types of the serotoninergic receptor. The primary targets of 5-HT release from EC 
cells are the mucosal projections of afferent neurons including extrinsic afferent 
neurones, which convey sensory information to the CNS, and intrinsic afferent 
neurones, which initiate local peristaltic and secretory reflexes. Within the CNS, 
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SERT fine tunes serotoninergic transmission and is abundant within the cortical and 
limbic areas, regions that are involved in the emotional aspects of behaviour [288].  
  
4.4 Transcription of the Serotonin Transporter Gene  
A single SERT gene has been identified in humans. It is located on chromosome 
17q11.2, is 37.8Kb in length and comprises 630 amino acids. The start codon is 
located in exon-2, and the SERT protein is coded for the nucleotide sequence from 
exon-2 to exon-14 [289]. The human SERT gene controls transcription of mRNA, 
itself controlled by a promoter with a highly polymorphic sequence in exon-1, 
containing the 5-HTTLPR, which consists of a 43-bp deletion or insertion resulting 
in an S or an L allele and has been proposed to influence the transcriptional 
efficiencies of the SERT gene. In a series of studies it has been shown that when 
transfected into human SERT-expressing cell lines, the S and L alleles of the 5-
HTTLPR differentially modulate the transcriptional activity of the SERT promoter 
region [236]. The effect of 5-HTTLPR length variability on SERT function was 
determined by examining the relationship between 5-HTTLPR genotype, SERT gene 
transcription and 5-HT uptake activity in human placental choriocarcinoma cells 
[290]. Cells homozygous for the L allele of the 5-HTTLPR produced higher 
concentrations of SERT mRNA than cells containing one or two copies of the S 
allele. For membrane preparations of the same cells, the rate of 5-HT uptake from 
the extracellular space was two times higher in the cells homozygous for the L 
allele than in cells containing one of two copies of the S allele. Further in vitro 
evidence for the differential activity of the 5-HTTLPR on SERT transcription comes 
from studies of mRNA concentrations in the raphe complex in human post-mortem 
brains and in platelet 5-HT uptake and content [291, 292]. Heinz et al. measured 
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the availability of SERT using volumetric neuroimaging of the raphe area in eight 
healthy controls who had been genotyped for the 5-HTTLPR. Those subjects with 
the S allele of the 5-HTTLPR had a significantly lower 5-HT expression in the 
midbrain. Taken together, these studies demonstrate that genotypic variation in the 
5-HTTLPR influences the transcription and function of the SERT. The S allele can 
therefore be considered “dominant” in the reduction of SERT function, with a 
consequential rise in 5-HT in the synaptic cleft (see Figure 33). 
 
 
 
 
Figure 33 – Transcriptional variations in the 5-HTTLPR. The S allele variant of the 5-HTTLPR 
(purple) of the SERT gene produces significantly less SERT mRNA than the L allele (red). This 
leads to a reduction in the function of SERT, resulting in reduced clearance of synaptic 5-HT. 
Adapted from Canli and Lesch, Nature Neuroscience, 2007 [293]  
 
4.5 Evidence Implicating the Serotonin Transporter Long 
Polymorphic Region in Neuroticism and Affective Disorders 
Recent interest has focused on the genetic basis of complex personality traits such 
as neuroticism, which has been demonstrated to be a risk factor for the 
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development of affective disorders and heightened pain sensitivity in health and 
disease [294]. Evidence suggests that personality traits such as neuroticism are 
heritable, but influenced significantly by environmental and non-genetic influences 
[295]. Approximately 50% of the variation in neuroticism is thought to be genetic in 
origin, with the remainder accounting for environmental and other unknown 
factors. In twin studies, the shared environment may account for only 5% of the 
variance, whereas the non-shared environment, representing an individual’s unique 
set of life experiences, contributes up to 35% [296]. Personality traits can therefore 
be best regarded as the result of a complex and variable interaction between these 
variables (see Figure 34). 
 
Figure 34 – Personality is influenced by a number of parameters including genetic factors and 
shared and non-shared environment.  
 
However, it would be naïve to expect that a single gene would influence an 
inherently complex trait such as personality. Indeed, it has been proposed that the 
genetic component of neuroticism, based on the variance explained by known 
candidate genes, is accounted for by up to a hundred genes [296]. As 5-HT is a 
major neurotransmitter in the CNS, it is not surprising that polymorphisms of the 
5-HTTLPR have been evaluated to ascertain if they scale up to the behavioural level 
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and hence influence personality. For example, it has been shown that individuals 
that carry the S allele have higher levels of neuroticism than those with the L allele, 
although this association subtly accounted for only 3-4% of the genetic variance 
[236]. It has been nearly 15 years since this initial report and a number of studies 
have attempted to replicate these findings. Disappointingly, they have described 
conflicting results and consequently raised concerns regarding the strength of this 
relationship. These conflicting results are likely to be sequelae of the considerable 
variation in the methods used to evaluate personality and the need to study a 
considerable number of subjects in order to have a sufficient sample size to 
confidently detect a difference (see Table 9 and Table 10). 
  
A recent meta-analysis by Schinka et al. demonstrated that, whilst there was no 
evidence to support the association between anxiety and 5-HTTLPR 
polymorphisms, neuroticism, when measured using the five-factor personality scale 
proposed by McCrae and Costa [297], demonstrated an association between the 
presence of the S allele and neuroticism (d=0.23)††.  
 
These studies suggest that there is a small but definite association between 5-
HTTLPR and neuroticism, especially when measured using the five factors of 
personality. However, further examination of this polymorphism and its interaction 
with other candidate genes is warranted. 
                                            
* Effect size, as given by the d-statistic, was calculated in this meta-analysis as the difference in anxiety 
and neuroticism measures between genotypes divided by the pooled standard deviation of the 
group. Conventionally, d-values are interpreted as follows: 0.2, 0.5 and 0.8 are considered to be 
indications of small, medium and large effect sizes, respectively. 
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5-HTTLPR Genotype 
SS genotype LS genotype LL genotype Author Year 
Mean SD N Mean SD N Mean SD N 
Ethnicity 
Cruz [298] 1995 13.50 5.70 20 10.30 4.60 26 12 5.4 26 Caucasian 
Jorm [299] 1998 4.36 3.50 155 4.49 3.27 350 4.42 3.33 254 Caucasian 
Willis –
Owen 
[300] 
(singletons) 
2005 14.15 9.98 129 13.65 10.09 327 13.22 10.19 274 Caucasian 
Willis –
Owen 
[300] 
(siblings) 
2005 12.39 9.03 97 13.98 8.74 254 11.90 9.27 177 Caucasian 
Willis –
Owen 
[300] 
(singletons) 
2005 4.73 4.38 755 4.74 3.84 2029 4.88 4.37 1391 Caucasian 
Munafo 
[301] 
2006 14.59 5.94 46 11.71 5.77 129 12.59 5.78 76 Caucasian 
Middeldorp 
[302] 
2007 32.62 10.13 203 32.30 10.05 283 32.64 10.77 86 Caucasian 
Schmitz 
[303] 
2007 13.49 5.99 143 12.55 5.81 196 11.23 5.53 71 Caucasian 
Totals 13.73 8.7 1548 12.97 8.6 3594 12.86 8.5 2355  
Table 9 - The distribution of neuroticism scores using the EPQ-R across the 5-HTTLPR genotypes from the literature. 
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5-HTTLPR Genotype 
SS genotype LS genotype SS genotype Author Year 
Mean SD N Mean SD N Mean SD N 
Ethnicity 
Lesch [236] 1996 56.3 11.2 95 56.6 12.0 247 53.1 11.5 163 Caucasian 
Nakamura 
[304] 
1997 142.99 9.55 128 143.29 10.88 55 137.33 9.45 3 
Japanese 
Flory [305] 1999 47.5 9.4 37 51.4 10.1 112 50.5 10.8 76 Caucasian 
Kumakiri 
[306] 
1999 104 22 85 104.5 22 48 103.6 25.9 11 
Japanese 
Du [307] 2000 41.98 10.32 40 39.93 8.49 86 40.42 9.24 60 Caucasian 
Greenberg 
[308] 
2000 59.02 12.25 66 60.17 11.21 217 56.29 11.65 114 
Caucasian 
Hu [309] 2000 57.67 11.46 135 58.55 11.95 390 54.65 11.73 234 Caucasian 
Osher [310] 2000 91.5 25.6 39 92.8 23.8 70 92.3 24.3 35 Caucasian 
Brummett 
[311] 
2003 39.8 9.2 13 40.2 8.8 51 44.8 9 35 
Caucasian 
Umekage 
[312] 
2003 103.9 21.1 103 99.1 15.3 46 101.50 17.1 10 
East Asian 
Jacob [313] 2004 95.89 31.49 40 94.18 25.65 140 98.18 23.17 101 Caucasian 
Lang [314] 2004 31.6 7.2 41 29.9 7.6 102 28.8 5.74 85 Caucasian 
Sen [314] 2004 87.8 18.86 83 84.5 20.83 183 79.9 19.41 149 Caucasian 
Dragan 
[315] 
2006 24.23 7.14 22 24.85 9.3 74 19.73 9 100 
Caucasian 
Vormfelde 
[316] 
2006 91.5 6.1 69 89 22 90 86.5 26 36 
Caucasian 
Schmitz 
[317] 
2007 2.96 0.82 143 2.89 0.75 196 2.75 0.68 71 
Caucasian 
Stein [318] 2008 48.62 9.87 68 47.97 9.98 108 47.3 10.38 71 Caucasian 
Totals 66.31 35 1207 65.87 35.3 2215 64.37 35.1 1354  
Table 10 - The distribution of neuroticism scores across the NEO-personality inventory as per genotype. SD = standard deviation, N = number of subjects. 
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4.6 Evidence implicating Serotonin Transporter Long 
Polymorphic Region in Hypothalamic Pituitary Adrenal Axis 
Reactivity 
Several investigators have found that individuals who possessed the S allele, either 
in the homozygous or heterozygous form, of the 5-HTTLPR exhibited higher levels 
of depression as a function of exposure to stressful life events [319, 320, 321]. 
However, the mechanisms that underlie this moderation of stress reactivity are 
incompletely understood. Findings from other work suggest that the HPA axis may 
be involved in the modulation of stress reactivity. For instance, in knockout mice 
with reduced function or absent SERT, it has been shown that there is a greater 
increase in ACTH in response to stress [322]. In humans, it has been observed that 
the SS genotype of the 5-HTTLPR confers an increase in risk for the development 
of depression in response to stressful events, thereby providing evidence that 
genotype may increase sensitivity to stress [323]. 
 
Based on this evidence, a recent study by Gotlib et al. hypothesised that carriers of 
the S allele are characterised by hypercortisolaemia because they are biologically 
more reactive to stress, i.e. display greater stress reactivity [324]. They studied 67 
females, stratified for the risk of depression by virtue of family history, who were 
stressed using a standardised mental arithmetic task whilst assessing salivary 
cortisol and 5-HTTLPR genotype. Those who were homozygous for the S allele had 
a higher and more sustained cortisol response, suggesting genotype may influence 
the biological activity of the HPA axis in response to stress. This study therefore 
implicates 5-HTTLPR in the modulation of HPA axis responses to stress.   
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4.7 Evidence Implicating the Serotonin Transporter Long 
Polymorphic Region in Pain Responsiveness 
5-HT has been associated with nociceptive transmission and pain modulation in a 
number of pivotal studies, particularly those demonstrating the spinal analgesic 
action of 5-HT released from the brainstem [325, 326]. There is accumulating 
experimental and clinical evidence that SERT function and 5-HTTLPR genotype may 
play an important role in modulating nociception. In animal models, pharmacological 
manipulation of the SERT function has been shown to alter pain sensitivity [327]. In 
humans, Kosek et al. investigated the influence of 5-HTTLPR on pain sensitivity and 
analgesic response to opioids in healthy volunteers [328]. Subjects were asked to 
rate pain to thermal stimulation, before and after intravenous injection of the 
selective µ opioid agonist remifentanil. Those with the genotype coding for low 
SERT expression, akin to the presence of the S allele, had an increased analgesic 
response. This study suggests that in the acute phase there is an increased analgesic 
response to opiates that is, in part, genotype-dependent.  
 
In a recent study by Fukudo et al., the impact of the 5-HTTLPR on brain activation 
to colorectal distension was assessed in healthy volunteers [82]. It was shown that 
those subjects with the SS genotype had a larger increase in regional cerebral blood 
flow to colorectal distension with specific activation in the left ACC and 
parahippocampal gyrus. These brain regions have been shown to be important in 
processing the affective-motivational aspects of pain. This data suggests that those 
with the SS genotype respond to gut signals more readily in the “emotional” areas 
of the brain. Although this study has its limitations, in terms of the relatively small 
number of participants and that it only studied Japanese subjects, it does propose a 
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mechanistic explanation of why the SS genotype has been associated with IBS, a 
disorder linked with abnormal central processing of visceral pain.  
 
4.8 Evidence Implicating the Serotonin Transporter Long 
Polymorphic Region in Autonomic Function 
Interactions between 5-HTTLPR polymorphisms and the ANS have not been 
studied directly, although peripheral 5-HT influences autonomic function‡‡. More 
recently, it has been described in a rodent model that fluctuations in central 5-HT 
modulate autonomic function [329]. In humans, there is indirect evidence to suggest 
that, in patients with panic disorders, impairment of SERT may be related closely to 
dysregulation of the SNS [330]. In another study, Williams et al. evaluated the 5-
HTTLPR genotype against cerebrospinal fluid concentrations of 5-
hydroxyindoleacetic acid (5-HIAA), a metabolite of 5-HT, and BP/HR responses to 
a mental stress task [331]. It was found that those participants with the L allele had 
higher levels of 5-HIAA and cardiovascular responsiveness to the stress task, 
providing evidence that 5-HTTLPR polymorphisms may alter the quantity of 5-HT 
in the CNS. Whilst the measures performed in that particular study do not give an 
indication as to the nature of the alterations of reactivity within the ANS, the 
results are consistent with the proposition that 5-HT can influence autonomic 
reactivity. Thus, there is a considerable knowledge gap that needs addressing to 
ascertain the influence, if any, of 5-HTTLPR on sympathetic and parasympathetic 
function.  
 
                                            
‡‡ In 1948, Rapport et al. discovered a vasoconstricting chemical within the serum, and since it 
affected vascular tone they named it 5-HT. 
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4.9 Aims and Hypothesis 
Taken together, the studies outlined above have provided evidence that SERT and 
5-HTTLPR influence personality, the reactivity of the HPA axis, ANS and 
nociception. Therefore, I hypothesised that reduced function of SERT, indexed by 
the presence of the dominant S allele, may be a contributory factor to the pain 
phenotypes described in Chapter 3. I chose the 5-HTTLPR to index SERT, rather 
than other genes in the 5-HT system as discussed in depth in Ichikawa et al.’s study, 
as it has been widely studied previously and I had access to primers to genotype 
subjects [332]. I also sought to investigate the effect of 5-HTTLPR on different 
measures of personality, baseline autonomic function, HPA axis responses and 
sensitivity to visceral and somatic pain. 
 
4.10 Materials and Methods 
4.10.1 Genotyping 
Venous blood samples were taken from all subjects, apart from six, at the time they 
participated in the study described in Chapter 3, and were stored at -80ºC in EDTA 
tubes (Vacutainer, Beckton Dickinson, UK) until DNA extraction and genotyping 
were undertaken. Samples were defrosted for three hours and DNA extraction 
was undertaken using a modified salting out technique [235], quantified using a full-
spectrum spectrophotomer (Nanodrop DL100, Thermo Scientific, Wilmington, 
USA) and subsequently stored at -20°C prior to genotyping. 5-HTTLPR 
polymorphisms were evaluated using PCR. The insertion/deletion polymorphism of 
the 5-HTTLPR was typed using the forward primer 5’-GGCGTTGCCGCTCTGAATGC-
3’ and reverse 5’-GAGGGACTGAGCTGGACAACCAC-3’ [237]. Primer concentrations 
were titrated to allow only amplification with exact primer with genomic DNA. 8µL 
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of PCR reaction mixture containing buffer (TDMH mix) 200mM of dATP, dTTP, 
dGTP and dCTP (Bioline Ltd, London, UK); 0.32u Taq polymerase (Biotaq TM, 
Bioline Ltd, London, UK) and 80ng of DNA. Next, 5µL of primer mix was added 
and dispensed under 10µL of mineral oil. This was amplified using a PCR machine 
(PTC-200, MJ Research, Waltham MA, USA). After denaturing at 96°C for one 
minute, the cycling parameters were as follows: five cycles of 96°C for 25 seconds, 
70°C for 45 seconds and 72°C for 45 seconds; 21 cycles of 96°C for 25 seconds, 
65°C for 50 seconds and 72°C for 45 seconds; and four cycles of 96°C for 25 
seconds, 55°C for 60 seconds and 72°C for 120 seconds. PCR products were 
electrophoresed on a 2% agarose gel (Bioline Ltd, London, UK) containing 10µL of 
Sybr Safe (Invitrogen, UK) in 0.5% tris-borate EDTA acid buffer (Sigma Ltd, Poole, 
UK) at 200V for 90 minutes. The amplification products were visualised under UV 
light and classified as S or L alleles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35 - A representative 2% agarose gel stained with Sybr Safe showing the three genotypes of 
the 5-HTTLPR - LS, SS & LL genotypes from left to right. 
 
4.11 Statistical Analysis 
Calculations for deviation from Hardy-Weinberg equilibrium were performed using 
the !2 test. Categorical variables are expressed as percentages, and the !2 test or 
Fisher’s exact test were used to compare groups. Continuous variables are 
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expressed as mean ± SEM or range. Error bars on graphs are all mean ± SEM unless 
stated otherwise. Where appropriate, the SS and LS genotypes were considered 
together and compared to the LL genotype. Mann-Whitney U Tests were used to 
compare genotype against psychological trait, cortisol variables, pain ratings and 
thresholds. Multi-group comparisons were undertaken with an ANOVA with 
Bonferroni correction. P<0.05 was taken to indicate statistical significance. 
 
4.12 Results 
4.12.1 Demographics  
A total of 107 subjects were successfully genotyped (63 male, median age 27.5 
years, range 19-53 years). From the initial 120 subjects, six declined to give blood 
for genotyping, and DNA extraction was unsuccessful in seven subjects for 
technical reasons. Of the 107 subjects, 77 were Caucasian (73.9%), 16 Asian 
(14.9%), 9 Japanese (8.4%) and 3 Afro-Caribbean (2.8%). 
  
4.12.2 Serotonin Transporter Long Polymorphic Region Genotype Distributions 
The allele and genotype frequencies are shown in Table 11, where subject ethnicity 
is classified as Caucasian or non-Caucasian, as suggested by Kohen et al. [333]. 
Genotype distributions were in Hardy-Weinberg equilibrium for both Caucasians 
and non-Caucasians (!2 1.12 p 0.29 and !2 0.48 p 0.48, respectively). 
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 Allele Allele 
frequency 
Genotype Genotype 
frequency 
L 0.59 LL 30.8 
LS 44.9 
Overall 
S 0.4 
SS 24.2 
     
L 0.6 LL 37.8 
LS 42.6 
Caucasian 
S 0.4 
SS 19.5 
     
L 0.52 LL 7 
LS 50 
Non-Caucasian 
S 0.48 
SS 43 
Table 11 - The distribution of allele and genotype frequency of the 5-HTTLPR according to 
ethnicity. 
 
4.12.3 Serotonin Transporter Long Polymorphic Region Genotype and 
Personality and Anxiety Variables 
For the BFI, the mean traits scores (± SD) were as follows: extroversion 3.57 
(±0.07), neuroticism 2.7 (± 0.04), openness 3.8 (±0.05), conscientiousness 3.7 
(±0.06) and agreeableness score 3.8 (±0.08). For the EPQ-R, extroversion 16.2 
(±0.46), psychoticism 5.1 (±0.33) and neuroticism 9.7 (±0.6). Mean STAI-S and 
STAI-T were 32.10 (±0.79) and 35.22 (± 0.84), respectively. Genotypic differences 
with respect to these variables are shown in Table 12. Specific genotype was also 
evaluated for the two measures of neuroticism. One-way ANOVA with Bonferroni 
correction on these samples revealed that the SS genotype had higher neuroticism 
scores than the LL genotype and both BFI and EPQ-R methods of measuring 
neuroticism (F(2,105)=3.8, p=0.02, !=0.1 and F(2,105)=6.4, p=0.002, !=0.11, 
respectively) (see Figure 36). Mean differences and confidence intervals between 
genotype and neuroticism are shown in Table 13. EPQ-R neuroticism scores for SS 
genotype and LS genotype were not different in this study, in comparison to other 
eight data sets in the literature (two-tailed t-test, p=0.46 and p=0.1, respectively. 
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The EPQ-R neuroticism score in this study was lower than in previously published 
studies (two-tailed t-test, p=0.002) (see Figure 37). It is interesting to note that 
despite extroversion and neuroticism being negatively correlated (see section 3.7.2, 
page 141), there was no difference in extroversion score for either the BFI or EPQ-
R between genotypes. 
 Present S Allele of 
5-HTTLPR  
(mean ± SEM) 
Absent S Allele of 
5-HTTLPR  
(mean ± SEM) 
P-Value 
Two-tailed 
Mann-Whitney U Test 
Big Five Inventory 
Extroversion 3.5 ± 0.09 3.6 ± 0.16 0.61 
Neuroticism 2.9 ± 0.12 2.3 ± 0.17 0.007 
Openness 3.8 ± 0.08 3.8 ± 0.06 0.98 
Agreeableness 3.7 ± 0.07 3.9 ± 0.11 0.06 
Conscientiousness 3.6 ± 0.07 3.8 ± 0.12 0.15 
Eysenck Personality Questionnaire 
Extroversion 16.5 ± 0.88 17 ± 0.5 0.9 
Psychoticism 4.9 ± 0.39 5.6 ± 0.58 0.3 
Neuroticism 10.9 ± 0.72 7.2 ± 0.94 0.005 
Spielberger State and Trait Anxiety Inventory 
State anxiety 34.1 ± 1.1 29.7 ± 1.2 0.02 
Trait anxiety 37.7 ± 1.2 30.7 ± 1 0.0006 
Table 12 - The influence of 5-HTTLPR on personality factors as measured by the BFI, EPQ-R and 
STAI-S/T. 5-HTTLPR polymorphisms are grouped according to the presence of the S Allele (SS & 
LS genotype) or its absence (LL genotype). 
 
 
Figure 36 - Genotypic differences in neuroticism scores as measured using the BFI (panel A) and 
EPQ-R (panel B). Presence of the S allele is associated with higher neuroticism scores. 
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Figure 37 - Neuroticism scores using the EPQ-R in the eight available data sets from the literature, 
and the overall results (in red) in comparison to the current study (in blue) (plots are mean ± SD). 
Panel A shows the SS genotype, panel B the LS genotype and panel C the LL genotype. 
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 Mean 
difference 
95% 
confidence 
interval 
T P<0.05 
Big Five Inventory 
LL vs. LS -0.53 -1.1 - 0.05 2.2 No 
LL vs. SS -0.69 -1.3 – 0.02 2.5 Yes 
LS vs. SS -0.16 -0.8 – 0.45 0.64 No 
Eysenck Personality Questionnaire 
LL vs. LS -3.5 -6.7 – 0.2 2.6 Yes 
LL vs. SS -5.4 -9.1 - -1.6 3.5 Yes 
LS vs. SS -1.9 -5.4 – 1.6 1.3 No 
Table 13 - Mean differences between neuroticism score across 5-HTTLPR genotypes. 
 
4.12.4 Serotonin Transporter Long Polymorphic Region Genotype and 
Hypothalamic Pituitary Adrenal Axis Responses to Visceral and Somatic 
Pain 
Those individuals with the L allele had a lower cortisol at baseline (240nMol/L ± 
16.22 vs. 309.1 nMol/L ± 20.1, p0.04) following somatic pain (323.1nMol/L ± 17.1 vs. 
363.3 nMol/L ± 19.8, p=0.3) and visceral pain (334 nMol/L ± 22.46 vs. 425.2nMol/L 
± 20.8, p=0.008) than those with the S allele (see Figure 39). Cortisol reactivity was 
also evaluated by examining the percentage change in serum cortisol following 
somatic or visceral pain. Those with the L allele had a reduction in the degree of 
change of cortisol to somatic pain (26.6% ± 10.9 vs. 33.8% ± 5.9, p=0.4) and visceral 
pain (30.1% ± 4.7 vs. 43.9% ± 2.4) than those with the S allele, respectively (see 
Figure 40).  
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Figure 39 - Cortisol responses to somatic and visceral pain by genotype. 5-HTTLPR polymorphisms 
are grouped according to the presence of the S Allele (SS & LS genotype) or its absence (LL 
genotype). 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 - Cortisol reactivity to somatic and visceral pain by genotype. 5-HTTLPR polymorphisms 
are grouped according to the presence of the S Allele (SS & LS genotype) or its absence (LL 
genotype). 
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4.12.5 Serotonin Transporter Long Polymorphic Region Genotype and 
Responses to Pain 
Those individuals with the L allele tolerated an increased quantity of balloon 
distension and habituated more to visceral pain than those with the S allele. Nail 
bed pressure and somatic pain habituation were not different between the two 
genotypic groups. Affective ratings of pain unpleasantness or intensity were not 
different between the genotypes (see Table 15). 
 
 Present S Allele of 
5-HTTLPR  
(mean ± SEM) 
Absent S Allele of 
5-HTTLPR  
(mean ± SEM) 
P-Value 
Two tailed  
unpaired t-test 
Somatic Pain 
Median Nail Bed 
Pressure (N) 
74.7 ± 3.6 69.6 ± 2.2 0.19 
Median 
Unpleasantness 
rating (VRS score) 
6.13 ± 0.28 6.3 ± 0.18 0.67 
Median Intensity 
rating (VRS score) 
7.76 ± 0.43 7.6 ± 0.1 0.27 
Habituation (Slope) 0.023 ± 0.003 0.026 ± 0.004 0.55 
Visceral Pain 
Median Balloon 
volume (ml) 
34.6 ± 1 39.8 ± 1.3 0.01 
Median 
Unpleasantness 
rating (VRS score) 
7.7 ± 0.18 7.5 ± 0.14 0.33 
Median Intensity 
rating (VRS score) 
7.3 ± 0.18 7.3 ± 0.15 0.92 
Habituation (Slope) 0.027 ± 0.002 0.021 ± 0.001 0.06 
Table 15 - Stimulus and pain rating across the genotypes. 5-HTTLPR polymorphisms are grouped 
according to the presence of the S Allele (SS & LS genotype) or its absence (LL genotype). 
 
 
4.12.6 Serotonin Transporter Long Polymorphic Region Genotype and 
Autonomic Nervous System Parameters 
The 5-HTTLPR genotype was not associated with any baseline ANS parameters. 
However, when dynamic change occurred in CVT, indexed by comparing the mean 
!change in CVT in the 30 seconds pre- vs. the 30 seconds post-stimulus, individuals 
with the S allele increased their CVT to visceral pain with a trend to do the same 
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for somatic pain, although the latter did not reach statistical significance (see Table 
16). 
 Present S Allele of 
5-HTTLPR  
(mean ±SEM) 
Absent S Allele of 
5-HTTLPR  
(mean ±SEM) 
P-Value 
Two tailed  
unpaired t-test 
Baseline Autonomic Parameters 
HR (bpm) 69.6 ± 1.8 68.1 ± 1.3 0.54 
SBP (mmHg) 127.8 ± 3.7 126 ± 1.8 0.62 
DBP (mmHg) 59.2 ± 2.7 62.3 ± 1.6 0.32 
MBP (mmHg) 81.3 ± 2.8 83.4 ± 1.6 0.48 
CVT (LVS) 10.5 ± 0.8 9.1 ± 0.5 0.15 
CSB (!RR/!mmHg) 8.1 ± 0.6 7.1 ± 0.5 0.22 
Sudomotor skin 
responses (µS) 
3.4 ± 0.7 3 ± 0.5 0.69 
Dynamic CVT Changes to Pain 
!CVT to somatic 
pain (%) 
-3.3 ± 4.9 7.8 ± 4.8 0.07 
!CVT to visceral 
pain (%) 
-2.1 ± 4.9 26.8 ± 6.6 0.006 
Table 16 - Baseline ANS parameters and change in CVT to visceral and somatic pain as per 5-
HTTLPR genotype. 5-HTTLPR polymorphisms are grouped according to the presence of the S Allele 
(SS & LS genotype) or its absence (LL genotype). 
 
4.12.7 Serotonin Transporter Long Polymorphic Region Genotype in Pain 
Phenotypes 
In Chapter 3, two distinct and reproducible phenotypes were defined using two-
step cluster analysis. Individuals with the LL genotype (absent S allele) were over-
represented in cluster 2 (see Figure 41). 
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Figure 41 - 5-HTTLPR genotype by pain phenotype. (!2 7.21, p=0.007, odds ratio 3.2, 95% 
confidence interval 1.3 – 7.6). 
  
4.13 Discussion 
The aim of this study was to evaluate the role of the 5-HTTLPR genotype across a 
number of diverse, yet complementary, measures. The pattern of findings observed 
in this study provides novel evidence linking polymorphisms of the 5-HTTLPR with 
personality, visceral pain toleration, HPA axis reactivity and dynamic efferent PNS 
changes to visceral pain. In addition, these results support the hypothesis that there 
is a genetic component to the pain phenotypes defined in Chapter 3. 
 
4.13.1 Genotype and Allele Frequency between Ethnicities 
Although this sample, relative to many larger, population-based studies, is small, the 
allele and genotype frequencies are consistent with previously published work [333, 
334]. Differences in population/ethnicity genetic structure between cases and 
controls have been proposed as a major cause of heterogeneity that has been 
observed amongst 5-HTTLPR candidate gene studies [335]. Moreover, ancestry 
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differences corresponding to various ethnic groups may be important in 
determining disease risk factors. Previous studies have shown that the allelic 
frequencies between Caucasians and Asians are different, with the S allele frequency 
being 0.42 in the former and 0.79 in the latter [336, 337]. In general agreement with 
these results, in the data presented in this study, S allele frequency was 0.4 amongst 
Caucasian subjects and 0.48 in non-Caucasian subjects. The differences that I found 
between my non-Caucasian group and the published data are probably due to the 
classifications used in this study. As the number of participants from the non-
Caucasian ethnicities was relatively small (28 subjects out of 107), to try and sub-
classify this group into other ethnicities to yield meaningful results would be 
unsound. The non-caucasians were not distributed differently across the clusters 
(see section 3.7.8, page 150). However, in a recent paper by Kohen et al., 
ethnicities were classified in the same manner§§ as in this study for similar reasons 
[333]. As their results are in Hardy-Weinberg equilibrium, the non-Caucasian 
genotype frequencies given in this study can be extrapolated to give an S allele 
frequency of 0.45 and an L allele frequency of 0.55 (cf. 0.48 and 0.52, respectively). 
As such, it is not unreasonable to surmise that the population contained herein is 
representative. Recently, Noskova et al. found differences in allelic frequencies 
within different European groups, thereby prompting the suggestion that classifying 
Caucasian individuals into a homogenous ethnic group may be an over-simplification 
[335].  
 
                                            
§§ In their paper, Kohen et al. refer to their classification of ethnicity as “white” and “non-white” 
rather than as Caucasian or non-Caucasian.  
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Given the assertion that the S allele is associated with an increased risk of affective 
disorders and pathological behaviours, it could be reasonably expected that 
variation in the frequency of the S allele between ethnic groups would be reflected 
in the different prevalence rates of these disorders [338]. However, when the 
lifetime morbidity rates of affective disorders are compared across populations, 
Asians were found to have lower rates than Europeans [331]. Likewise, personality 
traits display a degree of ethnic variation, with Europeans scoring higher on 
measures of extroversion than Asians [339].  
 
4.13.2 Serotonin Transporter Long Polymorphic Region Genotype and 
Personality and Anxiety Measures 
The data contained in this study suggests an association between 5-HTTLPR 
polymorphisms and the personality construct of neuroticism and anxiety. Central to 
this finding is the demonstration that neuroticism displays a “gene-dose” effect, in 
that LL genotypes have the lowest neuroticism scores, heterozygotes have a trend 
towards intermediate scores and the SS genotype has the highest scores. This 
assertion displays good validity even when neuroticism is measured using two 
different scales, i.e. the BFI or the EPQ-R. On one hand this is not surprising, as the 
neuroticism scales of the BFI and EPQ-R highly correlate with one another, as 
shown in Chapter 3. On the other hand, whilst the BFI and EPQ-R both purport to 
measure neuroticism, they do so in different ways. Neuroticism, as measured by 
the BFI, is one of the major domains in the lexically defined five-factor personality 
model. In contrast to this lexical approach, Eysenckian theory posits that 
neuroticism is a psychological manifestation of physiological differences. For 
instance, more neurotic individuals have a lower threshold for activating of the ANS 
to minor stressors. It would be expected that, because EPQ-R has a more 
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”biological” basis for its definition, any genotypic associations would be stronger. In 
contrast to the results of this study, a meta-analysis of the association between 
EPQ-R neuroticism and 5-HTTLPR has been shown to be weaker than the NEO-
personality inventory [340]. A possible explanation for this is that many of the 
studies included in the meta-analysis included subjects with concomitant medical 
disorders, potentially introducing a source of bias. It is interesting that when 
comparing the SS and LS genotypes for EPQ-R neuroticism the results presented 
here were not different to the other eight studies in the literature using the same 
methods. However, the LL genotype in this study had a lower EPQ-R neuroticism 
score in comparison to the other studies. The likely explanation for this is that the 
overall results may have been skewed, e.g. Middeldorp et al., who reported higher 
levels of neuroticism across all genotypes [302]. 
 
Both the BFI and EPQ-R contain subscale facets that comprise the respective 
neuroticism scales. Common to both measures is state and trait anxiety, which I 
have further evaluated in this study through the STAI-S and STAI-T. Consistent 
with the results from Gonda et al., the presence of the S allele was associated with 
a higher state and trait anxiety score [341].  
 
As previously discussed, the S Allele is considered functionally dominant. In this 
regards, this study provides empirical evidence that the presence of the S allele also 
has a dominant effect on measures of neuroticism. For example, when using either 
the BFI or EPQ-R, neuroticism scores did not differ significantly between the LS or 
the SS genotype. Overall, this study confirms the association between 5-HTTLPR 
polymorphisms, state anxiety, trait anxiety and neuroticism. My results support the 
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suggestion 5-HTTLPR polymorphisms can be considered to be one component of 
these polygenic complex traits.  
4.13.3 Serotonin Transporter Long Polymorphic Region Genotype and 
Hypothalamic Pituitary Adrenal Axis Reactivity to Pain 
The findings described extend the understanding of the relationship between 5-
HTTLPR polymorphisms and responsiveness of the HPA axis to pain. 5-HTTLPR, 
and by inference the 5-HT system, may be a critical mechanism in the stress 
response to pain. In this study the LL genotype had lower cortisol levels at baseline, 
following somatic pain and visceral pain. The lower levels of cortisol during pain in 
the LL genotype are not a function of the lower baseline, as there was a trend for 
carriers of the S allele to see greater reactivity of the HPA axis to somatic pain. In 
response to visceral pain this greater difference in HPA axis reactivity was 
significant. Despite pilot data showing that the degree of HPA axis activation was 
not a function the order of randomisation of the visceral and somatic stimulus it is 
possible that the HPA axis data may have been biased due to the lack of 
randomisation. This could account for the absolute differences that were seen in 
Gotlib et al.’s study although my results were in broad overall agreement [324].  
 
Several lines of evidence have suggested that the serotoninergic system plays an 
important role in regulating activation and feedback within the HPA axis. For 
example, in animals it has been shown that 5-HT activates the HPA axis by 
stimulating CRH, thereby triggering ACTH release and subsequent corticosteroid 
secretion [342]. In humans, Gotlib et al. demonstrated increased reactivity of the 
HPA axis in those subjects with the SS genotype, but could not elicit differences 
between the LS and LL genotype to a mental stress task [324]. This is in contrast to 
the data presented here, where S allele carriage predicted greater reactivity of the 
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HPA axis. These differences in findings may have important implications for future 
studies in that the type, nature and duration of the experimental stressor, i.e. 
mental stress vs. pain, are of importance when attempting to study genetic 
influences on HPA axis function.  
 
4.13.4 Serotonin Transporter Long Polymorphic Region Genotype, Pain and 
Autonomic Nervous System Parameters 
Of all the variables analysed, only the mean tolerated visceral stimulus was 
associated with genotype. In particular, affective ratings of pain intensity and 
unpleasantness were not associated with genotype. 5-HT is a major 
neurotransmitter in areas of the brain concerned with the affective motivational 
and cognitive evaluative aspects of pain processing such as the limbic system, insula 
and orbitofrontal cortex [343]. This finding was therefore surprising, as previous 
evidence has established that 5-HTTLPR genotype alters SERT function, leading to 
alterations in 5-HT availability and function with the CNS, potentially giving rise to 
differences in affective rating of pain. A recent study by Aoki et al, scrutinised the 
relationship between pain sensitivity to cold and pressure and the rs3813034 SNP 
in the SCL6A4 gene [344]. Whilst they highlighted differences in personality 
measures as a function of genotype, no differences were found in pain sensitivity 
that could be attributable to the genotype. Therefore, it is likely that genotypic 
differences in the SCL6A4 gene have no effect on the affective ratings of pain or 
habituation to that pain, but do have an association with the toleration of visceral 
stimulus. This latter finding from this study should be interpreted with caution, as 
the difference between the genotypes in terms of median visceral stimulus tolerated 
was 5.2mls, which in overall terms is small.  
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5-HTTLPR genotype was not associated with any of the baseline ANS parameters. 
However, when the dynamic changes of CVT to pain were examined, genotype was 
associated with the degree and direction of CVT change. Those with the S allele 
were more likely to increase their CVT to pain, whereas those with the L allele 
were more likely to withdraw. The inference from these findings is that, whilst 
there are no genotypic differences in baseline autonomic parameters, efferent PNS 
tone from the brainstem in responses to pain may be influenced by 5-HTTLPR 
genotype. 
  
4.13.5 Serotonin Transporter Long Polymorphic Region Genotype Differences 
within the Pain Phenotypes 
A central finding of this study is the genotypic differences that were seen between 
the pain phenotypes. The LL genotype was over-represented in cluster 2, thereby 
providing evidence that there is a genetic component to multidimensional pain 
phenotypes. In simple terms, it is quite possible that the LL genotype confers a 
reduction in the levels of neuroticism, and hence ANS and HPA axis responses to 
pain are purely a reflection of this (see panel A, Figure 42). However, an intriguing 
possibility, and potentially more plausible, given the SERT function is not confined 
to the CNS, is that 5-HTTLPR genotype subtly influences dynamic ANS and HPA 
axis response to pain at multiple levels of the pain neuromatrix (see panel B, Figure 
42). The evidence contained herein vindicates the second of these arguments as 
being more likely, as I have demonstrated several associations between 5-HTTLPR 
genotype, personality and dynamic ANS and HPA axis responses to pain.  
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Figure 42 – Demonstrates the two potential effects of the 5-HTTLPR on the overall pain 
phenotypes. Panel A suggests a singular influence of 5-HTTLPR on personality and, hence, 
responses. Panel B suggests a multi-level influence on each component of the pain phenotype. 
 
4.14  Study Limitations 
Whilst it is speculative to make definitive conclusions about the link between 5-
HTTLPR polymorphisms and the parameters that this study examined based on a 
sample of 107 subjects, it is of note that many of these results agree with larger 
studies and meta-analyses that have been published previously.  
 
I did not assess the SNP of an A!G substitution, located at nucleotide 6 within the 
first two extra 22-bp repeats that characterise the L allele, giving rise to a triallelic 
5-HTTLPR [345]. The LA allele has enhanced transcriptional activity of SERT in 
comparison to the LG allele, the latter being more similar to the S allele. Therefore, 
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there is a possibility that the triallelic 5-HTTLPR may have influenced these results 
to some extent. This possibility should be explored in future studies. 
 
4.15  Conclusions 
In this chapter, I have demonstrated that polymorphisms within the 5-HTTLPR are 
associated with personality traits, measures of anxiety, HPA axis reactivity and 
dynamic ANS responses to pain. In particular, the S allele was associated with 
higher neuroticism and anxiety scores with higher baseline cortisol and a more 
reactive HPA axis in conjunction with CVT withdrawal to pain. Additionally, this 
study shows that the 5-HTTLPR may represent a genetic component of the pain 
phenotypes and possibly exert that influence at multiple points in the pain 
neuromatrix. It is likely that many genes that variably interact with each other and 
the environment to form complex phenotypes such as the ones I have described 
for pain. Future work must focus on identifying other putative candidate genes that 
may play a contributory role in these phenotypes. 
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Chapter 5 – Reproducibility of Human 
Psychophysiological Responses to Visceral and 
Somatic Pain 
5 Human Psychophysiological Responses to Visceral & Somatic 
Pain 
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5.1 Chapter Overview 
Sequential measures of pain are of central importance in evaluating responses to 
interventions in both the clinical and research environments. However, variations in 
the pain experience may influence an individual’s rating of pain. Many factors have 
been proposed to explain these differences including sex, age and ethnicity, 
psychological factors such as anxiety, previous experience and expectation. I sought 
to evaluate the stability of psychophysiological responses to visceral and somatic 
pain in an unselected cohort of subjects recruited from the participants studied in 
Chapter 3 (study 1). Subjects were studied to the same protocol as in study 1. 
Reproducibility was assessed using the Bland Altman method, intra-class correlation 
coefficients and the coefficient of reproducibility. Thirty healthy subjects (16 male) 
with a mean age of 32.4 years (range 20-54 years) completed the study. The 
demographics and personality trait characteristics of the subjects were 
representative of those in study 1. The mean time period between the studies’ 
subjects was 48.1 weeks (range 29-68 weeks). Personality traits and the mean 
quantity of somatic and visceral stimulus were reproducible, although this was not 
the case for state anxiety. Basal HPA and ANS axis tone, and responses to somatic 
and visceral pain, were reproducible between the studies. Dynamic CVT changes 
had excellent reproducibility, while two-step cluster analysis identified two 
psychophysiological clusters with similar characteristics to those seen in study 1. 
Cluster membership was stable with 28 subjects remaining in the same cluster as in 
study 1. This data provides evidence that pain phenotypes are stable over a period 
of one year.  
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5.2 Introduction 
Psychophysical measurement of pain is a critically important aspect of both acute 
and chronic pain management. In most clinical situations, multiple sequential 
assessments of pain are required during a course of treatment, yet an individual’s 
pain rating may vary substantially. The reasons for this are multiple but include 
variations in the individual’s pain experience and variations in how the individual 
reports the pain. Clearly, these temporal differences present considerable 
challenges by impeding effective treatment in the clinical environment and reduce 
statistical power in the research setting. Thus, assessment of the temporal variation 
in pain measurement is a critical component not only of the validation of any pain 
scaling procedure, but also in the development of putative pain phenotypes.  
 
Therefore, objective measures of pain have both clinical and experimental salience, 
and a gargantuan effort has been invested into investigating the feasibility and 
appropriateness of pain testing paradigms and pain measuring scales [346, 347]. It is 
important to consider the factors that have been proposed to explain this 
difference. Biological and physical factors may influence pain perception through 
intra- and inter-individual differences in personality, genetics and environmental 
factors. Among the variables influencing pain perception, such as sex, age and 
ethnicity, psychological factors such as anxiety, previous experience and 
expectation are of primary importance [348]. For instance, it has been recognised 
that pain thresholds can be reduced in situations that induce anxiety, although the 
neuroanatomical basis of this has only recently been elucidated using functional 
brain imaging studies. In somatic pain, Berna et al. found that negative mood 
induction activated areas of the brain such as the PfC, ACC and the hippocampus, 
whereas in visceral pain Coen et al. demonstrated that areas such as the ACC, 
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insula and the inferior frontal gyrus in the right hemisphere were preferentially 
activated [349, 350]. Thus, the reproducibility of pain measurements must depend, 
at least in part, on how well the contextual impact of pain on an individual is 
controlled for, as this influences central processing of pain and therefore 
physiological responses.  
 
Many carefully designed studies have attempted, with varying success, to control for 
these factors, but statistical analysis, and hence results, can be misleading. For 
example, studies from the later 1970s evaluated the reproducibility, or test-retest 
reliability, of VAS and VRS with simple correlational methods [351, 352]. Both 
scales have been shown to have strong direct correlations, which were reported to 
be consistent with excellent test-retest reliability. Herein lies a major 
methodological criticism – simple correlation only assesses the strength of a 
relationship, rather than the actual agreement between elements [353]. The 
alternative statistical methods proposed to assess the agreement between two 
(temporally) separate measures are coefficient of repeatability (CR) and intra-class 
correlational coefficients (ICC). The dogma of the reproducibility of VAS was not 
really challenged until the mid 1990s, when Yarnitsky et al. employed non-
correlational methods [354]. Studying a large group of healthy volunteers across a 
four-week period, when assessing the pain ratings of supra-threshold thermal pain, 
they found that the CR was very large, ranging from 3.8-4.7, relative to a VAS of 10. 
In the case of a coefficient of repeatability of 3.8, there would be a 95% probability 
that a pain experience was rated as 6/10 at one time point and subsequently rated 
between 2.2/10 to 9.8/10 at the next. Clearly, such a large variation renders the 
method of pain evaluation used in this study of limited utility. However, close 
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attention on the part of the experimenter can improve repeatability. It has been 
suggested that the reproducibility of psychophysical responses to pain can be 
maximised by averaging responses to brief stimuli and by ensuring the 
interpretation of the scales remains constant over time [355].  
 
In the preceding sections, I have outlined the role of anxiety in influencing central 
responses to pain, as well as the statistical difficulties of previous studies. However, 
the considered constant of the laboratory environment is an important influence on 
reproducibility. Chesler et al. evaluated the influence of the experimental 
environment in animal responses to nociception [356]. They demonstrated that 
factors even more important than the genotype in influencing reproducibility were 
the experimenter performing the test, and that nociception can be affected by many 
additional laboratory factors including season/humidity, cage density, time of day, 
sex and order of testing. 
 
Thus, a considerable number of factors can influence the reproducibility of 
responses to pain. In this chapter, I shall determine the stability of the pain 
phenotypes identified in Chapters 3 and 4 in an unselected cohort of 30 subjects, 
taking into account the factors that have been previously proposed as affecting such 
stability. 
 
5.3 Hypothesis 
Therefore, my hypothesis was that multidimensional pain phenotypes are stable at a 
period of one year.  
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5.4 Methods 
5.4.1 Subjects 
Thirty healthy volunteers, aged 18-60 years, were recruited from the cohort 
studied in Chapter 3 and studied one year after the initial study. Subjects were 
recruited solely based on availability. Ethical approval for the study was granted by 
the East London and the City Ethics Committee 2 (ref 08/H0703/47) and 
performed in accordance with the Declaration of Helsinki. Exclusion criteria were 
the same as in Chapter 3. All female participants were studied during the follicular 
phase of their menstrual cycle. Those subjects who exceeded the self-deception 
score, as assessed by the WAI, were excluded from the analysis [258].  
 
5.4.2 Pain Induction Techniques 
5.4.2.1 Visceral Pain Induction – Oesophageal Balloon Distension 
Commercially available oesophageal distension catheters, with an inflatable balloon 
mounted at the distal end (Sandhill, UK), were used during the study. Subjects were 
intubated with the oesophageal catheter, with the aid of a water-based lubricating 
jelly (KY Jelly, Johnson & Johnson), either trans-nasally or per-orally according to 
preference. The balloon was positioned in the mid/distal oesophagus at 32cm ab 
oral or 34cm ab nares. Local anaesthetic spray was not used during intubation. Each 
painful stimulus was achieved by inflating the balloon at a rate of 5mls/second to the 
subject’s PTT. The PTT was defined as the point at which the subject could not 
tolerate further stimulation. Subjects were then asked to rate the pain on a VRS 
measuring intensity (10, worst imaginable pain, to 0, no sensation) and 
unpleasantness (10, worst imaginable unpleasantness, to 0, neutral).  
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5.4.2.2 Somatic Pain Induction – Nail Bed Pressure 
A strain gauge (Mecmesin, UK) was mounted on to a specially designed spring-
loaded device such that the extension probe incorporated a thin, blunt rod applied 
to the subjects’ right thumb 5mm from the cuticle, producing a stimulus of nail bed 
pressure ranging from touch to painful. Each painful somatic stimulus was achieved 
by applying nail bed pressure manually to the subject’s PTT. Pain intensity and 
unpleasantness were rated on the VRS scale, as per visceral pain.  
 
5.4.3 Personality, Psychological State and Trait Measures 
Self-report validated questionnaires were administered to evaluate psychological 
state and trait measures. BFI and EPQ-R were used to measure the personality 
traits of neuroticism and extroversion [259, 260]. State and trait anxiety were 
assessed using STAI-S and STAI-T [261]. 
 
5.4.4 Autonomic Measures 
Digital arterial BP was measured using the photoplethysmographic technique 
(Portapress, Finapress, Amsterdam, Netherlands). ECG (ECG) electrodes (Ambu 
Blue Sensor P, Denmark) were placed in the right and left subclavicular areas and 
cardiac apex following skin preparation (Nuprep, Weaver & Co, USA), to reduce 
impedance and improve signal. ECG was acquired at a rate of 5kHz using a 
commercially available biosignals acquisition system, which allows validated ANS 
parameters to be measured in real time (Neuroscope, Medifit Instruments, UK). 
Autonomic parameters were recorded according to the recommendations of the 
European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology Task Force [238]. 
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SCR, a measure of sympathetic sudomotor response to stimuli, were measured 
[262]. Skin on the right index and ring fingers was wiped with water and allowed to 
dry. Skin conductance electrodes were then attached to the subject and the skin 
impedance for that subject zeroed using a commercially available bioamp (Powerlab, 
AdInstruments, UK). Skin impedance was recorded and subsequently analysed off 
line. 
 
5.4.5 Cortisol Measurement 
Serum total cortisol was assayed by the Blood Services Department at the Royal 
London Hospital using a chemiluminescence immunoassay (Nichols Advantage, 
Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). 
 
5.5 Protocol 
Subjects attended for one visit lasting three hours. On arrival they completed a 
consent form and subsequently had their height and weight measured. Subjects 
were studied in the afternoon (from 1400-1600hrs) in a temperature-controlled 
(21-22° C), quiet laboratory. Subjects were reclined at 45 degrees on a bed or 
reclining chair. The ANS recording equipment was subsequently attached and five 
minutes of baseline data (resting/no stimulation) acquired. All subjects had an 18G 
intravenous cannula (Venflon, Beckton Dickinson, UK) placed in the left antecubital 
fossa and blood was taken for baseline serum cortisol. A three-way needle-free 
valve port was attached to the intravenous cannula to limit cross contamination 
between successive cortisol samples (SmartSite Extension Set, Cardinal Health, 
Rolle, Switzerland). Subjects received seven somatic stimuli to PTT with a 10-
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minute rest period after the stimuli were completed. Subsequently, subjects were 
intubated with the oesophageal distension catheter and allowed to rest for 10 
minutes. The subjects then received seven visceral stimuli to PTT. Subjects received 
a verbal cue five seconds prior to each stimulus delivery to attempt to standardise 
any effects of anticipation. If the stimulus contained any artefact (such as coughing, 
sneezing, movement or swallowing), it was rejected and not subsequently analysed. 
Venous blood for cortisol (Vacutainer, Beckton Dickinson, UK) was sampled at 
baseline, two minutes after the final visceral stimulation and then again two minutes 
after the final somatic stimulation. 
 
5.6 Statistical Analysis 
Categorical variables are expressed as percentages, and the Chi-squared test or 
Fisher’s exact test were used to compare groups. Continuous variables are 
expressed as mean ! SEM. The ANS and HPA axis data was normally distributed 
(Shapiro-Wilk test !"0.05) and group comparisons were undertaken using a two-
tailed Student’s t-test. Mann-Whitney U Tests were used to compare personality 
state and trait. Two-step cluster analysis was performed, with input factors defined 
a priori as per study 1 (Chapter 3). Agreement was assessed using a two-way, 
random effects, single measure ICC model, .CR and Bland Altman plots. The CR is 
the maximum difference that is likely to occur between repeated measurements, 
and is defined as 1.96 x # $(d2-d1)
2/n-1, where d2-d1 is the difference between the 
first and second measurements and is quoted in the original units without 
transformation. Confidence intervals for the ICC and the repeatability coefficient 
were calculated according to the methods of Scheffe [357]. ICC were interpreted 
according to suggestions made by Yen et al. as: - excellent (0.75-1), moderate (0.4-
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0.74) or poor (0-0.39) [358]. Cohen’s kappa statistic was used as a measure of the 
reproducibility of cluster membership. Commercially available statistics packages 
(SPSS, Chicago, IL, USA and GraphPad, San Diego, CA, USA) were used for the 
analysis. P values <0.05 were considered to be of statistical significance.  
 
5.7 Results 
5.7.1 Subject Characteristics 
Thirty healthy subjects were recruited to the study (16 male) with a mean age of 
32.4 years (range 20-54 years) and a mean BMI of 26.3 kg/m2 ! 0.38 kg/m2. Of the 
30 subjects, 23 were Caucasian (76.7%), six were Asian (20%) and one Afro-
Caribbean (3.3%). The mean time period between subjects participating in the study 
presented in Chapter 3 and participating in this study was 48.1 weeks (range 29-
68). All subjects completed the study.  
 
5.7.2 Representative Nature of the Reproducibility Cohort 
Subjects who were restudied were demographically representative in terms of sex, 
BMI and ethnicity of those studied in study 1 (Chapter 3) (see Table 17). The mean 
age of the reproducibility cohort was significantly older.  
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Variable Study 1  
(n=120) 
Study 2  
(n=30) 
P value 
Sex  
(male : female) 
68 : 52 16 : 14 0.84 
Age 
(years - mean ± SEM) 
28.9 ± 0.76 32.47 ± 1.7 0.04 
BMI (kg/m2 - mean ± 
SEM  
25.68 ± 0.38 25.22 ± 0.81 0.56 
Ethnicity  
(Caucasian: non-
Caucasian) 
89 : 31 23 : 7 1 
BFI Neuroticism  
(mean ± SEM) 
2.7 ± 0.08 2.52 ± 0.16 0.4 
BFI, Extroversion  
(mean ± SEM) 
3.57 ± 0.07 3.7 ± 0.15 0.46 
Spielberger State 
Anxiety  
(mean ± SEM) 
32.1 ± 0.79 30.63 ± 1.5 0.41 
Spielberger Trait 
Anxiety  
(mean ± SEM) 
35.22 ± 0.84 34.37 ± 1.7 0.66 
Table 17 - Demographical and personality data across the two cohorts. 
 
5.7.3 Reproducibility of Personality Traits 
The mean, SEM and ICC for each of the personality measures is shown in Table 18. 
The EPQ-R and the BFI measures of extroversion and neuroticism had good 
reproducibility with ICC of 0.95, 0.9, 0.78 and 0.7, respectively. Furthermore, 
reproducibility was also good for STAI-T with an ICC of 0.94, although STAI-S had 
minimal reproducibility the CR showing a strong skew of the data thus implying a 
large variation in the STAI-S response. 
 
 209 
 
Personality variable 
Study 1 
Mean ± SEM 
Study 2 
Mean ± SEM 
ICC 
(95% 
confidence 
interval) 
CR 
(95% 
confidence 
interval) 
EPQ-Neuroticism 9.33 ± 0.09 9.34 ± 0.06 
0.95 
(0.9-0.97) 
0.67 (-0.7-
0.99) 
EPQ-Psychoticism 5.39 ± 0.22 5.21 ± 0.11 
0.85 
(0.78-0.91) 
0.34 (-0.55-
0.86) 
EPQ-Extroversion 16.88 ± 0.33 16.66 ± 0.04 
0.9 
(0.82-0.96) 
0.44 (-0.46-
0.66) 
BFI-Neuroticism 2.62 ± 0.18 2.52 ± 0.16 
0.78 
(0.58 – 0.89 
0.62 (-1.3 – 
1.5) 
BFI-Extroversion 3.73 ± 0.15 3.7 ± 0.13 
0.7 
(0.46 – 0.84) 
1.1 (-1.15 – 
1.22) 
BFI-Openness 3.9 ± 0.08 3.94 ± 0.07 
0.62 
(0.3-0.8) 
0.8 (-0.9 – 
0.83) 
BFI-Agreeableness 3.84 ± 0.14 3.85 ± 0.1 
0.68 
(0.35-0.85) 
1.18 (-1.2 – 
1.2) 
BFI-
Conscientiousness 
3.87 ± 0.12 3.79 ± 0.11 
0.65 
(0.3-0.81) 
1.31 (-1.24 – 
1.4) 
STAI-Trait 33.3 ± 1.7 32.5 ± 1.8 
0.94 
(0.89-0.97) 
3.19 (-5.4 – 
7) 
STAI-State 30.5 ± 1.4 30.3 ± 1.5 
0.54 
(0.23-0.75) 
15 (-15 – 
15.3) 
Table 18 - The reproducibility of personality traits. 
 
5.7.4 Reproducibility of Stimulus Toleration and Affective Ratings of Pain 
Intensity and Unpleasantness 
Reproducibility of the mean visceral and somatic stimulus toleration was good with 
ICC of 0.74 and 0.87, respectively. Participants’ verbal ratings of pain intensity and 
unpleasantness of visceral and somatic pain were higher in comparison to the initial 
study. The inference from this data, in agreement with other studies, is that an 
individual’s affective ratings of pain are not reproducible, (see section 5.8). The 
reproducibility of the affective ratings of pain, indexed by ICC, was poor (see Table 
19). 
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Variable 
Study 1 
Mean ± SEM 
Study 2 
Mean ± SEM 
ICC 
(95% confidence 
interval) 
CR 
(95% confidence 
interval) 
Median nail bed 
pressure (N) 
78.18 ± 2.7 76.39 ± 3.23 
0.87 
(0.74-0.94) 
16.5  
(-18.4 – 14.73) 
Median somatic 
unpleasantness 
rating 
6.13 ± 0.27 7.48 ± 0.23 
0.05 
(-3.1-0.39) 
3  
(-2 – 4) 
Median somatic 
pain intensity 
rating 
7.56 ± 0.16 7.43 ± 0.24 
0.08 
(-2.8-0.42) 
3  
(-3.2 – 2.9) 
Median balloon 
volume (ml) 
44.7 ± 1.4 41 ± 1.6 
0.74 
(0.53-0.87) 
6.3  
(-6.1 – 10.9) 
Median visceral 
pain 
unpleasantness 
rating 
7.68 ± 0.22 7.72 ± 0.23 
0.44 
(0.1-0.69) 
2.5  
(-2.52 – 2.59) 
Median visceral 
pain intensity 
rating 
7.44 ± 0.17 7.46 ± 0.24 
0.37 
(0.02-0.64) 
2.94  
(-2.95 – 2.99) 
Table 19 - The reproducibility of stimulus toleration and affective ratings of pain. 
 
 
5.7.5 Reproducibility of Hypothalamic Pituitary Adrenal Axis Responses to 
Pain 
Cortisol results were available in all participants for both studies. The 
reproducibility of baseline cortisol and cortisol responses to somatic and visceral 
pain was moderate to good with ICCs of 0.65, 0.7 and 0.65, respectively (see Table 
20 and Figure 43). 
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Variable 
Study 1 
Mean ± SEM 
Study 2 
Mean ± SEM 
ICC 
(95% confidence 
interval) 
CR 
(95% confidence 
interval 
Baseline cortisol 
(nMol/L) 
261.7 ± 22.6 282.5 ± 22 
0.65  
(0.38-0.81) 
140.4  
(-145 – 176) 
Post somatic 
pain cortisol 
(nMol/L) 
326.2 ± 19.9 358.1 ± 23.76 
0.7  
(0.46-0.85) 
155.9  
(-130 – 181) 
Post visceral 
pain cortisol 
(nMol/L) 
356.1 ± 26.54 402.4 ± 29.17 
0.65  
(0.38-0.81) 
172  
(-174 – 220) 
Table 20 - The reproducibility of HPA axis responses to pain. 
 
 
Figure 43 - The reproducibility of hypothalamic pituitary adrenal axis responses to pain. 
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5.7.6 Reproducibility of Autonomic Nervous System Responses to Pain 
The reproducibility of ANS parameters at baseline, and following somatic and 
visceral pain, is shown in Table 21. Apart from baseline HR and the HR in response 
to somatic pain, all of the ANS parameters measured had moderate to good 
reproducibility. 
 
5.7.7 Reproducibility of Dynamic Cardiac Vagal Tone Responses to Pain 
Dynamic change refers to the change in CVT in the 30 seconds prior to a 
nociceptive stimulus in comparison to the 30 seconds post-stimulus. The 
reproducibility of the dynamic CVT changes to somatic and visceral pain was good, 
with ICC of 0.8 (95% confidence interval 0.6-0.9) and 0.95 (95% confidence interval 
0.9-0.97), respectively. Figure 44 shows Bland-Altman plots for the differences in 
dynamic CVT changes to pain. Twenty-nine out of 30 points lie within +/- 2 
standard deviations of the difference between measurements for somatic pain, with 
all points lying within +/- 2 standard deviations of the difference between 
measurements for visceral pain. This indicates that there was no bias or systematic 
error. 
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Figure 44 - Bland-Altman Plots showing the agreement between dynamic cardiac vagal tone 
changes to somatic pain (panel A) and visceral pain (panel B). 
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Baseline Somatic Pain Visceral Pain 
 
Study 
1 
Mean (±SEM)  
Study 
2 
Mean (±SEM)  
ICC 
(95% 
confidenc
e interval) 
CR  
(95% 
confidenc
e interval) 
 
Study 
1 
Mean (±SEM)  
Study 
2 
Mean (±SEM)  
ICC 
(95% 
confidenc
e interval) 
CR  
(95% 
confidenc
e interval) 
 
Study 
1 
Mean (±SEM)  
Study 
2 
Mean (±SEM)  
ICC 
(95% 
confidenc
e interval) 
CR  
(95% 
confidenc
e interval) 
HR 
(bpm) 
66 ±1.9 
67.6 
±1.7 
0.53 
(0.22-
0.74) 
18.8 
(-17-
20) 
HR 
(bpm) 
67.7 
±2.5 
72.8 
±1.76 
0.25 
(-1.1-
0.56) 
28.8 
(-23.8-
34) 
HR 
(bpm) 
72.5 
±1.6 
73.4 
±1.8 
0.65 
(0.39-
0.82) 
15.1 
(-14.3-
16.5) 
SBP 
(mmHg) 
122.6 
±2.05 
125.9 
±2.27 
0.47 
(0.33- 
0.75) 
30.1 
(-25.1 
– 38.3) 
SBP 
(mmHg) 
139.2 
±3.27 
146.8 
±2.75 
0.41 
(0.07– 
0.67) 
51.6 
(-36.4-
66.8) 
SBP 
(mmHg) 
137.7 
±3.9 
148 
±2.75 
0.28 
(-0.8-
0.58) 
35.8 
(-29.6-
42.1) 
DBP 
(mmHg) 
59.9 
±3.1 
63.1 
±1.68 
0.39 
(0.04-
0.65) 
29.8 
(-26.5-
32.9) 
DBP 
(mmHg) 
85.5 
±3.99 
98.2 
±2.05 
0.48 
(0.15-
0.71) 
30.1 
(-18.7-
41.5) 
DBP 
(mmHg) 
66.99 
±2.38 
74.36 
±1.75 
0.63 
(0.35 – 
0.8) 
19.44 
(-12.1-
26.82) 
MBP 
(mmHg) 
78.2 
±2.2 
83.2 
±1.84 
0.71 
(0.47-
0.85) 
16.6 
(-11.6 
– 21.7) 
MBP 
(mmHg) 
89.8 
±2.6 
95.4 
±1.9 
0.72 
(0.48-
0.87) 
38 
(-31.6-
42.8) 
MBP 
(mmHg) 
92.5 
±2.54 
98.3 
±2.33 
0.78 
(0.62-
0.86) 
17.1 
(-11.1-
22.89) 
CVT 
(LVS) 
10.09 
±0.9 
9.67 
±0.79 
0.81 
(0.64-
0.91) 
5.7 
(-6.2-
5.37) 
CVT 
(LVS) 
9.13 
±0.78 
12.52 
±2.3 
0.98 
(0.94-
0.99) 
15.3 
(-14.1-
16.2) 
CVT 
(LVS) 
11.54 
±1.7 
12.4 
±2.3 
0.81 
(0.64-
0.91) 
14.7 
(-13.86 
-15.56) 
CSB 
(!RR/!m
mHg) 
7.61 
±0.75 
7.07 
±0.64 
0.8 
(0.65-
0.9) 
4.5 
(-5.1-4) 
CSB 
(!RR/!m
mHg) 
6.36 
±0.5 
6.17 
±0.46 
0.78 
(0.59-
0.89) 
3.45 
(-3.64-
3.26) 
CSB 
(!RR/!m
mHg) 
6.4 
±0.43 
6.59 
±0.48 
0.75 
(0.65-
0.9) 
3.31 
(-3.12-
3.51) 
SCR 
(µS) 
2.77 
±0.43 
2.57 
±0.37 
0.53 
(0.22-
0.74) 
4.28 
(-4.5-
4.13) 
SCR 
(µS) 
19.3 
±1.89 
16.59 
±1.36 
0.71 
(0.22-
0.74) 
14 
(-16.2-
11.9) 
SCR 
(µS) 
16.9 
±2.02 
17 ±1.7 
0.9 
(0.82-
0.96) 
8.5 
(-8.48-
8.55) 
Table 21 - The reproducibility of autonomic nervous system parameters at baseline, following somatic and visceral pain. 
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5.7.8 Reproducibility of Cluster Analysis 
A two-step cluster analysis was performed with the input parameters of 
neuroticism, extroversion, baseline CVT and !change in CVT to visceral and 
somatic pain. These input parameters were defined a priori based on those used in 
Chapter 3. The optimum solution was two clusters, with cluster 1 containing eight 
subjects (26.6%) and cluster 2 containing 22 subjects (73.4%). These proportions 
were no different to those observed in Chapter 3 (!2 1.25, p=1.65, odds ratio 1.05, 
95% confidence interval 0.67 – 4.04) (see Figure 45). 
 
 
 
Figure 45 - Distribution of clusters in 120 subjects studied in Chapter 3 and the reproducibility 
cohort studied in this chapter. 
 
 
 
The cluster silhouette coefficient was 0.6. The psychophysiological differences of 
the clusters were similar to those presented in Chapter 3. Cluster 1 had higher 
neuroticism scores, but lower extroversion scores with higher trait anxiety 
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(unpaired t-test all p<0.01). At baseline, cluster 1 had a higher resting HR, SCR and 
cortisol with lower CVT and CSB (unpaired t-test all p<0.01). In response to 
somatic pain, cluster 1 tolerated less stimulus, habituated less, had higher cortisol 
and increased CVT and CSB (unpaired t-test all p<0.01). In response to visceral 
pain, similar patterned responses were observed. Cluster 2 had the converse 
profile. Based on this data, the temporal stability of the cluster membership can be 
interrogated for the 30 subjects restudied (see Table 22). Cohen’s ! was 0.83, 95% 
confidence interval 0.6-1. 
 
Study 1 
 
Cluster 1 Cluster 2 
Cluster 1 7 1 
St
u
d
y 
2
 
Cluster 2 1 21 
 
Table 22 - Demonstrates the stability in change of cluster membership between study 1 and study 
2 for the 30 subjects studied twice. Twenty-eight subjects remained in the same cluster (21 in 
cluster 2 and 7 in cluster 1) with two subjects changing cluster (one moving from cluster 2 in study 
1 to cluster 2 in study 2 and one subject moving from cluster 1 to cluster 2). 
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5.8 Discussion 
In this study I have demonstrated, in a representative cohort, that the 
multidimensional pain phenotypes demonstrated in Chapter 3 are stable over a 
period of one year. These patterned physiological responses to pain that were 
demonstrated in Chapter 3 are reproducible in the majority of subjects. In the 
subsequent sections I shall examine the reproducibility of each of the individual 
components that make up the pain phenotype. 
 
5.8.1 Representative Characteristics 
In the subjects that were restudied, there was a non-significant trend towards 
lower neuroticism, state and trait anxiety scores, with higher extroversion scores 
than the initial cohort. This may reflect a degree of self-selection bias, as the 
subjects were recruited based solely on their availability and willingness to be 
restudied. The differences in these measures are not surprising, as higher anxiety 
and depressive symptoms have been shown to reduce willingness to participate in 
clinical trials [359]. Furthermore, the personality trait of extroversion has been 
shown to alter subjective and physiological responses to drugs in phase 1 clinical 
trials [360]. Although the differences in extroversion, neuroticism and state and 
trait anxiety were apparent in this study, these were not statistically significant. 
However, with the relatively large sample size, these effects, whilst being 
acknowledged, hopefully should only be minimal. Of interest was that the 
reproducibility cohort was significantly older, 28.9 years vs. 32.47 years, but it must 
be borne in mind that all subjects in this study were themselves one year older. 
When this is controlled for, this significance is lost. 
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5.8.2 Intra-individual Reproducibility of Neuroticism and Extroversion Scores 
The personality traits of neuroticism and extroversion, when measured both by the 
BFI and EPQ, had moderate to excellent ICC at one year. This data suggests that 
these personality traits are stable over time, in agreement with previously published 
work. For instance, the NEO-personality inventory of the correlational coefficients 
for test-retest reliability for neuroticism and extroversion were 0.87, 0.86 and 0.83 
and 0.82 at three months and six years, respectively [297]. The EPQ-R correlational 
coefficient of test-retest reliability was 0.92 and 0.9 for neuroticism and 
extroversion, respectively, at four weeks [361]. However, a recently published 
meta-analysis of the pattern of change in personality traits across adulthood found 
that extroversion increased whilst neuroticism decreased [362].  
 
5.8.3 Reproducibility of Spielberger State/Trait Anxiety Inventory 
Whilst the ICC for STAI-T was excellent, it was poor for STAI-S – in agreement 
with previous studies. For example, the ICC of the STAI has been reported as 0.54 
and 0.86 for state and trait anxiety, respectively [201]. These findings were 
confirmed further in a study by Rule et al., who evaluated 29 male undergraduate 
students before and after a stressful social situation, finding ICC of 0.40 and 0.86, 
respectively [202]. It is likely that the poor reproducibility of STAI-S, observed in 
these studies and ours, is a reflection of a degree of “habituation” to the study, as 
at the second visit the subject has experienced the laboratory environment and 
experimental protocol.  
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5.8.4 Reproducibility of Hypothalamic Pituitary Adrenal Axis Responses to 
Visceral and Somatic Pain 
The reproducibility of cortisol responses to pain was moderately good, although 
the CR was larger than expected. There was a trend for cortisol at baseline, 
following somatic pain and following visceral pain, to be higher in study 2 in 
comparison to study 1. This increase cannot be explained by an elevation in anxiety 
levels, as state and trait anxiety were lower in study 2 (see Table 17). However, it 
must be noted that the STAI-S and STAI-T measures self-reported psychological 
anxiety rather than the physiological manifestations of such anxiety. Nevertheless, 
the pattern of increase from baseline was similar between studies, as seen in Figure 
43. There is a paucity of data in the literature examining the reproducibility of 
serum cortisol responses to pain. In a study by Viardot et al., the night time salivary 
cortisol measures in 20 healthy volunteers had excellent day-to-day reproducibility, 
as indexed by an ICC of 0.78 [363]. In a rodent model, ACTH and corticosterone 
responses exposed to three novel environments were found to be highly 
reproducible, suggesting that HPA axis responsiveness to stress is a consistent 
individual trait, despite differences in the absolute physical characteristics of the 
three novel environments [364]. Similarly, in this study, the pattern of response of 
an increase in cortisol following somatic pain and a further increase following 
visceral pain was reproducible.  
 
5.8.5 Reproducibility of Autonomic Responses to Visceral and Somatic Pain 
Many studies, including the data presented in Chapter 3, have evaluated the 
responses of the ANS to pain [214, 365]. In this study the reproducibility of the 
autonomic measures of HR, SBP, DBP, MBP and SCR were moderate, in agreement 
with previously published data. The repeatability of autonomic responses to pain, 
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using the traditional measures of HRV, has been addressed in three studies with 
conflicting results. Firstly, Fasano et al. evaluated the reproducibility of autonomic 
responses (BP and HR) to a cold pressor test in 17 healthy volunteers [366]. They 
divided these healthy volunteers into two groups, the first having the test 
performed three times on the same day and the second having the test performed 
three times on three consecutive days. The first group displayed reasonable test-
retest reliability, with an ICC of 0.57, although this repeatability was poor in the 
second group. Secondly, Jáuregui-Renaud et al. evaluated the repeatability of 
frequency domain measures of HRV in 20 healthy volunteers in response to cold 
pressor tests two weeks apart. The cold pressor test induced a significant increase 
in HR and BP, but changes were variable on the HRV measurements (either a 
decrease or an increase). Repeatability of responses was evident for 95-100% of the 
subjects. Although intra-individual repeatability of HRV measurements for the tests 
was higher than 95%, CR reflected considerable inter-individual differences among 
the subjects of 0.38 to 0.03 for HF and LF:HF parameters, respectively. Finally, 
Colloca et al. more recently examined autonomic responses, using HR and GSR, to 
thermal pain in 33 healthy volunteers on three separate occasions over a three-
week period [367]. They found a high correlation among the three sessions for pain 
thresholds, pain ratings and HR responses, indicating a high degree of 
reproducibility, although the authors noted that significant habituation to noxious 
stimuli occurred.  
 
Whilst this evidence is conflicting, collectively the results from these studies must 
be interpreted with caution. These studies did not control for anxiety levels or 
personality and were not conducted in accordance with the recommendations of 
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the European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology Task Force [238]. In particularly these studies did not all control 
for conditions in the laboratory environment.  However, it is interesting that the 
reproducibility of the Neuroscope specific parameter of CVT in this study seemed 
to have much greater reproducibility in this study at baseline, following somatic and 
visceral pain. 
 
To the best of my knowledge only one study has examined the reproducibility of 
the Neuroscope-specific measure of CVT. Murray et al. examined the 
reproducibility of CVT measurements in comparison with conventional time and 
frequency domain HRV analysis [368]***. They studied 50 subjects, 11 of which were 
healthy volunteers, making two five-minute recordings of autonomic variables with 
a two to three-minute interval between recordings. They found that the short-term 
reproducibility of a five-minute recording of CVT is moderate with reasonable 
comparability to spectral analysis of HRV. Whilst this study was conducted in 
accordance with the aforementioned recommendations, it is not without its 
limitations. For example, the study was conducted in a heterogeneous group of 50 
healthy and patient subjects, with only 38 recordings being suitable for analysis due 
to trace artefact. Furthermore, the authors report that the CVT correlation 
coefficient was 0.95, although this may be misleading in that used in this way this 
coefficient is a surrogate marker of agreement, rather than as a strength of relation 
[353]. To further illustrate this important point, let us consider another example. 
Skin thickness can be measured using a device known as the Harpenden calliper 
                                            
*** In Murray et al.’s paper, the authors refer to CVT as the cardiac index of parasympathetic activity. 
These terms are synonymous.  
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[369], which measures skin fold thickness, and skin thickness per se is derived by 
dividing skin fold by a factor of two. If we were to plot skin fold thickness against 
skin thickness, we should get a perfect straight line with a correlation coefficient of 
1.0, but the two measurements would not agree in that we could not mix skinfold 
thickness and skin thickness obtained by the two methods, since one is twice the 
other. Similarly, in Murray’s paper, when the Bland-Altman method was applied to 
CVT measurements, the variation between recordings was considerable – the 95% 
confidence interval for the second recording was 0.72-1.40, i.e. the second 
recording was between 72%-140% of the first 95% of the time. Therefore, it is 
difficult to make an assessment of the reproducibility of CVT on this paper. In 
contrast, the data for CVT presented herein shows good reproducibility of CVT, as 
indicated by an ICC greater than 0.8 at baseline, following somatic and visceral pain. 
Whilst I did not calculate the coefficient of variation, as ICCs are considered a 
more informative measure of reproducibility, the differences in the results may be 
accounted for by the considerable time lag between visits in this study, i.e. one year 
in this study in comparison to two five-minute sequential recordings on the same 
day. Sadly, there is not a subgroup analysis of the healthy volunteers in Murray et 
al.’s study, which may have had more relevance to the data presented here. In 
contrast to Murray et al.’s study, a criticism that may be levelled at my study is that 
fitness levels were not assessed, particularly in light of the fact that these could 
change over a period of one year. Fitness levels have been shown to influence CVT, 
and not controlling for this could have introduced some bias in my data [62].  
 
One of the most striking findings of the study performed in Chapter 3 was the 
pattern of dynamic CVT response to pain, with some subjects increasing their 
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efferent PNS tone (freeze/tonic immobility) whilst others withdrew it (fight or 
flight). As this is a measure of the percentage change in the 30 seconds prior to the 
painful stimulus, compared to the 30 seconds after the stimulus, in some ways it is 
independent of the absolute CVT value itself. Notably, reproducibility of this 
measure of dynamic change was excellent, and in particular the ICC for visceral 
pain was 0.97, suggesting that this particular patterned response was highly 
reproducible. It is interesting to note that the change in CVT to visceral and 
somatic pain was very reproducible, yet STAI-S was not. It is interesting that STAI-S 
was not associated with a statistically significant difference in the cluster analysis 
performed in chapter 3 (see section 3.7.8) thus suggesting that anxiety levels, as 
assessed by STAI, are not a major, or defining, influence on the cluster/ pain 
phenotypes.  
 
5.8.6 Reproducibility of Cluster Analysis and Pain Phenotypes 
The two-step cluster analysis, using the same input parameters defined in Chapter 
3, favoured a two-cluster solution with similar psychophysiological characteristics as 
defined previously. Whilst the homozygous proportions of those subjects in cluster 
1 vs. cluster 2 were not statistically different between study 1 and study 2, it was 
interesting to observe that they were 39.1% : 60.9% vs. 26.6% : 73.4%, respectively. 
As the clusters are partially defined based on personality, these differences may be 
accounted for by considering that those participants in the reproducibility cohort 
had lower neuroticism and higher extroversion scores, thus making it more likely 
that they belonged to cluster 2, possibly reflecting a degree of self-selection bias 
based on their willingness to re-participate. A possible approach in further studies 
would be to identify participants based on their cluster membership and actively 
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recruit for reproducibility studies based on these. However, this particular 
approach was outside the scope of this study, as I sought to study the 
reproducibility of psychophysiological responses to pain in an unselected cohort 
and therefore recruited solely based on subject availability.  
 
The degree of cluster separation in this study, as given by the cluster silhouette 
coefficient, was not as strong as in Chapter 3, at 0.6 vs. 0.79, respectively. Although 
a cluster silhouette coefficient of !0.6 is taken to indicate a good degree of 
separation between the clusters, the reduction observed in this study is most likely 
a result of the fewer numbers of subjects recruited to this study. It would have 
been interesting to restudy all the subjects who participated in study 1, but 
practically this was not possible. The design of future studies, particularly involving 
patient populations, should consider the limitations of cluster analysis in identifying 
psychophysiological differences and thus recruit an appropriate number of 
participants. Based on the data presented here, it would be reasonable to consider 
that a study population of at least 30 subjects is the minimum required to detect 
these differences. 
 
The overall pain phenotypes based on the results presented in this study do seem 
to exhibit a stable pattern of traits over a period of one year for the majority of 
study participants. However, one subject changed their cluster (phenotype) 
membership from cluster 1 to 2 and one from cluster 2 to cluster 1 when 
restudied. Further analysis to elucidate the cause of these changes was not 
attempted, as the numbers who changed groups were (reassuringly) too small for a 
meaningful interpretation of any possible differences. Reviewing the raw data for 
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these subjects did not reveal that they were on the border of any obvious effect, 
such as personality/anxiety traits, autonomic, genetic or HPA axis variables.  
 
However, potential differences in these subjects may relate to subtle changes in 
personality traits, such as reduced or increased state anxiety, at the point a subject 
was restudied. Overall, though, these results suggest that psychophysiological 
responses to visceral and somatic pain are reproducible, but further work must 
concentrate on how to modulate these responses either through influencing 
personality traits using psychological means or by influencing ANS responses 
pharmacologically. The ability to influence pain phenotypes may have considerable 
therapeutic implications for patients with chronic pain disorders. However, we 
must be cautious in interpreting this data a reflecting absolute stability of the 
clusters over time as the data may mean the 30 subjects that we re-studied just 
happened to be very representative of the larger cohort. 
 
5.9 Conclusions 
In conclusion, for the first time I have demonstrated in an unselected cohort of 
healthy volunteers that personality traits, autonomic and HPA axis responses to 
visceral and somatic pain, in addition to pain phenotypes, are reproducible 
phenomena at a period of one year. Further work is now warranted to investigate 
the stability of responses in a longitudinal study over a number of years. 
Furthermore, the prevalence – and possible relevance – of pain phenotypes in 
chronic pain disorders may lead to important and novel observations of their 
pathophysiology, but may also open new avenues in the development of efficacious 
therapeutic measures. 
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Chapter 6 – Psychophysiological Responses to 
Visceral and Somatic Pain in Functional Chest Pain 
of Presumed Oesophageal Origin – A Case Control 
Study  
6 Psychophysiological Responses to Visceral and Somatic Pain in 
FCP of Presumed Oesophageal Origin – A Case Control Study 
Responses to Visceral & Somatic Pain 
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6.1 Chapter Overview 
FCP of presumed oesophageal origin is a condition defined by midline chest pain in 
the absence of evidence of gastro-oesophageal reflux disease or oesophageal 
dysmotility. Many authorities consider FCP to be a similar clinical entity to NCCP. 
Indirect evidence suggests that it is a common disorder with a heterogeneous 
aetiology. In the preceding studies presented in this thesis, I have identified two 
reproducible, multidimensional pain phenotypes. The clinical salience of these pain 
phenotypes is unknown. I sought to evaluate personality traits, polymorphisms of 
the 5-HTTLPR and ANS/HPA axis responses to somatic and visceral pain in a 
cohort of patients with FCP vs. age-, sex- and ethnicity-matched healthy controls. 
Twenty patients were recruited to the study (nine male) with a mean age of 38.7 
years (range 21-59 years). Twenty healthy volunteers were recruited to the study 
(nine male) with a mean age of 35.6 years (range 22-49). Subjects had personality 
traits measured using validated questionnaires and had validated ANS parameters 
measured at baseline and continuously thereafter. All subjects had venous blood 
taken at baseline for genetic analysis of the SERT and cortisol. Subjects received 
seven somatic stimuli (nail bed pressure) to PTT, with a two-minute inter-stimulus 
interval, followed by seven visceral stimuli (mid/distal oesophageal distension) to 
PTT, with a two-minute inter-stimulus interval. Serum cortisol was measured after 
somatic and visceral pain. Patients had higher neuroticism and state/trait anxiety 
with lower extroversion scores in comparison to the controls. There was no 
difference in polymorphisms of the SERT between the two groups. Patients had 
higher baseline serum cortisol, HR and parasympathetic tone in comparison to the 
controls. The pattern of HPA axis activation was not different between the groups. 
Patients’ pain toleration threshold was lower for somatic and visceral pain. Affective 
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ratings of pain intensity and unpleasantness were not different between the groups. 
In response to somatic and visceral pain, patients increased their parasympathetic 
tone. Two-step cluster analysis revealed the presence of two psychophysiological 
groups, cluster 1 (n=17, 42.5%), which had higher neuroticism and anxiety scores 
with lower extroversion scores, and was sympathetically active at rest with higher 
serum cortisol and had the S allele of the SERT. Cluster 1 increased 
parasympathetic tone to visceral and somatic pain. Cluster 2 (n=23, 57.5%) had the 
converse profile. Patients were over-represented in cluster 1 (p=0.01). This study 
provides further evidence for the existence of two distinct human pain phenotypes. 
Furthermore, this study provides novel evidence that phenotyping pain responses 
have a clinical salience in patients with FCP. Further work is now warranted to 
evaluate these responses in a larger cohort of patients with FCP, and in patients 
with other disorders of chronic pain such as IBS. 
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6.2 Introduction 
Functional oesophageal disorders are a group of four FGID disorders characterised 
by chronic symptoms that lack an identifiable structural or metabolic abnormality. 
The pathophysiological mechanisms that underlie the genesis of symptoms are 
incompletely understood, although a combination of psychosocial and physiological 
factors have been proposed [370]. Central to these disorders is chronic, 
unexplained (chest) pain, which is often referred to as NCCP or FCP of presumed 
oesophageal origin (FCP). The Rome III multinational consensus defines FCP as 
“...midline chest pain or discomfort that is not of burning quality in the absence of evidence 
for gastro-oesophageal reflux disease or histopathological based motility disorders for the 
last 3 months with symptom onset at least 6 months prior to diagnosis.” [5] Despite such 
efforts to improve diagnostic criteria, this group or clustering of symptoms is 
known under a variety of guises. There are over 20 synonyms for this disorder, for 
instance cardiac syndrome X, effort syndrome, neurocirculatory asthenia and 
soldiers’ heart, which span a number of disciplines including cardiology, 
gastroenterology and psychosomatic medicine. For the purposes of this chapter, 
hereafter I shall consider the terms NCCP and FCP synonymous with one another. 
 
With such a wide variation in nomenclature and classification it is not surprising 
that there is a paucity of data concerning the epidemiology of this disorder. 
Tentative inferences can be made from data extracted from negative cardiac 
evaluation for chest pain. Studies suggest that up to 30% of coronary angiograms 
may be normal, and the incidence of FCP may be in the order of 500,000 new cases 
per annum in the United States [371, 372]. In a study of patients being referred to a 
rapid access chest pain clinic in the UK, the final diagnosis in 49% was NCCP [373]. 
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There is no evidence to suggest that patients with FCP suffer excess mortality, but 
they do have long-term symptoms. Eslick et al. found that up to 75% of patients 
diagnosed with NCCP continued to report symptoms four years after follow-up 
[374]. A previous study by the same group also suggested that patients with NCCP 
have impairment of their functional status, increased use of healthcare resources 
and work absenteeism [375]. NCCP is not confined to Western populations, with a 
recent report from Japan citing the prevalence to be 35% [376]. A number of 
pathophysiological mechanisms have been proposed to underlie FCP including 
oesophageal dysmotility, VH, dysautonomia and psychological factors.  
 
6.2.1 Oesophageal Dysmotility 
Estimates vary as to the rates of oesophageal dysmotility in patients with FCP. 
Whilst the Rome III criteria specifically state that there should be no 
histopathological evidence of oesophageal dysmotility, this criterion is not extended 
to manometric parameters. Dysmotility does seem to be common in this disorder, 
with one study reporting that approximately 30% of patients had oesophageal 
dysmotility, as assessed by standard manometry [377]. However, this seemingly 
large proportion may, in fact, be an underestimation, as a more recent study of 100 
patients with NCCP showed that only 8% had normal oesophageal motility [378]. 
Thus, the nature of the relationship between FCP and oesophageal dysmotility is  
not yet fully resolved, which may be due primarily to the confounding factor of 
retrospectively establishing a history of chest pain in patients with oesophageal 
dysmotility, in whom it was not the initial presenting complaint.  
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6.2.2 Oesophageal Hypersensitivity 
Oesophageal hypersensitivity is characterised by allodynia – whereby a non-painful 
stimulus is perceived as being painful – and is considered by many leading 
authorities in the field to be the germane hypothesis in explaining many functional 
oesophageal disorders [96]. The concept of oesophageal hypersensitivity was first 
proposed in the mid-1980s by Richter et al., who found that, in comparison to 
healthy controls, a high percentage of patients with NCCP reported pain to intra-
luminal oesophageal balloon distension [379]. In a larger case control study of 50 
patients with NCCP vs. 30 healthy volunteers, balloon distension induced chest 
pain in 56% of patients vs. 20% of healthy volunteers, giving a diagnostic yield of 48% 
[380]. Therefore, balloon distension of the oesophagus lacks the diagnostic 
sensitivity for it to be a useful biomarker in routine clinical practice.  
 
The mechanisms that contribute to the development, and maintenance, of 
oesophageal hypersensitivity and allodynia have only recently been elucidated, most 
notably using techniques such as neurophysiology and functional neuro-imaging. 
Several studies using balloon or electrical distension have demonstrated 
oesophageal allodynia in vivo [153, 381]. CS can be induced in the proximal 
oesophagus following experimental acid exposure in the distal oesophagus, 
suggesting that occult gastro-oesophageal reflux could explain the underlying 
pathophysiology in a proportion of patients with NCCP [153]. In patients with 
NCCP, abnormalities relating to the cerebral processing of intra-oesophageal 
stimuli have also been demonstrated. Hobson et al. examined oesophageal-evoked 
cortical potentials to electrical stimulation in a cohort of 32 patients with NCCP vs. 
12 healthy controls [382]. The NCCP group could be subdivided into three distinct 
groups based on their pain thresholds and latencies, indicating that the 
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pathophysiology of NCCP may be multidimensional, perhaps as a result of the 
following factors: a) increased afferent pathway sensitivity, b) abnormal cortical 
processing potential or (c) factors such as pain hypervigilance. In another study, 
Hollerbach et al. studied eight subjects with NCCP and compared them to 12 
healthy controls [383]. Cortical evoked responses were lower in the NCCP 
patients during electrical stimulation, suggesting that the increased perception of 
oesophageal stimulation in this group may be due to the enhanced cerebral 
processing of visceral sensory input rather than hyperalgesia emanating from 
visceral sensory afferents.  
 
6.2.3 Dysautonomia 
In a canine model, Gilbert et al. demonstrated the presence of a viscerocardiac 
reflex, to coronary artery vasoconstriction indirectly induced by oesophageal 
balloon distension, which could be abolished by either atropine or a vagotomy. This 
study provides further evidence for the role of the PNS in nociception [384]. A 
series of studies by Tougas et al. provided convincing evidence that patients with 
NCCP demonstrate exaggerated brainstem autonomic responses to oesophageal 
acidification. For instance, in 28 patients with NCCP, 19 had chest pain induced by 
the infusion of acid into the distal oesophagus. This was associated with decreased 
vagal tone at rest but increased vagal outflow in pain, suggesting vagal mediation of a 
pseudo-affective response in these patients [385]. A criticism of this study was that 
autonomic activity was assessed using power spectral analysis of HRV, a technique 
used for autonomic analysis that is considered by many to have methodological 
limitations [66].  
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6.2.4 Psychological Comorbidity 
Psychological comorbidity is present in up to 43% of patients with NCCP [386]. 
This comorbidity includes panic disorders, generalised anxiety disorder, phobic 
disorder, major depression and somatisation [387]. Clouse and Lustman studied 50 
patients, who were referred for oesophageal manometry, and independently 
evaluated them for psychiatric diagnoses to determine whether there was any 
association between psychiatric illness and oesophageal motility disorders [388]. 
They found that 25 (50%) patients had non-specific motility abnormalities, of which 
84% had a concomitant psychiatric diagnosis. Of note is that those patients in 
whom manometry was normal – only eight (31%) – had a psychiatric diagnosis. 
Another study showed that, in an unselected cohort of patients attending an 
emergency department, whose chief complaint was chest pain, 25% met the DSM-
IV criteria for panic disorder [389]. Whether psychiatric comorbidity is a primary 
cause, a predisposing factor, a co-morbid illness or sequelae to NCCP or FCP, is 
yet to be fully determined. 
 
Considering this evidence, it is likely that afferent, central, efferent and 
psychological mechanisms are important in the development and maintenance of 
symptoms in NCCP and probably FCP. Currently, the diagnosis of FCP is one of 
exclusion, and this being the case it is not surprising that treatment strategies are, 
at best, of limited efficacy. The main thrust of treatment in FCP is centred on 
influencing oesophageal pain pathways using pain modulators, muscle relaxants and 
psychotherapeutic techniques. Patient satisfaction with treatments is low, and again 
it is unsurprising that symptoms often display an unacceptable degree of chronicity 
[390]. Considering the huge disease burden and impairment of quality of life 
associated with FCP, further research is needed to characterise the 
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psychophysiological responses to pain in patients with FCP. By using 
multidimensional techniques encompassing genetics of the SERT, personality traits, 
autonomic and HPA axis responses to visceral and somatic pain in a case control 
design, I aimed primarily to delineate further the relative contributions of these in 
the pathophysiology of FCP. My secondary aim was to examine whether one of the 
reproducible multidimensional pain phenotypes is over-represented in patients with 
FCP.  
 
6.3 Hypothesis 
Therefore, my hypothesis was that patients with FCP display distinct 
psychophysiological responses to visceral and somatic pain, in comparison to age, 
sex and ethnicity matched healthy controls identified in chapter 3. Further 
distinctions between patients with FCP and healthy controls using cluster analysis 
may establish whether patients are over-represented in a particular pain phenotype.  
 
6.4 Methods 
6.4.1 Subjects 
Twenty patients with FCP and 20 healthy age, sex, ethnicity-matched volunteers 
were recruited for the study. No formal sample size calculation was undertaken and 
this was a preliminary observational study. All subjects were naïve to the 
experimental protocol and had never taken part in research studies examining pain. 
The study was approved by the East London and the City Ethics Committee 2 (ref 
08/H0703/47/substantial amendment 1). The study was performed in accordance 
with the Declaration of Helsinki.  
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6.4.1.1 Inclusion Criteria for Patients with Functional Chest Pain 
Subjects in whom the primary presenting complaint was chest pain, whom had 
subsequently undergone oesophageal manometry and 24-hour pH-metry in the 18 
months prior to the commencement of this study, were identified from electronic 
records from the GI Physiology department at the Royal London Hospital. 
Physiological traces of the oesophageal manometry and 24-hour pH-metry were 
then individually reviewed, and subjects with normal motility and reflux time less 
than 4% were identified. The endoscopy and histopathological databases at the 
Royal London Hospital were then interrogated and cross-referenced to ascertain 
those subjects who had a normal diagnostic upper GI endoscopy and histology. 
Based on negative findings in each of these, eligible subjects were then contacted by 
letter inviting them to participate in the study. Those subjects who replied to the 
postal invitation were then contacted by telephone to establish if their 
symptomatology remained consistent with the Rome III definition of FCP, i.e. 
midline chest pain or discomfort that is not of burning quality in the absence of 
evidence for gastro-oesophageal reflux disease or histopathological-based motility 
disorders for the last three months, with symptom onset at least six months prior 
to diagnosis. The upper age limit for inclusion into the study was 65 and the lower 
age limit 18. All menstruating female subjects were studied during the follicular 
phase of their cycle. 
 
6.4.1.2 Exclusion Criteria for Patients with Functional Chest Pain 
Subjects taking regular analgesic, anti-secretory or central acting medications such 
as tricyclic antidepressants, opiates, proton pump inhibitors, H2 antagonists, or 
non-steroidal anti-inflammatory medications were excluded. In addition, subjects 
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taking medications that may influence autonomic responses, such as beta-blockers 
or beta-agonists, were also excluded. Those with subclinical anxiety or depression 
were also excluded using the validated Hospital Anxiety Depression scale. Current 
smokers were not excluded from the study, but were asked not to smoke for 24 
hours before the study. In addition, subjects were asked to refrain from consuming 
alcohol for 24 hours prior to participation in the study. Pregnant females were 
excluded. Those subjects who exceeded the self-deception (lie) score, as assessed 
by the WAI, were excluded from the subsequent analysis [258].  
 
6.4.1.3 Inclusion Criteria for Healthy Volunteers 
Subjects aged between 18-65 years, who had no past medical history of current or 
chronic pain, GI, neurological, cardiovascular or psychiatric problems, were 
recruited to the study. Subjects were asked to refrain from alcohol and smoking for 
24 hours prior to the study. All female subjects were studied during the follicular 
phase of their menstrual cycle. 
 
6.4.1.4 Exclusion Criteria for Healthy Volunteers 
Those currently taking any medications and those with subclinical anxiety or 
depression were also excluded using the validated Hospital Anxiety Depression 
scale [208, 257]. Pregnant females were excluded. Those subjects who exceeded 
the self-deception (lie) score, as assessed by the WAI, were excluded from the 
analysis [258].  
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6.4.2 Pain Induction Techniques 
6.4.2.1 Visceral Pain Induction – Oesophageal Balloon Distension 
Commercially available oesophageal distension catheters, with an inflatable balloon 
mounted at the distal end (Sandhill, UK), were used during the study. Subjects were 
intubated trans-nasally with the catheter, with the aid of a water-based lubricating 
jelly (KY Jelly, Johnson & Johnson). The balloon was positioned in the mid/distal 
oesophagus at 34cm ab nares. Local anaesthetic spray was not used during 
intubation. Painful stimulation was achieved by inflating the balloon at a rate of 
5ml/second to the subject’s PTT. The PTT was defined as the point at which the 
subject could not tolerate further stimulation. Subjects were then asked to rate the 
pain on a VRS measuring intensity (10, worst imaginable pain, to 0, no sensation) 
and unpleasantness (10, worst imaginable unpleasantness, to 0, neutral).  
 
6.4.2.2 Somatic Pain Induction – Nail Bed Pressure 
A strain gauge (Mecmesin, UK) was mounted on to a specially designed spring-
loaded device such that the extension probe incorporated a thin, blunt rod applied 
to the subjects’ right thumb, 5mm from the cuticle, producing a stimulus of nail bed 
pressure ranging from touch to painful. Each painful somatic stimulus was achieved 
by applying nail bed pressure manually to the subject’s PTT. Pain intensity and 
unpleasantness were rated on a VRS with identical anchor statements as those for 
visceral pain.  
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6.4.3 Personality, Psychological State and Trait Measures 
Self-report validated questionnaires were administered to evaluate personality state 
and trait measures. The BFI was used to measure the personality traits of 
neuroticism and extroversion [259, 260]. State and trait anxiety were assessed 
using the STAI-S and STAI-T [261]. 
 
6.4.4 Autonomic Measures 
Digital arterial BP was measured using the photoplethysmographic technique, 
whereby a cuff was attached to the inter-phalangeal portion of the right middle 
finger, which is used to calculate MBP (Finapress, Amsterdam, Netherlands). ECG 
electrodes (Ambu Blue Sensor P, Denmark) were placed in the right and left 
subclavicular areas and cardiac apex, following skin preparation (Nuprep, Weaver & 
Co, USA), to reduce impedance and improve signal. ECG was acquired at a rate of 
5 kHz using the Neuroscope, measuring HR, SBP, DBP, MAP, CVT and CSB. 
Autonomic parameters were recorded according to the recommendations of the 
European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology Task Force [238]. 
 
SCR are a measure of sympathetic sudomotor response to stimuli, through changes 
in electrical impedance [262]. Skin on the right index and ring fingers was wiped 
with water and allowed to dry. Skin conductance electrodes were then attached to 
the subject’s fingers and the skin impedance for that subject was zeroed using a 
commercially available biosignals acquisition system (Powerlab, AdInstruments, UK). 
Skin impedance was then recorded and subsequently analysed off line. 
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6.4.5 Cortisol Measurement 
Serum total cortisol was assayed by the Blood Services Department at the Royal 
London Hospital using a chemiluminescence immunoassay (Nichols Advantage, 
Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). 
 
6.4.6 Genotyping of the Serotonin Transporter Long Polymorphic Region 
DNA was extracted using a modified salting out technique [235], and then stored at 
-20°C for genotype analysis. 5-HTTLPR polymorphisms were evaluated using SSP-
PCR. The insertion/deletion polymorphism of the 5-HTTLPR was typed in duplicate 
using previously published primers [84, 237], as per the protocol detailed in chapter 
4. The amplification products were visualised under UV light and classified as S or L 
alleles. Two investigators, blinded to each other’s results in addition to 
psychological and autonomic data, read the amplification products. In cases of 
disagreement the samples were rerun.  
 
6.5 Protocol 
Each subject attended for one visit lasting three hours. On arrival, they completed a 
consent form and then their height and weight were measured. They subsequently 
completed the validated personality questionnaires. Subjects were studied in the 
afternoon (from 1400-1600hrs) in a temperature-controlled (21-22° C), quiet 
laboratory. Subjects were reclined at 45 degrees on a bed. The ANS recording 
equipment was subsequently attached and five minutes of baseline data (resting/no 
stimulation) acquired. All subjects had an 18G intravenous cannula (Venflon, 
Beckton Dickinson, Oxford, UK) placed in the left antecubital fossa, and blood was 
taken for baseline serum cortisol and a further sample stored in EDTA tube at -
 241 
80°C (Vacutainer, Beckton Dickinson, Oxford, UK) for subsequent analysis of the 
5-HTTLPR genotype. A three-way needle-free valve port was attached to the intra-
venous cannula to limit cross contamination between successive cortisol samples 
(SmartSite Extension Set, Cardinal Health, Switzerland). Subjects received seven 
somatic stimuli to PTT followed by a 10-minute rest period. Subsequently, subjects 
were intubated with the oesophageal distension catheter and allowed to rest for 10 
minutes. Subjects then received seven visceral stimuli to PTT. Subjects received a 
verbal cue five seconds prior to each painful stimulus, in an attempt to standardise 
any effects of anticipation. If the stimulus contained any artefact (such as coughing, 
sneezing, movement or swallowing) it was rejected and not subsequently analysed. 
Venous blood for cortisol (Vacutainer, Beckton Dickinson, Oxford, UK) was 
sampled two minutes after the final somatic stimulation and then again two minutes 
after the final visceral stimulation.  
 
6.6 Statistical Analysis 
Categorical variables are expressed as percentages, and the Chi-squared test or 
Fisher’s exact test were used to compare groups. Continuous variables are 
expressed as mean ! SEM (!SEM). The ANS and HPA axis data was normally 
distributed and group comparisons were undertaken using two-tailed Student’s t-
test and, for multi-group comparisons, one-way ANOVA with Bonferroni 
correction. Mann-Whitney U Tests were used to compare personality psychological 
trait and state scores. Correlational analysis was performed using Pearson or 
Spearman’s correlation as appropriate. Two-step cluster analysis was performed 
with input factors of neuroticism, extroversion, baseline CVT and dynamic changes 
in CVT to visceral and somatic pain being defined a priori. Commercially available 
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statistics packages (SPSS, Chicago, IL, USA and GraphPad, San Diego, CA, USA) 
were used for the analysis. P values <0.05 were considered to be of statistical 
significance.  
 
6.7 Results 
6.7.1 Subject Characteristics 
Twenty patients were recruited to the study (nine male) with a mean age of 38.7 
years (range 21-59 years) and a mean BMI (BMI) of 29.1kg/m2 ± 1.1kg/m2. A further 
twenty healthy volunteers were recruited to the study (nine male) with a mean age 
of 35.6 years (range 22-49) and a mean BMI of 25.8kg/m2 ± 1.4kg/m2. All subjects 
were Caucasian. Three patients did not complete the study – one was excluded, as 
they exceeded the self-deception score, and two did not tolerate oesophageal 
intubation. Healthy controls were chosen from those in chapter 3 based on 
matching the age, sex and ethnicity of those recruited to this study. Groups were 
matched for sex, age and ethnicity, although the patient group had a trend towards 
a higher BMI (see Table 23). 
 
Variable Patients 
(n=17) 
Controls 
(n=20) 
P value 
Sex  
(Male: female) 
7 : 10 9 : 11 1 
Age 
(years - mean ± SEM) 
38.7 ± 2.1 35.6 ± 1.9 0.27 
BMI (kg/m2 - mean ± 
SEM  
29.1 ± 1.1 25.8 ± 1.4 0.08 
Ethnicity  
(Caucasian: non-
Caucasian) 
17 : 0 20 : 0 1 
Table 23 – Demographic comparison of the patient and control groups.  
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6.7.2 Psychological Characteristics 
Patients had higher anxiety and depression scores, as assessed by the HADS, in 
comparison to the controls (p=0.0005 and p=0.0002, respectively). Patients had 
higher neuroticism (p=0.0001) and lower extroversion scores (p=0.003) than the 
controls. Patients had higher state and trait anxiety scores than the controls 
(p=0.0001 and p=0.0007, respectively) (see Table 24).  
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Psychological variable 
Patients  
(n=17) 
Mean ± SEM 
Controls 
(n=20) 
Mean ± SEM 
P Value 
HADS – Anxiety 4.65 ± 0.47 2.45 ± 0.34 0.0005 
HADS-Depression 4.82 ± 0.63 1.9 ± 0.36 0.0002 
BFI-Neuroticism 3.67 ± 0.25 2 ± 0.36 0.0001 
BFI-Extroversion 3.04 ± 0.42 4.2 ± 0.23 0.003 
BFI-Openness 3.45 ± 0.16 3.8 ± 0.13 0.09 
BFI-Agreeableness 3.81 ± 0.25 4.1 ± 0.19 0.17 
BFI-Conscientiousness 3.78 ± 0.28 4.3 ± 0.3 0.25 
STAI-Trait 43.5 ± 2.47 28.4 ± 8.5 0.009 
STAI-State 41.7 ± 2.6 27.7 ± 2.2 0.0007 
Table 24 - The psychological characteristics of patients vs. controls. All statistical tests were 
undertaken with the Mann-Whitney U Test. 
 
6.7.3 Stimulus Toleration 
The mean somatic stimulus tolerated by patients was 48.4N ± 3.38 vs. 70.61N ± 3.6 
for the controls (two-tailed unpaired t-test p<0.0001). The mean visceral stimulus 
tolerated by patients was 30mls± 1.8 vs. 50.9mls± 6.9 for the controls (two-tailed 
unpaired t-test p=0.009) (see Figure 46). 
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Figure 46 - The mean somatic (panel A) and visceral (panel B) stimulus tolerated by patients and 
controls. Controls tolerated an increased mean quantity of both somatic and visceral stimulus in 
comparison to patients. * p<0.0001. 
 
6.7.4 Affective Ratings of Visceral and Somatic Pain 
There was no difference in the affective ratings of pain intensity or unpleasantness 
for somatic and visceral pain between patients and controls (see Table 25). It is 
interesting to note that both patients and controls rated visceral pain as more 
unpleasant than somatic pain suggesting that the visceral pain induction induced a 
similar adverse affective experience for both groups. In some ways this is surprising 
as I may have expected the patients to have rated both types of pain as more 
unpleasant. 
Affective Rating 
Patients  
(n=17) 
Mean ± SEM 
Controls 
(n=20) 
Mean ± SEM 
P Value 
Somatic Pain  
Intensity 
7.72 ± 0.29 7.62 ± 0.31 0.81 
Somatic Pain 
Unpleasantness 
6.26 ± 0.24 6.28 ± 0.3 0.94 
Visceral Pain  
Intensity 
7.26 ± 0.25 7.62 ± 0.47 0.51 
Visceral Pain 
Unpleasantness 
7.44 ± 0.28 7.39 ± 0.44 0.93 
Table 25 - Affective ratings of visceral and somatic pain for patients and controls. Statistical 
analysis was undertaken using unpaired t-tests. 
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6.7.5 Hypothalamic Pituitary Adrenal Axis Responses to Pain 
Sequential serum cortisol results were available in all subjects who completed the 
study. Mean baseline serum cortisol, mean post-somatic pain serum cortisol and 
mean post-visceral pain cortisol were higher in patients than controls (see Figure 
47). However, there were no differences in the degree of change at any of the time 
points between patients and controls when baseline cortisol is controlled for (see 
Table 26).  
 
 
 
Figure 47 - Serum cortisol at baseline, post somatic pain and post visceral pain in patients and 
controls. 
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Serum Cortisol 
Patients (n=17) 
Mean ± SEM 
Controls (n=20) 
Mean ± SEM 
P Value 
Baseline Cortisol (nMol/L) 
 
355 ± 26 247.9 ± 27.7 0.01 
Post Somatic Pain Cortisol 
(nMol/L) 
471.3 ± 42.4 280 ± 32.2 0.002 
Post Visceral Pain  
Cortisol (nMol/L) 
481.7 ± 41.2 324.1 ± 31.7 0.006 
Percentage Change from 
Baseline to Somatic Pain 
(%) 
37.4 ± 9.4 33.4 ± 14.2 0.83 
Percentage Change from 
Somatic Pain to Visceral 
Pain (%) 
3.2 ± 6.4 4.6 ± 0.7 0.91 
Percentage Change from 
Baseline to Visceral Pain 
(%) 
38.4 ± 10.9 40 ± 4.25 0.94 
Table 26 - Mean cortisol (upper half) and percentage change (lower half) at baseline, post somatic 
pain and post visceral pain for patients and controls. Statistical analysis was undertaken with 
unpaired t-tests and the Mann-Whitney U test. 
 
6.7.6 Autonomic Nervous System Responses to Pain 
At baseline, patients had an elevated HR and SCR with lower CVT and CSB in 
comparison to the controls (see yellow boxes in Table 27). At baseline, no 
differences were apparent in any of the other autonomic variables. In response to 
somatic and visceral pain, patients had lower CSB and SCR (see yellow boxes in 
Table 27). During somatic and visceral pain, no differences were apparent in any 
other autonomic variable. 
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Baseline Somatic Pain Visceral Pain 
 Patients 
Mean (±SEM) 
Controls 
Mean (±SEM) P value  
Patients 
Mean (±SEM) 
Controls 
Mean (±SEM) P value  
Patients 
Mean (±SEM) 
Controls 
Mean (±SEM) P value 
HR 
(bpm) 
75.9 ±4.7 67.2 ±1.7 0.04 HR 
(bpm) 
78.9 
±3.2 
77.9 
±3 
0.83 HR 
(bpm) 
74.2 
±2.4 
75 
±2.6 
0.84 
SBP 
(mmHg) 
129.1 
±6.6 
136.2 
±4.7 
0.39 SBP 
(mmHg) 
141.1 
±5.12 
140.6 
±5.1 
0.93 SBP 
(mmHg) 
145.3 
±4.8 
138.5 
±9.8 
0.63 
DBP 
(mmHg) 
62.6 
±3.1 
63.1 
±1.8 
0.84 DBP 
(mmHg) 
73.7 
±3.08 
67.2 
±3.5 
0.18 DBP 
(mmHg) 
71.9 
±3.4 
68.7 
±5.44 
0.61 
MBP 
(mmHg) 
88.9 
±2.3 
91.4 
±3.5 
0.86 MBP 
(mmHg) 
96.1 
±2.8 
91.9 
±3.6 
0.38 MBP 
(mmHg) 
96.4 
±3.5 
91.9 
±6.55 
0.55 
CVT 
(LVS) 
5.5 
±0.84 
11.76 
±1.6 
0.003 CVT 
(LVS) 
8.94 
±1.1 
9.83 
±0.44 
0.55 CVT 
(LVS) 
9.88 
±1.5 
8.5 
±0.33 
0.41 
CSB 
(!RR/!mmHg) 
4.79 
±0.92 
8.76 
±1.27 
0.02 CSB 
(!RR/!mmHg) 
4.91 
±0.88 
7.6 
±0.74 
0.02 CSB 
(!RR/!mmHg) 
4.35 
±0.49 
6.9 
±0.65 
0.008 
SCR 
(µS) 
4.2 
±0.9 
2.05 
±0.27 
0.05 SCR 
(µS) 
16.08 
±1.1 
22.15 
±2.07 
0.03 SCR 
(µS) 
15.81 
±1.2 
20.91 
±2.5 
0.004 
Table 27 - Autonomic variables at baseline, post somatic pain and post visceral pain in patients and controls. Variables that were significantly different are highlighted in 
yellow. Comparisons were undertaken with a two-tailed unpaired t-test. 
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6.7.7 Dynamic Autonomic Nervous System Responses to Pain 
The dynamic peri-stimulus pain-related change in autonomic variables was examined 
by calculating !change by comparing the 30 seconds pre- vs. the 30 seconds post-
stimulus; time points considered to demonstrate the maximal change in these 
parameters [215]. In response to somatic pain, patients’ HR increased less than 
controls’, with a concomitant reduction in SBP. Furthermore, in patients there was 
a marked increase in parasympathetic tone (CVT and CSB) in response to pain, 
which was not evident in the controls (see panels A and B, respectively, in Figure 
48). Similarly, in visceral pain, patients slowed their HR, with an associated drop in 
SBP with parasympathetic activation (CVT and CSB) (see panels C and D, 
respectively, in Figure 48), and sympathetic withdrawal (SCR). Controls 
demonstrated the converse profile (see Table 28). 
 
Peri-stimulus Dynamic Somatic Pain Changes 
 Patients 
Mean (±SEM) 
Controls 
Mean (±SEM) 
P value 
!HR (%!bpm) 0.27 ± 1.4 8.3 ± 2.6 0.01 
!SBP (%!mmHg) -0.27 ± 0.6 2.9 ± 1.1 0.03 
!DBP (%!mmHg) 1.07 ± 0.68 2.8 ± 1.08 0.18 
!MBP (%!mmHg) 1.22 ± 0.45 3.12 ± 0.99 0.07 
!CVT (%!LVS) 53 ± 18.6 -14.1 ± 5.2 0.002 
!CSB (%!!RR/!mmHg) 13.24 ± 6.3 -24.8 ± 11.7 0.01 
!SCR (%!µS) 0.09 ± 1.7 15.88 ± 1.4 0.007 
Peri-stimulus Dynamic Visceral Pain Changes 
 Patients 
Mean (±SEM) 
Controls 
Mean (±SEM) 
P value 
!HR (%!bpm) -1.69 ± 1.2 5 ± 1.35 0.002 
!SBP (%!mmHg) -1.66 ± 0.9 3.5 ± 1.4 0.008 
!DBP (%!mmHg) -0.98 ± 1.1 3.1 ± 1.66 0.06 
!MBP (%!mmHg) -0.85 ± 0.9 3.6 ± 1.7 0.02 
!CVT (%!LVS) 105.7 ± 38 -15.9 ± 4.5 0.008 
!CSB (%!!RR/!mmHg) 36.97 ± 17 -21.8 ± 8.5 0.008 
!SCR (%!µS) -0.73 ± 0.2 12.78 ± 0.8 0.006 
Table 28 - Dynamic peri-stimulus change in autonomic parameters to somatic and visceral pain in 
patients and controls. The statistical analysis was undertaken using a two-tailed Mann-Whitney U 
Test. 
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Figure 48 - Dynamic cardiac vagal tone and cardiac sensitivity to the baroreflex changes to somatic 
pain (panels A and B) and to visceral pain (panels C and D) between patients and controls. The 
statistical analysis was undertaken using a two-tailed Mann-Whitney U Test. * p<0.001.  
 
6.7.8 Serotonin Transporter Long Polymorphic Region Genotyping  
All controls were genotyped successfully. 15 out of 17 patients (one refused to give 
blood for genotypic analysis and one subject’s sample was lost, as the blood bottle 
shattered during the defrosting process). Genotype distributions were in Hardy-
Weinberg equilibrium (!2 3.125, p=0.08). Allele and genotype frequency are detailed 
in Table 29. 
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 Allele 
Allele 
frequency 
Genotype 
Genotype 
frequency 
L 0.57 LL 40 
LS 34.2 Overall 
S 0.43 
SS 25.8 
     
L 0.47 LL 26.67 
LS 40 
Patients  
(n=17) S 0.53 
SS 33.33 
     
L 0.67 LL 55 
LS 25 
Controls  
(n=20) S 0.33 
SS 20 
Table 29 - Allele and genotype frequencies of the 5-HTTLPR. 
 
Subjects were genotypically grouped based on the presence of the dominant S allele 
(i.e. the SS and LS genotypes) or its absence (i.e. the LL genotype). The presence of 
the S allele was not over-represented in the patient group in comparison to the 
control group: !2 2.81, p=0.09, odds ratio 3.3, 95% confidence interval 0.79-14.25 
(see Figure 49). 
 
Figure 49 - Distribution of 5-HTTLPR genotype based on presence or absence of S allele in patients 
and controls:  !2 2.81, p=0.09, odds ratio 3.3, 95% confidence interval 0.79-14.25. 
 
6.7.9 Cluster Analysis 
Pooling the data from patients and controls, a two-step cluster analysis was 
performed, as this was a large data set with normally and non-normally distributed 
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data. Input parameters were neuroticism, extroversion, baseline CVT and !change 
in CVT to visceral and somatic pain. These input parameters were defined a priori 
based on a previous study [214]. The optimum solution was two clusters, with 
cluster 1 containing 17 subjects (45.9%) and cluster 2 containing 20 subjects (54%). 
The cluster silhouette coefficient was 0.73. Further comparison of means and 
categorical variables between the two groups is shown in Table 30. 
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Variable Cluster 1 (n=17) Cluster 2 (n=20) P Value 
Demographics 
Male: Female 7 : 10 9 : 11 1 
 Mean Age 34.23 ± 2.1 36.95 ± 3.94 0.89 
Personality Traits Mean (±SEM) Mean (±SEM)  
BFI Neuroticism 3.7 ± 0.24 1.95 ± 0.15 <0.0001 
BFI Extroversion 2.92 ± 0.26 4.36 ± 0.15 0.0002 
STAI-T 41.6 ± 32.4 30.3 ± 2.89 0.007 
STAI-S 39.38 ± 3.75 31.13 ± 3.25 0.11 
5-HTTLPR Genotype 
S Allele : No S Allele 15 : 2 5 : 13 <0.0001 
HPA Axis Mean (±SEM) Mean (±SEM)  
Baseline Cortisol  
(nMol/L) 
343.2 ± 23.25 239.7 ± 37.32 0.03 
Post-somatic Pain Cortisol 
(nMol/L) 
418.1 ± 22.75 292.6 ± 54.29 0.04 
Post-visceral Pain Cortisol 
(nMol/L) 
449.7 ± 33.35 316.4 ± 55.8 0.054 
Baseline Autonomics Mean (±SEM) Mean (±SEM)  
HR (bpm) 68.2 ±2.88 62.2 ± 0.9 0.003 
MBP (mmHg) 79.4 ± 3.2 80.5 ± 1.8 0.44 
CVT (lvs) 5.15 ± 0.68 12.16 ± 1.5 0.0005 
CSB (!RR/!mmHg) 6.02 ± 0.69 8.77 ± 0.32 0.0002 
SCR (µS) 2.08 ± 0.49 2.78 ± 0.12 0.43 
Somatic Pain Mean (±SEM) Mean (±SEM)  
Mean stimulus (N) 57.6 ± 2.89 72.8 ± 2.1 0.0001 
Habituation 
(!% 1st vs. final stimulus) 29.15 ± 12.59 40.95 ± 11.03 0.49 
!HR (%) -0.12 ± 2.2 8.67 ± 3.44 0.0002 
!MBP (%) -0.9 ± 1.1 0.32 ± 0.56 0.52 
!CVT (%) 47.67 ± 14.58 -12.3 ± 4.6 0.001 
!CSB (%) 33.3 ± 8.1 -0.9 ± 6.1 0.001 
!GSR (%) 0.01 ± 0.9 4.99 ± 0.9 0.009 
Visceral Pain Mean (±SEM) Mean (±SEM)  
Mean stimulus (ml) 30.1 ± 2.11 44.3 ± 2.45 0.0009 
Habituation 
(!% 1st vs. final stimulus) 60.08 ± 5.5 80.75 ± 14.38 0.19 
!HR (%) -2.2 ± 1.2 4.78 ± 1.0 0.003 
!MBP (%) -3.25 ± 2.2 -2.89 ± 0.42 0.67 
!CVT (%) 94.01 ± 31.22 -15.43 ± 3.5 0.002 
!CSB (%) 32.3 ± 15.09 -2.99 ± 6.0 0.007 
!GSR (%) -1.22 ± 0.42 3.8 ± 0.9 0.01 
Table 30 - Phenotypic differences between clusters. Demographic, personality traits, baseline 
autonomic, visceral and somatic pain differences between cluster 1 and cluster 2 are shown. For 
categorical variables, p value is derived from Fisher's exact test and all other continuous variables 
were compared using unpaired t-tests or the Mann-Whitney U test depending on the manner of 
the distribution of data. 
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In summary, cluster 1 had higher neuroticism scores, lower extroversion scores, 
higher trait anxiety scores and the presence of the S allele of the 5-HTTLPR. At 
baseline, cluster 1 had a higher resting HR, SCR and cortisol with lower CVT and 
CSB. In response to somatic pain, cluster 1 tolerated less stimulus, had higher 
cortisol and increased CVT and CSB with an attenuated HR response. In response 
to visceral pain, similar patterned responses were observed, although differences in 
cortisol did not reach statistical significance. Cluster 2 displayed the converse 
profile. Thus, cluster 1 was sympathetically active at rest, with an increase in 
parasympathetic tone to pain, whereas cluster 2 was parasympathetically active at 
rest, with an increase in sympathetic tone to pain. In cluster 1, there were 12 
patients and 5 controls and in cluster 2 there were 5 patients and 15 controls: !2 
7.2, p=0.008, odds ratio 7.2, 95% confidence interval 1.68-30.81 (see Figure 50). 
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Figure 50 - The distribution of patients and controls as defined by cluster analysis in cluster 1 and 
2. Patients were over-represented in cluster 1: !2 7.2, p=0.008, odds ratio 7.2, 95% confidence 
interval 1.68-30.81. 
 
6.8 Discussion 
FCP is a common disorder in which the patho-aetiology of symptoms is poorly 
understood. In this study I have presented novel data implicating the role of 
personality traits, the ANS and HPA axis in its pathophysiology in a small case 
control study. Furthermore, I have provided evidence that patients with FCP are 
over-represented in the “neurotic” pain phenotype.  
 
One of the considerable challenges in comparing the results of this study to others 
is the wide variety of definitions that may or may not pertain to, or describe, the 
same disorder. Whilst I have chosen to regard NCCP and FCP as the same clinical 
entity for the purposes of this chapter, it could be argued that it is not valid to 
consider the diagnostic constructs as one single disorder. Furthermore, the group 
that I chose to study was defined by the Rome III criteria, my aim being to recruit 
as homogenous a group of patients as possible. Currently, there is not a widely 
accepted definition for NCCP. However, to the best of my knowledge, there are 
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no studies in FCP that provide convincing evidence of its existence as a separate 
entity to other disorders of chronic pain. The definition provided by the working 
party of the functional oesophageal disorders section of the Rome III committee is 
that of consensus expert opinion rather than objective scientific evidence. 
Nonetheless, this definition of FCP (similar to other definitions within the Rome 
framework) is useful in improving homogeneity amongst study participants and 
facilitating meaningful comparison between studies. Nonetheless, there is mounting 
evidence that unexplained chest pain may be in fact part of a spectrum of chronic 
pain disorders including FM and IBS [391]. Given these limitations in the diagnostic 
nomenclature, it remains useful to compare the data presented in this study with 
that pertaining to FCP and NCCP. 
 
6.8.1 Personality Characteristics 
The personality characteristics of FCP patients were markedly different to those of 
the healthy controls. Patients had higher anxiety, neuroticism and depression scores 
in comparison to their control counterparts. This is in agreement with other 
studies of NCCP, although there is a paucity of data in FCP per se. Previous studies 
have demonstrated that patients with NCCP had higher rates of neuroticism (odd 
ratio 1.14 95% confidence interval 1.02-1.31) and anxiety (odd ratio 1.13 95% 
confidence interval 1.03-1.24) but not depression when compared to healthy 
controls. Thus, personality traits do appear to be a relevant feature of FCP, but 
their role is likely to be complex. Specific personality traits, anxiety and 
somatoform disorders have been demonstrated to be over-represented in FCP 
[392]. However, to date, none of these specific personality traits has been 
reproducibly and reliably segregated with any demonstrable physiological 
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abnormalities. This raises the possibility that they have a variable, and possibly 
inconsistent, interaction in producing the symptomatic state; the true effect of 
personality traits on the disorder may be through mediating symptom severity. 
These studies and ours provide evidence of psychological comorbidity in FCP, 
although their precise role remains unclear. 
 
6.8.2 Pain Tolerance Levels 
Patients tolerated less mean somatic and visceral stimulus in comparison to the 
controls, suggesting that they have a degree of global hyperalgesia. This is likely to 
be a “true” finding, as all participants were naïve to this study. Visceral hyperalgesia 
per se has been demonstrated in a number of studies, and has been proposed as a 
“key player” in the pathogenesis of FCP. Up to 80% of patients exhibit significantly 
lower sensory thresholds for balloon distension-induced chest pain when compared 
with controls [393]. Technological advances in impedance planimetry, a technique 
that allows the concomitant assessment of oesophageal sensory and motor 
properties during graded intra-luminal balloon distension, has facilitated 
considerable advances in understanding the complex biomechanical properties of 
the human oesophagus [394]. Using this technique, Rao et al. demonstrated that 
patients with NCCP have a 50% reduction in their sensory threshold in comparison 
to healthy controls, providing further evidence for the role of hyperalgesia in the 
pathogenesis of FCP [395]. A number of studies have suggested that the 
hyperalgesia observed in a proportion of patients with FCP may be due to 
oesophageal dysmotility [377, 396]. However, the pattern of dysmotility, ranging 
from nutcracker oesophagus to hypotension of the lower oesophageal sphincter, is 
inconsistent across these studies. A recently published study by Thoua et al. 
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evaluated oesophageal motility and sensitivity in patients with erosive and non-
erosive reflux disease [397]. Surprisingly, patients without overt inflammation, i.e. 
those with non-erosive reflux disease, had higher pain sensitivity to acid infusion, 
with greater sensitivity observed in the proximal oesophagus. It is known that the 
proximal third of the oesophagus shares more in common embryologically with 
somatic structures than with the “true visceral” distal two-thirds of the 
oesophagus, and thus it may potentially exhibit intermediate properties between 
visceral and somatic structures in response to a noxious stimulus [398, 399]. 
Therefore, in Thoua et al.’s study, it is possible that increased sensitivity seen in the 
proximal oesophagus in patients with non-erosive disease may be related to a 
degree of somatic pain hyperalgesia. Despite these inferences, there is an absence 
of evidence to suggest that patients with FCP suffer an excess of somatic 
hypersensitivity. Somatic pain hypersensitivity has been shown to be important in 
contributing to the chronic, unexplained somatic pain suffered by patients with FSD, 
such as FM [400]. Somatic hyperalgesia has also been observed in other FGID such 
as IBS [401]. Somatic hypersensitivity may be an overlapping feature between these 
disorders. The mechanisms involved in this somatic pain hypersensitivity are 
relatively well established and have been shown to occur from an increase in CNS 
responsiveness to sensory stimuli. One of the most important mechanisms involved 
is the increased excitability of spinal cord neurones from the process of CS. 
Evidence for the neurophysiological basis for CS comes from animal models of 
chronic somatic pain, which have shown that following injury/inflammation there is 
heightened activity of the C fibre neurones that encode nociceptive transmission, 
inducing activation of NMDA receptors expressed on dorsal horn spinal neurones 
to increase their excitability and field of responsiveness [153]. CS in humans 
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manifests as either allodynia (a previously non-painful stimulus becoming painful) 
and/or hyperalgesia. Pharmacological antagonism of the NMDA receptor with 
ketamine has been shown to attenuate or reverse secondary hyperalgesia/allodynia 
in healthy volunteers and in some chronic pain syndromes. Ketamine has been 
shown to be an efficacious analgesic in chronic pain syndromes such as complex 
regional pain syndrome. Despite concerns regarding side effects, it was well 
tolerated by patients [402]. Consequently, targeting the biological mechanisms that 
facilitate the development and persistence of CS has led to novel therapeutic 
strategies in the treatment of chronic pain. Given that this study has demonstrated 
that patients with FCP have somatic and visceral hyperalgesia, further work is 
particularly warranted to evaluate the efficacy, and feasibility, of using NMDA 
antagonists in treating this disorder. 
 
6.8.3 Patterned Autonomic Responses to Pain 
In this study, I found that patients with FCP had an elevated HR, SCR with lower 
CVT and CSB at baseline in comparison to controls, suggesting that patients had 
relatively higher sympathetic and lower parasympathetic tone at rest. These findings 
are in agreement with those of Tougas et al., who found that patients with NCCP 
who developed pain following oesophageal acidification had higher baseline HR and 
vagal tone [385]. Furthermore, Tougas et al. reported that vagal outflow increased 
in acid-sensitive patients compared to those without acid sensitivity, reflecting the 
dynamic ANS responses that were seen in the patient group in this study. This 
suggests that the acid-sensitive patients with NCCP may be similar, in terms of the 
profile of their ANS response to painful/noxious stimuli, to patients with FCP as 
defined by the Rome III criteria. An interesting proposal in explaining why patients 
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increase their vagal tone to noxious stimuli relates to personality. Although Tougas’ 
studies did not assess personality in patients with NCCP, it is not unreasonable to 
suggest that the patients in their study may have had similar neuroticism and anxiety 
scores. Previous evidence from the literature has suggested that, in health, those 
with higher neuroticism scores have lower pain thresholds [403]. Coupled with the 
more recent observations that PNS plays an important role in the facilitation of an 
analgesic state, it is entirely possible that this transient increase in parasympathetic 
tone to pain in patients with NCCP/FCP, who are likely to have higher neuroticism 
scores and be more sensitive to pain ab initio, could be a hitherto under-recognised 
compensatory analgesic mechanism. In this study, I have shown that the PNS 
responds in a dichotomous way, as indexed by CVT and CSB, to pain, i.e. it displays 
withdrawal or activation, while the direction and magnitude of response are similar 
to both somatic and visceral pain stimulus. This observation has a number of 
potential ramifications. Firstly, this data demonstrates that the pattern of ANS 
response to a series of noxious stimuli is similar for visceral and somatic pain in 
patients with FCP. In future, this observation could potentially obviate the need for 
invasive visceral stimulation when evaluating ANS responses to pain in this patient 
group. Secondly, if the increase in vagal tone to pain in patients with FCP is in fact a 
compensatory analgesic mechanism, electrically or pharmacologically stimulating the 
vagus nerve may present an exciting treatment avenue through the augmentation of 
the possible analgesic parasympathetic response to pain. 
 
6.8.4 Hypothalamic Pituitary Adrenal Axis Responses to Pain 
To the best of my knowledge, HPA axis responses to pain have not been evaluated 
in patients with FCP in response to somatic and visceral pain. Whilst patients had 
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higher absolute levels of serum cortisol at each of the three sampling time points, 
the pattern of response, when baseline was controlled for, was very similar. It is 
therefore possible that these differences are a reflection of the differential state 
anxiety scores between patients and controls. A recent study by Ristner et al. 
demonstrated in both healthy volunteers and patients with schizophrenia that 
baseline cortisol was related to anxiety levels, although the absolute levels of 
cortisol did not relate to symptom severity in the patient group [404]. Whilst it is 
difficult to relate the severity of psychological symptoms in a group of patients with 
schizophrenia to the severity of symptoms in patients with FCP, the higher levels of 
anxiety seen in both groups of patients may influence basal tone of the HPA axis. 
These sets of data potentially suggest a common central pathway linking anxiety 
levels with the HPA axis.  
 
6.8.5 Genetic Differences in Polymorphisms of the Serotonin Transporter  
This has been the first study in the literature to examine the salience of genetic 
polymorphisms in patients with FCP. There was a trend of over-representation of 
the S allele in patients with FCP in comparison to controls, although this did not 
quite reach statistical significance (p=0.09). As the epidemiological data relating to 
FCP is generally of an inferential nature, such as that given by patients presenting 
with chest pain who have negative cardiac angiography, there are no studies 
examining the genetic component of FCP in twin or familial aggregation studies. 
Such work is urgently needed, as identifying and delineating candidate 
polymorphisms may allow further insights in to the molecular pathophysiology of 
this disorder. Whilst I have not demonstrated a strong association between the 5-
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HTTLPR genotype and FCP, studying a larger group of patients may strengthen this 
putative association in the future.  
6.8.6 Clinical Relevance and Implications of Pain Phenotypes in Patients with 
Functional Chest Pain 
In this study, I have provided further evidence for the existence, in a further sample, 
of two pain phenotypes based on personality traits, polymorphisms of the 5-
HTTLPR, ANS and HPA axis responses to somatic and visceral pain. Moreover, the 
data presented in this study suggests that these pain phenotypes have a clinical 
salience, in that patients were over-represented in Cluster 1, the “neurotic pain 
phenotype.”  
 
These novel findings have important implications in future studies evaluating the 
pathophysiology of FCP. By predefining subjects with FCP, future studies using the 
methods contained herein may lead to considerable improvements in 
subject/participant homogeneity. Such an improvement in the homogeneity of 
subjects may open the gateway for further progress in advancing our understanding 
of the underlying pathophysiology of FCP. Furthermore, such phenotyping 
techniques may facilitate an improvement in diagnostic criteria, from their current 
form based on symptoms to one based on physiology. Perhaps the most important 
potential advantage of phenotyping patients’ pain responses may allow the 
identification of specific pathophysiological abnormality that drives the disease 
process, for instance whether it be personality or autonomic dysfunction. When 
considering the former, a study by Jones et al. demonstrated the efficacy of 
hypnotherapy in a randomised control trial of patients with NCCP that had not 
responded to acid suppression [405]. Following 12 sessions of individualised 
treatment with hypnosis, 80% of patients reported that they were “completely 
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better” or “moderately better” compared with 23% of the control group. The 
controls received supportive psychotherapy and a placebo tablet to ensure that the 
findings were not explained by expectancy or increased attention from the clinician. 
The greater effectiveness of hypnotherapy in this trial was confirmed by a reduction 
in chest pain intensity, improvement in health-related quality of life and a reduction 
is analgesic usage. This study has a number of strengths in that the investigators 
were blinded to which treatment arm the patient was in, and the statistical analysis 
was performed on an intention to treat basis. However, this was a small sample of 
28 patients and no follow-up data was presented. Hypnotherapy is known to 
reduce state and trait anxiety in patients with FGID, although whether it can effect 
changes in personality traits such as neuroticism have not been evaluated in this 
patient group [406]. Hypnotherapy could work by reducing sympathetic tone thus 
facilitating a change in autonomic responses rather than changes in personality. 
Further investigation of the mechanism of action of hypnotherapy, particularly in 
the cohort studied here, would be very interesting. As we, and others, have shown 
that trait anxiety and neuroticism are linked closely with one another, it is possible 
that Jones et al. succeeded in altering the pain phenotype of their patients with 
NCCP from cluster 1 to cluster 2 through influencing their psychological traits. This 
proposition may form the underlying mechanism of action of hypnotherapy in 
patients with FCP/NCCP. Further work is now warranted in patients with FCP to 
ascertain whether their pain phenotype can be influenced through psychological or 
pharmacological means. 
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6.9 Conclusions 
In this study, I have demonstrated that patients with FCP have both visceral and 
somatic hyperalgesia in comparison to controls. Furthermore, at baseline, patients 
have higher neuroticism and anxiety scores, with higher HR and lower 
parasympathetic tone. Cluster analysis has revealed the presence of two pain 
phenotypes based on personality traits, polymorphisms of the SERT and autonomic 
and HPA axis responses to somatic and visceral pain. Patients were over-
represented in one of these phenotypes, suggesting that these aforementioned 
variables may be linked to the pathophysiology of this disorder. These novel 
observations open up new avenues of research by potentially improving patient 
homogeneity in future studies. 
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Chapter 7 – Summary and General Discussion 
7 Summary and General 
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7.1 What have I Demonstrated in this Thesis? 
Over the course of the studies presented in this PhD thesis, I have made a number 
of original observations in the related fields of psychology, genetics and autonomic 
neuroscience. In summary, I have demonstrated the existence of two reproducible 
human pain phenotypes based on personality traits, polymorphisms of the SERT, 
ANS and HPA axis responses to somatic and visceral pain in both health and 
disease. The studies presented herein have shown progressively that exploring 
these factors using an integrated approach gives evidence for phenotypic differences 
in the manner in which humans respond to pain. In particular, I have demonstrated 
a number of novel observations, which are discussed in the following sections. 
 
7.1.1 A Novel Multidimensional Methodological Approach for Evaluating 
Human Psychophysiological Responses to Somatic and Visceral Pain  
My initial point of reference was the observation that many studies in the literature 
have singly, and occasionally dually, examined and implicated the factors studied in 
this thesis. However, to date, there has been little in the way of a convergence of 
effort to evaluate many of these factors in a single paradigm. In this aim, I have been 
successful in the modelling of human pain phenotypes using methods that have 
encompassed personality traits, genetic profiles and the responses of autonomic 
and HPA axes to pain using a simple and straightforward experimental process. I 
found that the paradigm I used throughout these studies was reliable in facilitating 
this convergent, investigative strategy.  
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7.1.2 Novel Application of Technological Developments in Autonomic 
Neuroscience 
I have utilised the improved temporal resolution of selective non-invasive measures 
of autonomic tone given by the Neuroscope system in the investigation of 
autonomic responses to pain. In particular, the beat-to-beat measure of CVT has 
allowed the identification of subtle changes in parasympathetic efferent tone in 
response to visceral and somatic pain.  
 
7.1.3 Novel Observations of Patterned Autonomic Nervous System 
Responses to Pain 
In these studies, I have demonstrated that in a proportion of subjects there is an 
increase in parasympathetic tone to pain, with a concomitant decrease in HR to 
pain in the immediate post-stimulus period. Of importance is the observation that 
the pattern of autonomic responses to pain was similar for visceral and somatic 
pain, potentially obviating the need for future studies to use invasive paradigms, 
such as oesophageal or rectal intubation, to study autonomic responses to visceral 
pain. In many ways these observations were surprising as the results contained 
herein provide evidence that somatic and visceral pain are processed in a similar 
fashion when one can consider them to be external and internal threats 
respectively. The fact that they are experimentally induced in the artificial 
environment of the laboratory may go some way to explain these observations. 
 
7.1.4 Novel Analysis Techniques to Determine Dynamic Time-Locked 
Autonomic Responses to Pain 
I have utilised a novel method to evaluate the dynamic change in autonomic tone to 
painful stimuli. Previous studies have suggested that the majority of the change in 
autonomic tone occurs in the 30 seconds after stimulus delivery [215]. By 
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comparing the 30 seconds prior to the stimulus to the 30 seconds after the 
stimulus, the pattern of response could be deduced and evaluated. The improved 
temporal resolution of the autonomic parameters given by the Neuroscope has 
greatly facilitated this particular aim. The majority of studies in the literature that 
have attempted to study the ANS in patient groups do not examine these dynamic 
changes and, if they do, instead compare change in autonomic tone to a baseline 
that is often measured many minutes or hours before stimulus delivery. Many, if not 
most, non-invasive physiological parameters display considerable “drift” over time, 
thus making comparison to such a baseline of limited value and validity. I have 
shown that the examination of time-locked dynamic changes in autonomic tone is 
possible in a patient population, and the more widespread adoption of such a 
method may lead to greater insights into possible patterns of autonomic activation 
in other prevalent clinical disorders. 
 
7.1.5 Novel Identification of Pain Phenotypes 
During the course of these studies, I have identified the presence of two human 
pain phenotypes in response to visceral and somatic pain. The first of these, 
occurring in approximately one-third of healthy participants, is characterised by the 
personality traits of neuroticism and anxiety in the presence of the S allele of the 
SERT, elevated cortisol and sympathetic tone at rest and an increase in 
parasympathetic tone in response to pain. The second profile displays the converse 
profile in the absence of the S allele of the SERT. I observed that these traits and 
responses are stable over the period of one year. The pain phenotypes I have 
identified in health also have a translational aspect, in that the first of these is over-
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represented in a population of patients with FCP. The key phenotypic differences 
are summarised in Figure 51. 
 
 
Figure 51 - Differences between the two pain phenotypes that have been identified and their 
relative representation among healthy volunteers and in patients with FCP. 
 
7.2 Specific Limitations of the Studies 
7.2.1 Age and Sex of Subjects 
Many studies have shown systematic differences in pain sensitivity between males 
and females [407, 408]. In the studies that comprise this body of work, I studied 
more males than females, yet the latter are consistently over-represented in 
disorders of chronic, unexplained pain such as IBS [409]. Whilst the absolute 
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numbers of females examined in these studies were relatively large, ideally I would 
have studied equal proportions. The cited gender differences in pain sensitivity have 
been proposed to be potentially a function of the oestrous cycle in females. Whilst I 
controlled for these differences, studying females in the follicular phase of their 
menstrual cycle, this was self-reported and may have introduced a degree of 
reporting bias on the part of the female participants. This issue could have been 
addressed by measuring serum progesterone, but this was impractical, as it would 
have introduced a large time delay in to the protocol from time of venesection to 
receiving the results back from the biochemistry laboratory. Although there was a 
wide age range amongst the participants, these studies were not adequately 
powered to investigate age differences in psychophysiological responses to pain.  
 
7.2.2 Small Number of Participants 
These studies were very labour intensive in terms of participant recruitment, data 
handling, processing and analysis. Coupled with the difficulties in recruiting healthy 
volunteers and patients for pain studies, and in particular studies necessitating 
invasive procedures such as intubation and venesection, the logistics of recruiting a 
larger number of participants would have been difficult, although not impossible. 
Despite this, the sample sizes of the studies presented in this thesis are satisfactory 
according to current trends for these types of studies. However, these findings 
must be regarded as provisional until such time as they can be confirmed, or indeed 
refuted, in a larger population-based study.  
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7.2.3 Reproducibility of Psychophysiological Responses 
I chose to study responses at a period of one year in order to control for possible 
variations in seasonal differences in pain sensitivity and HPA axis responses. The 
mean time in which I examined the reproducibility was 48.1 weeks, although 
variation in the time between studies ranged from 29-68 weeks. Ideally, the studies 
would have been completed exactly one year after the initial study, and whilst I 
strove to achieve this, this proved difficult due to subject availability. I chose to 
restudy one-quarter of the initial cohort, whose selection criteria were based solely 
on their availability and willingness to have the study repeated, therefore potentially 
introducing subject self-selection bias. My initial concern was that subjects who 
were willing to be restudied would not be representative in terms of their 
personality traits, a concern that was not borne out in the subsequent analysis. 
Ideally, I would have liked to have studied participants at multiple time points, for 
instance at one week, one month and then one year, but this proved to be 
impractical on a logistical level.  
 
7.2.4 Order Randomisation of the Pain 
During these studies I elected not to randomise the order in which participants 
received somatic and visceral pain. During the pilot work for these studies, 
participants were pseudo-randomised to receive somatic pain followed by visceral 
pain and vice-versa. This work did not demonstrate a difference in state anxiety 
scores, affective pain rating, autonomic responses or stimulus toleration between 
these groups. I concluded from this pilot work that the order in which the stimuli 
were presented to the subject did not influence the psychophysiological responses 
that I was attempting to measure. Thus, in order to improve the validity of 
comparison, I decided not to vary the order. Whilst this may have improved the 
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validity of comparison and made the statistical analysis more straightforward, it 
could be argued that other factors, such as habituation and descending modulatory 
influences, may have occurred following the delivery of the first type of stimulus 
(somatic pain), thereby potentially influencing responses to the second (visceral 
pain). This is a valid concern, but given the reasonable time gap of approximately 20 
minutes between the two types of pain, such influences may not have had such a 
significant impact on the results of the study. 
 
7.3 General Limitations of the Approaches Used 
7.3.1 Phasic Changes in Parasympathetic Autonomic Parameters 
Although I measured CVT and CSB in this series of studies, I shall limit this part of 
the discussion to CVT as it, and parameters purporting to measure a similar index, 
have generated the most interest and controversy in the psychophysiological 
literature. CVT is modulated at multiple levels, peripherally through baroreceptor 
modulation in serving homeostatic mechanisms, and centrally by sub-cortical areas 
such as PAG matter, amygdala and the pre-frontal cortices [410]. At a simplistic 
level, CVT is a binary measure, in that it can only increase or decrease in response 
to a stimulus, as has been demonstrated extensively in my studies. Whilst I did not 
examine recovery times, rebound changes and the habituation of these phasic 
changes specifically, the repertoire of change remains limited. Therefore, as these 
phasic changes are limited, attaching multiple and diverse explanations to their 
meaning or significance may be, in some respects, rather futile. Further studies using 
carefully controlled experimental conditions and time-locked experimental 
measures such as functional brain imaging or electrophysiological techniques may go 
some way to providing a more definite explanation as to the relevance and relative 
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importance of CVT change. I have shown a robust and reproducible relationship 
between CVT and personality/anxiety measures throughout these studies, but one 
must err on the side of caution in the interpretation of these relationships, as it is 
entirely possible that personality influences on CVT may only be evident under 
certain conditions, such as those used here. Thus, attempting to “map” a complex, 
multiply determined, polygenic, personality construct directly on to a physiological 
measure may be somewhat naïve. The challenge for the future, and the “proof of 
the (this) pudding”, will be successfully using these neurophysiological techniques in 
the identification of discriminatory biomarkers of clinically applicable sensitivity and 
specificity for personality constructs and physiological responses to pain. 
  
7.3.2 What Do Pain Phenotypes Really Index? 
In essence, the nature of the two pain phenotypes that have been identified in these 
studies links a number of factors that had been previously identified as potential 
candidates implicated in the pathophysiology of chronic pain. However, until now, 
these factors have not been studied together in an integrated fashion to delineate 
how each interacts with the other. The studies presented in this thesis provide a 
link between the seemingly divergent factors of personality traits, 5-HTTLPR and 
the pattern of HPA axis and ANS response using a convergent methodology. The 
methods that I have used, utilising the complex statistical technique of two-step 
cluster analysis, has enabled the identification of two groups based on these factors, 
thereby linking personality to genetics, to the pattern of response to pain of stress 
responsive systems. However, whether investigating the salience of an acute pain 
stimulus in a chronic pain disorder truly reflects abnormalities in nociceptive 
processing in patients remain a limitation in any such types of research. 
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7.3.2.1 Dichotomous or a Spectrum of Responses? 
The evidence that I have presented in this thesis has argued the existence of two 
pain phenotypes. The opposing argument centres on the observation that few, if 
any, biological or physiological systems are truly dichotomous in their nature, and 
therefore such a separation is purely arbitrary and artificial. Whilst there is 
considerable strength in the assertion that what has been measured is a spectrum 
of responses, I would argue that this may not necessarily be the case of pain 
responses. Firstly, these phenotypes have their basis across multiple inter-digitated 
biological systems. Secondly, I have demonstrated the existence of these two 
phenotypes across many individuals at multiple time points. Finally, the statistics for 
the defining difference are robust, particularly with respect to the silhouette of 
cohesion.  
 
7.3.2.2 Pain Phenotypes as Susceptibility Factors 
The pain phenotypes in these studies describe clusters of participants in whom 
patterns of personality traits, genetics and responses are similar. It is fascinating to 
note that many of the specific facets that underpin these phenotypes have been 
shown to be recurring features implicated in the pathophysiology of chronic pain 
syndromes. A key possibility arising from this work is that these factors coalesce to 
form pain phenotypes, and that these form susceptibility, or vulnerability, factors 
for the genesis of symptoms that define such illnesses. Consequentially, the 
identification of the factor or factors that trigger these vulnerability traits, thereby 
permitting the development of such illnesses, may be of supreme relevance in their 
prevention. Quite what these “trigger” factors will turn out to be is purely 
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hypothetical, but there is evidence to suggest that, particularly in IBS, infection or 
severe psychosocial stress may be important in the initiation of the illness [411].   
 
7.4 Clinical Implications and Translational Potential 
The profession, and society at large, are in the midst an FSD epidemic. Despite the 
considerable morbidity caused by these disorders, there has been a frustrating lack 
of progress in both the development of a mechanistic understanding of underlying 
pathophysiology and efficacious treatment strategies, in spite of a gargantuan effort 
from academia and the pharmaceutical industry alike. The key findings presented in 
this body of work have both implications and applications to both of these 
frustrations. 
 
7.4.1 Translational Implications 
The evidence presented herein has provided a unique and novel insight in to the 
bidirectional relations between pain and personality traits, based on biological 
substrates and processes underpinned through the contribution of genetics and 
stress responsive physiology. Rather than implicating a single factor in the 
pathophysiology of these disorders on a study-by-study basis, a more holistic, 
multidimensional approach to future work may increase the yield of future studies. 
 
7.4.2 Translational Applications 
The picture that has emerged from my work suggests that neuroticism is linked to 
anxiety and to higher sympathetic and HPA axis tone at rest with a parasympathetic 
response to pain, in combination with less habituation and increased pain sensitivity. 
Extroversion, on the other hand, is linked to sympathetic reactivity to pain and 
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reduced pain sensitivity. The role of neuroticism as a general risk factor for 
functional disorders has been well established, but its relative lack of sensitivity and 
specificity has limited its clinical usefulness. Thus, establishing multidimensional 
biomarkers through pain phenotyping, which encompasses neuroticism, may 
increase its mechanistic utility and discriminatory validity. Such phenotyping may aid 
in determining further investigative or therapeutic strategies. Although there is 
evidence to suggest that psychiatric comorbidity is undertreated in functional 
syndromes, it is common practice to use anti-depressants in their treatment. 
Therefore, patients who fit the “neurotic” pain phenotype may derive more clinical 
benefit from early therapy with anti-depressant therapy. Invasive investigations 
could then be deferred until there is a failure of therapeutic response, which itself 
could be monitored by repeating phenotyping studies. Similarly, the introduction of 
psychological therapy, such as cognitive behavioural therapy or hypnosis, may be 
introduced earlier, with objective responses being measured in a similar fashion. 
Conversely, those patients who fit the extrovert phenotype may warrant a more 
aggressive investigative strategy initially, as well as less aggressive anti-depressant or 
psychological therapies.  
 
7.5 Future Research Strategies 
7.5.1 Further Studies Evaluating the Prevalence of Pain Phenotypes in a Larger 
Population of Healthy Volunteers 
Further evaluation and validation/refutation of these putative human pain 
phenotypes needs to be undertaken in a larger cohort of healthy volunteers. Whilst 
the healthy volunteers studies presented in this thesis are among the largest of their 
kind, they are dwarfed in comparison to many population-based studies. Key 
difficulties that have beset many, if not most, studies of visceral pain are the 
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complexity associated with participant recruitment and safety concerns. Firstly, the 
recruitment of healthy volunteers, who derive no direct benefits from participating, 
is extremely difficult. Secondly, intubation and distension of any part of the GI tract 
carry a small, but significant, risk of viscus perforation. Thus large-scale population-
based studies that include visceral pain in their paradigm are almost impossible to 
conduct. In future, based on data presented in these studies, studying autonomic 
responses to visceral pain may not be necessary, as the responses to somatic and 
visceral pain are similar and therefore obviate the need to induce visceral pain. In a 
similar fashion, the use of abbreviated personality questionnaires and 
advances/increased affordability in high throughput genetic analysis techniques may 
facilitate the study of a large population-based cohort. 
 
7.5.2 Evaluation of Age, Sex and Ethnicity Differences 
The studies contained in this thesis were not designed, and thus not sufficiently 
powered, to detect age, sex and ethnicity differences. Further studies should focus 
on these differences in an attempt to delineate whether demographical factors 
confer any appreciable differences in pain responses. 
 
7.5.3 State Anxiety Modulation 
The first study in this thesis demonstrated that state anxiety differences can 
influence autonomic responses to visceral and somatic pain. Experimental 
manipulation of state anxiety could influence arousal and emotional valence/context 
of nociceptive stimuli and potentially influence the autonomic response. Paradigms 
that sought to increase, through self-biographical recall of adverse life events, or 
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decrease, through listening to relaxing music, state anxiety, may influence 
autonomic responses to pain. 
 
7.5.4 Further Genetic Analysis 
It would be extremely interesting to evaluate the salience of other candidate genes, 
which may determine the genetic role in pain phenotypes. Recent evidence has 
suggested that the dual-specific A kinase-anchoring protein 2 (AKAP10) functional 
polymorphism may influence HR and HRV [412]. The AKAP10 Val allele predicted 
greater resting HR and diminished HRV, suggesting that this variant may modulate 
the sensitivity of cardiac pacemaker cells to autonomic inputs. I would infer from 
these results that this polymorphism might be over-represented in the neurotic 
pain phenotype. In a similar fashion, autonomic regulation may be influenced by 
genetic polymorphisms in the choline transporter (CHT1), a component of 
acetylcholine neurotransmission [413]. Furthermore, a recent study, using 
functional brain imaging, suggested that CHT1 variation is related to differences in 
activity of the limbic system, an area of the brain that mediates behavioural and 
physiologic arousal [414]. These relations provide a rational biological 
mechanism/explanation by which genetic variation in cholinergic neurotransmission 
affects cognition, mood and autonomic cardiac function.  
 
The ultimate goal for evaluating the genetic component of pain phenotypes would 
be utilising the powerful method of a GWAS. Currently, the numbers of 
participants in these studies are too small to utilise this genetic epidemiological 
technique effectively. However, refining pain phenotyping methods, as discussed in 
section 7.5.1, page 277, may facilitate the evaluation personality traits and 
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autonomic responses to pain in a large population-based cohort in the context of 
the incorporation of a GWAS study. Ideally, evaluating subjects who were part of a 
larger GWAS study, such as those in the Wellcome Trust Case Control 
Consortium, would potentially facilitate a greater insight in to the genetic 
components of these pain phenotypes. 
  
7.5.5 Immune System Evaluation 
There has been a recent suggestion that the immune system acts as a “sixth sense.” 
[415]. An increase in understanding the manner in which the immune and nervous 
systems interact has been central to the development of the field of 
psychoneuroimmunology. The observation that the immune and nervous systems 
use a common set of neurotransmitters, ligands and receptors has led to the 
development of the hypothesis that the immune system may detect and respond to 
stressors, such as infectious pathogens, in a similar manner to “conventional” stress 
response systems such as the ANS. An important recent study evaluated the 
characteristics of the cellular and humoral immune responses in a group of patients 
with FGID [416]. Whilst the cellular immunophenotype between healthy controls 
and patients was similar, there was a shift towards a Th2 cytokine profile in the 
patients group. Although this was a preliminary study, this data has particular 
relevance, as 15 out of the 63 patients in this study had NCCP. These findings 
suggest that there may be immunological aspects to the pain phenotypes, and this 
warrants exploration in future studies.  
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7.5.6 Future Studies in Functional Syndromes 
Phenotyping pain in humans using the wide range of techniques in these studies may 
open a new avenue of integrated neuroscientific research into functional 
syndromes. The use of such a research strategy may improve our understanding of 
their complex pathophysiology. There is now a need to phenotype pain responses 
in other prevalent functional syndromes such as IBS and FM. Phenotyping pain 
responses in patients may improve homogeneity in future study participants, which 
itself may potentially lead to the development of more efficacious treatments 
strategies in the future.  
 
7.5.7 Potential Treatment Applications in Functional Somatic Syndromes 
The pivotal follow-on study from this work is the intriguing possibility of 
establishing whether it is possible to move subjects from one phenotype to the 
other. This may potentially be possible through pharmacological and non-
pharmacological interventions. Firstly, autonomic responses may be influenced using 
beta-blockers, deep breathing or electrical vagal stimulation. Secondly, 
hypothalamic-pituitary adrenal axis responses may be altered using vasopressin or 
pentagastrin, a cholecystokinin B agonist. Thirdly, personality and anxiety can be 
influenced by psychotherapeutic measures such as cognitive behavioural therapy. 
Finally, as discussed in section 7.5.3 (see page 278), the modulation of state anxiety 
and serotoninergic system may also influence pain phenotypes. These potential 
interventions are summarised in Figure 52. 
 
7.6 Concluding Remarks 
This project has been successful in adopting a multidimensional approach, utilising 
methodologies from divergent, yet complementary, branches of genetics, 
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psychology, neuroendocrinology and autonomic neuroscience in the development 
and characterisation of human pain phenotypes to visceral and somatic pain in both 
health and in patients with FCP. In health, it is possible that these factors may 
contribute to susceptibility factors for the development of disorders of chronic 
pain, and in disease may be involved in symptom genesis and persistence. Further 
work is now urgently warranted to further validate these phenotypes in health and 
to assess their relevance in disease. 
 
Figure 52 - Factors and strategies (green boxes) that may be used in future studies, which are 
known to influence the factors demonstrated to be of importance (blue boxes) in defining human 
pain phenotypes. 
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Appendix 2 – Pilot Data 
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Distension Volumes of Oesophageal Distension Catheters 
During the bench testing work I examined 20 self-made catheters and 10 Sandhill 
catheter. I used 10 Sandhill catheters rather than 20 due to their prices (£22.40 per 
unit). The mean distension volume that the self-made catheter mechanically failed 
was 65 mls, SD +/- 17.1 mls. The mean distension volume that the Sandhill catheter 
failed was 60mls, SD +/- 2.1 mls, (see Figure 53). 
 
 
Figure 53 - The comparison between the distension volumes that the catheters failed mechanically. 
Plots show mean +/- SEM. 
 
Rationale for choice of 7 Visceral & Somatic Stimuli  
During the pilot work, I administered a variable number of somatic (nail bed 
pressure) and visceral (oesophageal distension) to 8 volunteers (4 female, median 
age 24.3 years, range 22-28 years) in order to ascertain the balance between an 
individual habituating and sensitising to the stimuli. There was at least a 1 week 
interval between the subjects receiving the visceral and then the somatic stimuli. 
Following the administration of consecutive 20 stimuli, with 2 minutes inter-
stimulus interval, I found (co-incidentally) that 7 stimuli for both visceral pain (see 
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Figure 54) and somatic pain (see Figure 55) was the optimum number between an 
individual habituating and sensitising. 
 
Figure 54 - The pilot data of visceral stimuli demonstrating that 7 consecutive stimuli, with an inter-
stimulus interval of 2 minutes, was the optimum number between individuals habituating and 
sensitizing. Plots show mean +/- SEM. 
 
 
Figure 55 - The pilot data of somatic stimuli demonstrating that 7 consecutive stimuli, with an 
inter-stimulus interval of 2 minutes, was the optimum number between individuals habituating and 
sensitizing. Plots show mean +/- SEM. 
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Rationale for not Randomising the Order of Visceral & Somatic 
Stimuli  
During the pilot work, I studied 12 volunteers (6 female, mean age 28.3 years, range 
21 – 40 years) to ascertain whether there was an order effect in whether I 
administered somatic pain followed by visceral pain or vice versa. Subjects were 
studied to the same protocol as shown in Figure 23, with the only difference that 
subjects were pseudo-randomised in a counter-balanced fashion to receive either 
somatic followed by visceral pain (hereinafter termed group 1) or visceral pain 
followed by somatic pain (hereinafter termed group 2). Subjects were not informed 
in which order they would receive the pain but knew that they were going to 
receive both visceral and somatic stimuli. All 12 of the pilot subjects completed the 
study. There were no demographic, or psychological state or trait, differences 
between the two groups (see Table 31). 
 
Variable Group 1 
(n=6) 
Group 2 
(n=6) 
P value 
Sex  
(Male: female) 
3 : 3 3 : 3 1 
Age 
(years - mean ± SEM) 
27.8 ± 2.1 28.8 ± 2.5 0.77 
BMI  
(kg/m2 - mean ± SEM  
26.2 ± 1.3 27.0 ± 1.1 0.23 
Ethnicity  
(Caucasian: non-
Caucasian) 
5 : 1 4 : 2 1 
HADS-anxiety 1.33 ± 0.42 1.33 ± 0.49 1 
HADS-depression 0.83 ± 0.3 1.16 ± 0.47 0.57 
STAI-S 47 ± 4.5 40.8 ± 4.4 0.35 
STAI-T 48 ± 3.2 40.6 ± 4.7 0.29 
BFI-N 2.97 ± 0.42 3.12 ± 0.42 0.81 
BFI-E 3.58 ± 0.39 3.21 ± 0.27 0.45 
EPQ-R-N 13.17 ± 1.62 12.67 ± 2.15 0.86 
EPQ-R-E 17.5 ± 1.96 15.5 ± 1.8 0.47 
Table 31 - Demonstrates the differences in demographics and psychological state and traits 
between group 1 and group 2. 
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In terms of the HPA axis data, cortisol was sampled at baseline in both groups and 
again after the 1st set of stimuli and again after the 2nd set of stimuli. There are 
significant differences in the pattern of response between the two groups with 
group 1 (somatic followed by visceral pain) showing a step-wise progression across 
the study. In group 2, (who received visceral followed by somatic pain), there was 
an initial increase in cortisol to visceral pain followed by a drop to somatic pain. 
These data suggest that the mode of painful stimulation is important rather than the 
order.  
 
Figure 56 - Sequential cortisol results for the two group, * p<0.0001. 
 
Table 32 shows the mean autonomic data, for group 1 and group 2 at baseline, 
during the 1st set of painful stimuli and finally during the 2nd set of painful stimuli. No 
significant differences were observed between the two groups at baseline. Overall, 
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the order in which the stimuli were presented did not have a discernable influence 
on the autonomic variables that were measured. However, it is interesting to note 
that those in group 2, (visceral followed by somatic pain) had a non-significant trend 
towards having a higher heart rate following the first set of stimuli. This may have 
been a consequence of intubation and having the oesophageal distension catheter in 
situ. The 6 subjects who received somatic followed by visceral pain have been 
included in the analysis contained in chapter 3. 
 
Variable Group 1 (n=6) Group 2 (n=6) P Value 
Baseline Mean (±SEM) Mean (±SEM)  
HR (bpm) 76 ± 2.2 78.7 ± 2.81 0.09 
MBP (mmHg) 80.8 ± 9.9 82.3 ± 6.46 0.76 
CVT (lvs) 6.89 ± 1.5 7.01 ± 1.2 0.88 
CSB (!RR/!mmHg) 5.77 ± 0.69 8.51 ± 3.49 0.09 
SCR (µS) 2.91 ± 0.9 2.18 ± 0.8 0.17 
Following 1st Set of Stimuli Mean (±SEM) Mean (±SEM)  
HR (bpm) 82.27 ± 3.4 89.3 ± 7.1 0.053 
MBP (mmHg) 90.21 ± 6.47 88.62 ± 8.9 0.73 
CVT (lvs) 4.36 ± 1.52 5.65 ± 2.08 0.25 
CSB (!RR/!mmHg) 4.65 ± 1.34 5.11 ± 2.88 0.73 
SCR (µS) 26.44 ± 4.8 22.11 ± 1.2 0.06 
Following 2nd Set of Stimuli Mean (±SEM) Mean (±SEM)  
HR (bpm) 84.2 ± 5.8 88.1 ± 9.02 0.39 
MBP (mmHg) 89.32 ± 6.4 93.1 ± 8.1 0.39 
CVT (lvs) 4.51 ± 1.2 4.70 ± 1.8 0.85 
CSB (!RR/!mmHg) 4.23 ± 1.27 4.01 ± 0.88 0.73 
SCR (µS) 27.1 ± 2.3 25.41 ± 3.6 0.36 
 
Table 32 - The mean baseline autonomic, mean 1st set of stimuli and mean 2nd set of stimuli for 
the two groups. 
 
 
 
